Du benytter en nettleser vi ikke støtter. Se informasjon om nettlesere

19. Referanser

Aberizk, W. J., Silver, B., Henderson, I. C., Cady, B., & Harris, J. R. (1986). The use of radiotherapy for treatment of isolated locoregional recurrence of breast carcinoma after mastectomy. Cancer, 58(6), 1214-1218.

Abner, A. L., Recht, A., Eberlein, T., Come, S., Shulman, L., Hayes, D., . . . Harris, J. R. (1993). Prognosis following salvage mastectomy for recurrence in the breast after conservative surgery and radiation therapy for early-stage breast cancer. J Clin Oncol, 11(1), 44-48. https://doi.org/10.1200/jco.1993.11.1.44

Aebi, S., Gelber, S., Anderson, S. J., Láng, I., Robidoux, A., Martin, M., . . . Wapnir, I. L. (2014). Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial. The Lancet. Oncology, 15(2), 156-163. https://doi.org/10.1016/s1470-2045(13)70589-8

Afghahi, A., & Kurian, A. W. (2017). The Changing Landscape of Genetic Testing for Inherited Breast Cancer Predisposition. Curr Treat Options Oncol, 18(5), 27. https://doi.org/10.1007/s11864-017-0468-y

Albain, K. S., Barlow, W. E., Shak, S., Hortobagyi, G. N., Livingston, R. B., Yeh, I. T., . . . Hayes, D. F. (2010). Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. The Lancet. Oncology, 11(1), 55-65. https://doi.org/10.1016/s1470-2045(09)70314-6

Alkis, N., Durnali, A. G., Arslan, U. Y., Kocer, M., Onder, F. O., Tokluoglu, S., . . . Altundag, K. (2011). Optimal timing of adjuvant treatment in patients with early breast cancer. Med Oncol., 28(4), 1255-1259. https://doi.org/10.1007/s12032-010-9566-4

Alpert, T. E., Kuerer, H. M., Arthur, D. W., Lannin, D. R., & Haffty, B. G. (2005). Ipsilateral breast tumor recurrence after breast conservation therapy: outcomes of salvage mastectomy vs. salvage breast-conserving surgery and prognostic factors for salvage breast preservation. International journal of radiation oncology, biology, physics, 63(3), 845-851. https://doi.org/10.1016/j.ijrobp.2005.02.035

Alterio, D., Jereczek-Fossa, B. A., Franchi, B., D'Onofrio, A., Piazzi, V., Rondi, E., . . . Orecchia, R. (2007). Thyroid disorders in patients treated with radiotherapy for head-and-neck cancer: a retrospective analysis of seventy-three patients. Int J Radiat Oncol Biol Phys., 67(1), 144-150. https://doi.org/10.1016/j.ijrobp.2006.08.051

Amant, F., Han, S. N., Gziri, M. M., Vandenbroucke, T., Verheecke, M., & Van Calsteren, K. (2015). Management of cancer in pregnancy. Best practice & research. Clinical obstetrics & gynaecology, 29(5), 741-753. https://doi.org/10.1016/j.bpobgyn.2015.02.006

Amant, F., Loibl, S., Neven, P., & Van Calsteren, K. (2012). Breast cancer in pregnancy. Lancet, 379(9815), 570-579. https://doi.org/10.1016/s0140-6736(11)61092-1

Amant, F., Vandenbroucke, T., Verheecke, M., Fumagalli, M., Halaska, M. J., Boere, I., . . . Van Calsteren, K. (2015). Pediatric Outcome after Maternal Cancer Diagnosed during Pregnancy. The New England journal of medicine, 373(19), 1824-1834. https://doi.org/10.1056/NEJMoa1508913

Amant, F., von Minckwitz, G., Han, S. N., Bontenbal, M., Ring, A. E., Giermek, J., . . . Loibl, S. (2013). Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study. J Clin Oncol, 31(20), 2532-2539. https://doi.org/10.1200/jco.2012.45.6335

American College of Radiology. (2007). Practice guideline for the breast conservation therapy in the management of invasive breast carcinoma. Journal of the American College of Surgeons, 205(2), 362-376. https://doi.org/10.1016/j.jamcollsurg.2007.02.057

Amir, E., Seruga, B., Niraula, S., Carlsson, L., & Ocana, A. (2011). Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst., 103(17), 1299-1309. https://doi.org/10.1093/jnci/djr242

Anbazhagan, R., Fujii, H., & Gabrielson, E. (1999). Microsatellite instability is uncommon in breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 5(4), 839-844.

Anderson, S. J., Wapnir, I., Dignam, J. J., Fisher, B., Mamounas, E. P., Jeong, J. H., . . . Wolmark, N. (2009). Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer. J Clin Oncol., 27(15), 2466-2473. https://doi.org/10.1200/JCO.2008.19.8424

Andersson, M., Lidbrink, E., Bjerre, K., Wist, E., Enevoldsen, K., Jensen, A. B., . . . Langkjer, S. T. (2011). Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study. J Clin Oncol., 29(3), 264-271. https://doi.org/10.1200/Jco.2010.30.8213

Andre, F., Broglio, K., Roche, H., Martin, M., Mackey, J. R., Penault-Llorca, F., . . . Pusztai, L. (2008). Estrogen receptor expression and efficacy of docetaxel-containing adjuvant chemotherapy in patients with node-positive breast cancer: results from a pooled analysis. J Clin Oncol., 26(16), 2636-2643. https://doi.org/10.1200/JCO.2007.14.9146

Andre, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., . . . Group, S.-S. (2019). Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. The New England journal of medicine, 380(20), 1929-1940. https://doi.org/10.1056/NEJMoa1813904

André, F., Ciruelos, E. M., Juric, D., Loibl, S., Campone, M., Mayer, I., . . . Rugo, H. S. (2020). LBA18 - Overall survival (os) results from SOLAR-1, a phase III study of alpelisib (ALP) + fulvestrant (FUL) for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC). Annals of oncology : official journal of the European Society for Medical Oncology, 31, S1150-S1151.

Andre, F., Ismaila, N., Henry, N. L., Somerfield, M. R., Bast, R. C., Barlow, W., . . . Stearns, V. (2019). Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update-Integration of Results From TAILORx. J Clin Oncol, 37(22), 1956-1964. https://doi.org/10.1200/jco.19.00945

Antoniou, A., Pharoah, P. D., Narod, S., Risch, H. A., Eyfjord, J. E., Hopper, J. L., . . . Easton, D. F. (2003). Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet., 72(5), 1117-1130. https://doi.org/10.1086/375033

Appelt, A. L., Vogelius, I. R., & Bentzen, S. M. (2013). Modern hypofractionation schedules for tangential whole breast irradiation decrease the fraction size-corrected dose to the heart. Clin Oncol (R Coll Radiol), 25(3), 147-152. https://doi.org/10.1016/j.clon.2012.07.012

Arthur, D. W., Winter, K. A., Kuerer, H. M., Haffty, B., Cuttino, L., Todor, D. A., . . . White, J. R. (2020). Effectiveness of Breast-Conserving Surgery and 3-Dimensional Conformal Partial Breast Reirradiation for Recurrence of Breast Cancer in the Ipsilateral Breast: The NRG Oncology/RTOG 1014 Phase 2 Clinical Trial. JAMA oncology, 6(1), 75-82. https://doi.org/10.1001/jamaoncol.2019.4320

Arver, B., Isaksson, K., Atterhem, H., Baan, A., Bergkvist, L., Brandberg, Y., . . . Sandelin, K. (2011). Bilateral prophylactic mastectomy in Swedish women at high risk of breast cancer: a national survey. Ann Surg., 253(6), 1147-1154. https://doi.org/10.1097/SLA.0b013e318214b55a

Ashkanani, F., Sarkar, T., Needham, G., Coldwells, A., Ah-See, A. K., Gilbert, F. J., . . . Heys, S. D. (2001). What is achieved by mammographic surveillance after breast conservation treatment for breast cancer? Am J Surg, 182(3), 207-210. https://doi.org/10.1016/s0002-9610(01)00704-8

Association of Breast Surgery, The British Association of Plastic, Reconstructive and Aesthetic Surgeons, & The British Association of Aesthetic Plastic Surgeons. (2012). Lipomodelling Guidelines for Breast Surgery. London: ABS, BAPRAS og BAAPS. Retrieved from http://www.bapras.org.uk/docs/default-source/commissioning-and-policy/2012-august-lipomodelling-guidelines-for-breast-surgery.pdf?sfvrsn=0; 2012

Aubert, R. E., Stanek, E. J., Yao, J., Teagarden, J. R., Subar, M., Epstein, R. S., . . . Flockhart, D. A. (2009). Risk of breast cancer recurrence in women initiating tamoxifen with CYP2D6 inhibitors. J Clin Oncol., 27(18 suppl), abstract CRA508.

Avila, A., Bartholomew, A. J., Sosin, M., Deldar, R., Griffith, K. F., Willey, S. C., . . . Tousimis, E. A. (2020). Acute Postoperative Complications in Prepectoral versus Subpectoral Reconstruction following Nipple-Sparing Mastectomy. Plastic and reconstructive surgery, 146(6), 715e-720e. https://doi.org/10.1097/PRS.0000000000007326

Azim, H. A., Jr., Santoro, L., Russell-Edu, W., Pentheroudakis, G., Pavlidis, N., & Peccatori, F. A. (2012). Prognosis of pregnancy-associated breast cancer: a meta-analysis of 30 studies. Cancer Treat Rev, 38(7), 834-842. https://doi.org/10.1016/j.ctrv.2012.06.004

Azim, A. A., Costantini-Ferrando, M., & Oktay, K. (2012). Safety of Fertility Preservation by Ovarian Stimulation With Letrozole and Gonadotropins in Patients With Breast Cancer: A Prospective Controlled Study. J Clin Oncol., 26(16), 2630-2635. https://doi.org/10.1200/JCO.2007.14.8700

Aziz, S., Wik, E., Knutsvik, G., Klingen, T. A., Chen, Y., Davidsen, B., . . . Akslen, L. A. (2017). Extra-nodal extension is a significant prognostic factor in lymph node positive breast cancer. PLoS ONE, 12(2), e0171853. https://doi.org/10.1371/journal.pone.0171853

Bachelot, T., Bourgier, C., Cropet, C., Ray-Coquard, I., Ferrero, J. M., Freyer, G., . . . Pujade-Lauraine, E. (2012). Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol., 30(22), 2718-2724. https://doi.org/10.1200/JCO.2011.39.0708

Bailey, A. G., Brown, J. N., & Hammond, J. M. (2021). Cryotherapy for the prevention of chemotherapy-induced peripheral neuropathy: A systematic review. J Oncol Pharm Pract, 27(1), 156-164. https://doi.org/10.1177/1078155220959431

Baker, N. F., Baecher, K. M., Hart, A. M., Styblo, T. M., Carlson, G. W., & Losken, A. (2020). The impact of axillary node surgery on outcomes following immediate breast reconstruction. The breast journal, 26(11), 2170-2176. https://doi.org/10.1111/tbj.14070

Banke, A., Fosbøl, E. L., Møller, J. E., Gislason, G. H., Andersen, M., Bernsdorf, M., . . . Ejlertsen, B. (2018). Long-term effect of epirubicin on incidence of heart failure in women with breast cancer: insight from a randomized clinical trial. European journal of heart failure, 20(10), 1447-1453. https://doi.org/10.1002/ejhf.1168

Banuelos, J., Sabbagh, M. D., Roh, S. G., Nguyen, M. T., Lemaine, V., Tran, N. V., . . . Sharaf, B. (2019). Infections following Immediate Implant-Based Breast Reconstruction: A Case-Control Study over 11 Years. Plastic and reconstructive surgery, 144(6), 1270-1277. https://doi.org/10.1097/PRS.0000000000006202

Bardia, A., Hurvitz, S. A., Tolaney, S. M., Loirat, D., Punie, K., Oliveira, M., . . . Rugo, H. S. (2021). Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. The New England journal of medicine, 384(16), 1529-1541. https://doi.org/10.1056/NEJMoa2028485

Bartelink, H., Horiot, J. C., Poortmans, P., Struikmans, H., Van den Bogaert, W., Barillot, I., . . . Pierart, M. (2001). Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med., 345(19), 1378-1387. https://doi.org/10.1056/NEJMoa010874

Bartelink, H., Horiot, J. C., Poortmans, P. M., Struikmans, H., Van den Bogaert, W., Fourquet, A., . . . Collette, L. (2007). Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol., 25(22), 3259-3265.

Bartelink, H., Maingon, P., Poortmans, P., Weltens, C., Fourquet, A., Jager, J., . . . Collette, L. (2015). Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. The Lancet. Oncology, 16(1), 47-56. https://doi.org/10.1016/s1470-2045(14)71156-8

Baselga, J. (2011). Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer. Oncologist, 16 Suppl 1, 12-19. https://doi.org/16/suppl_1/12 [pii]

10.1634/theoncologist.2011-S1-12

Baselga, J., Campone, M., Piccart, M., Burris, H. A., 3rd, Rugo, H. S., Sahmoud, T., . . . Hortobagyi, G. N. (2012). Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med., 366(6), 520-529. https://doi.org/10.1056/NEJMoa1109653

Baselga, J., Cortes, J., Kim, S. B., Im, S. A., Hegg, R., Im, Y. H., . . . Swain, S. M. (2012). Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med., 366(2), 109-119. https://doi.org/10.1056/NEJMoa1113216

Baselga, J., Im, S. A., Iwata, H., Cortes, J., De Laurentiis, M., Jiang, Z., . . . Campone, M. (2017). Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. Oncology, 18(7), 904-916. https://doi.org/10.1016/S1470-2045(17)30376-5

Batist, G., Ramakrishnan, G., Rao, C. S., Chandrasekharan, A., Gutheil, J., Guthrie, T., . . . Lee, L. W. (2001). Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol., 19(5), 1444-1454. https://doi.org/10.1200/JCO.2001.19.5.1444

Beck, T. M., Hart, N. E., Woodard, D. A., & Smith, C. E. (1983). Local or regionally recurrent carcinoma of the breast: results of therapy in 121 patients. J Clin Oncol., 1(6), 400-405. https://doi.org/10.1200/JCO.1983.1.6.400

Bentzen, S. M., Agrawal, R. K., Aird, E. G., Barrett, J. M., Barrett-Lee, P. J., Bentzen, S. M., . . . Yarnold, J. R. (2008). The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet, 371(9618), 1098-1107.

Beral, V. (2003). Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet, 362(9382), 419-427. https://doi.org/10.1016/s0140-6736(03)14065-2

Beresford, M., Tumur, I., Chakrabarti, J., Barden, J., Rao, N., & Makris, A. (2011). A qualitative systematic review of the evidence base for non-cross-resistance between steroidal and non-steroidal aromatase inhibitors in metastatic breast cancer. Clin Oncol (R Coll Radiol), 23(3), 209-215. https://doi.org/10.1016/j.clon.2010.11.005

Bernstein, J. L., Teraoka, S., Southey, M. C., Jenkins, M. A., Andrulis, I. L., Knight, J. A., . . . Concannon, P. (2006). Population-based estimates of breast cancer risks associated with ATM gene variants c.7271T>G and c.1066-6T>G (IVS10-6T>G) from the Breast Cancer Family Registry. Hum Mutat, 27(11), 1122-1128. https://doi.org/10.1002/humu.20415

Berry, D. A., Cirrincione, C., Henderson, I. C., Citron, M. L., Budman, D. R., Goldstein, L. J., . . . Winer, E. P. (2006). Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA, 295(14), 1658-1667. https://doi.org/10.1001/jama.295.14.1658

Biganzoli, L., Wildiers, H., Oakman, C., Marotti, L., Loibl, S., Kunkler, I., . . . Audisio, R. (2012). Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). Lancet Oncol., 13(4), e148-e160. https://doi.org/10.1016/S1470-2045(11)70383-7

Bijker, N., Donker, M., Wesseling, J., den Heeten, G. J., & Rutgers, E. J. (2013). Is DCIS breast cancer, and how do I treat it? Curr Treat Options Oncol., 14(1), 75-87.

Bijker, N., Meijnen, P., Peterse, J. L., Bogaerts, J., Van Hoorebeeck, I., Julien, J. P., . . . Rutgers, E. J. (2006). Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853--a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol., 24(21), 3381-3387. https://doi.org/10.1200/Jco.2006.06.1366

Bijker, N., Peterse, J. L., Duchateau, L., Julien, J. P., Fentiman, I. S., Duval, C., . . . van de Vijver, M. J. (2001). Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. J Clin Oncol., 19(8), 2263-2271. https://doi.org/10.1200/JCO.2001.19.8.2263

Bines, J., Oleske, D. M., & Cobleigh, M. A. (1996). Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol, 14(5), 1718-1729. https://doi.org/10.1200/JCO.1996.14.5.1718

Bliss, J. M., Kilburn, L. S., Coleman, R. E., Forbes, J. F., Coates, A. S., Jones, S. E., . . . Coombes, R. C. (2012). Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study. J Clin Oncol., 30(7), 709-717. https://doi.org/10.1200/JCO.2010.33.7899

Blok, E. J., Kroep, J. R., Meershoek-Klein Kranenbarg, E., Duijm-de Carpentier, M., Putter, H., van den Bosch, J., . . . van de Velde, C. J. H. (2018). Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05). Journal of the National Cancer Institute, 110(1). https://doi.org/10.1093/jnci/djx134

Blough, J. T., Vu, M. M., Qiu, C. S., Mlodinow, A. S., Khavanin, N., Fine, N. A., & Kim, J. Y. S. (2018). Beyond 30 Days: A Risk Calculator for Longer Term Outcomes of Prosthetic Breast Reconstruction. Plastic and reconstructive surgery. Global open, 6(12), e2065. https://doi.org/10.1097/gox.0000000000002065

Blum, J. L., Dieras, V., Lo Russo, P. M., Horton, J., Rutman, O., Buzdar, A., & Osterwalder, B. (2001). Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer, 92(7), 1759-1768. https://doi.org/10.1002/1097-0142(20011001)92:7<1759::aid-cncr1691>3.0.co;2-a

Blum, J. L., Flynn, P. J., Yothers, G., Asmar, L., Geyer, C. E., Jr., Jacobs, S. A., . . . Wolmark, N. (2017). Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology). J Clin Oncol, 35(23), 2647-2655. https://doi.org/10.1200/jco.2016.71.4147

Blumgart, E. I., Uren, R. F., Nielsen, P. M., Nash, M. P., & Reynolds, H. M. (2011). Predicting lymphatic drainage patterns and primary tumour location in patients with breast cancer. Breast cancer research and treatment, 130(2), 699-705. https://doi.org/10.1007/s10549-011-1737-2

Body, J. J., Diel, I. J., Lichinitser, M. R., Kreuser, E. D., Dornoff, W., Gorbunova, V. A., . . . Bergstrom, B. (2003). Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol., 14(9), 1399-1405. https://doi.org/10.1093/annonc/mdg367

Body, J. J., Diel, I. J., Lichinitzer, M., Lazarev, A., Pecherstorfer, M., Bell, R., . . . Bergstrom, B. (2004). Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer, 90(6), 1133-1137. https://doi.org/10.1038/sj.bjc.6601663

Bonneterre, J., Roche, H., Kerbrat, P., Bremond, A., Fumoleau, P., Namer, M., . . . Chapelle-Marcillac, I. (2005). Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial. J Clin Oncol., 23(12), 2686-2693. https://doi.org/10.1200/JCO.2005.05.059

Bookman, M. A., & Longo, D. L. (1986). Concomitant illness in patients treated for Hodgkin's disease. Cancer Treat Rev, 13(2), 77-111. https://doi.org/10.1016/0305-7372(86)90015-0

Borner, M., Bacchi, M., Goldhirsch, A., Greiner, R., Harder, F., Castiglione, M., . . . Obrecht, J. P. (1994). First isolated locoregional recurrence following mastectomy for breast cancer: results of a phase III multicenter study comparing systemic treatment with observation after excision and radiation. Swiss Group for Clinical Cancer Research. J Clin Oncol., 12(10), 2071-2077. https://doi.org/10.1200/JCO.1994.12.10.2071

Borud, E. K., Alraek, T., & White, A. (2010). The Acupuncture on Hot Flashes Among Menopausal Women study: observational follow-up results at 6 and 12 months. Menopause, 17(2), 262-268. https://doi.org/10.1097/gme.0b013e3181c07275

Bose, R., Kavuri, S. M., Searleman, A. C., Shen, W., Shen, D., Koboldt, D. C., . . . Ellis, M. J. (2013). Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov, 3(2), 224-237. https://doi.org/2159-8290.CD-12-0349 [pii]

10.1158/2159-8290.CD-12-0349

Bouchardy, C., Rapiti, E., Blagojevic, S., Vlastos, A. T., & Vlastos, G. (2007). Older female cancer patients: importance, causes, and consequences of undertreatment. J Clin Oncol., 25(14), 1858-1869. https://doi.org/10.1200/JCO.2006.10.4208

Breast Cancer Association Consortium, Dorling, L., Carvalho, S., Allen, J., González-Neira, A., Luccarini, C., . . . Easton, D. F. (2021). Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women. The New England journal of medicine, 384(5), 428-439. https://doi.org/10.1056/NEJMoa1913948

Breast cancer screening. (2002). (IARC Handbooks of cancer prevention volume 7). Lyon: IARC Press.

Brinton, L. A., Key, T. J., Kolonel, L. N., Michels, K. B., Sesso, H. D., Ursin, G., . . . Cook, M. B. (2015). Prediagnostic Sex Steroid Hormones in Relation to Male Breast Cancer Risk. J Clin Oncol, 33(18), 2041-2050. https://doi.org/10.1200/jco.2014.59.1602

Brodowicz, T., Kostler, W. J., Moslinger, R., Tomek, S., Vaclavik, I., Herscovici, V., . . . Zielinski, C. C. (2000). Single-agent gemcitabine as second- and third-line treatment in metastatic breast cancer. Breast, 9(6), 338-342. https://doi.org/10.1054/brst.2000.0170

Broeders, M., Moss, S., Nystrom, L., Njor, S., Jonsson, H., Paap, E., . . . Paci, E. (2012). The impact of mammographic screening on breast cancer mortality in Europe: a review of observational studies. J Med Screen., 19 Suppl 1, 14-25. https://doi.org/10.1258/jms.2012.012078

Broglio, K. R., Quintana, M., Foster, M., Olinger, M., McGlothlin, A., Berry, S. M., . . . Berry, D. A. (2016). Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes: A Meta-Analysis. JAMA oncology, 2(6), 751-760. https://doi.org/10.1001/jamaoncol.2015.6113

Brohet, R. M., Velthuizen, M. E., Hogervorst, F. B., Meijers-Heijboer, H. E., Seynaeve, C., Collee, M. J., . . . Resource, H. (2014). Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations. J Med Genet, 51(2), 98-107. https://doi.org/10.1136/jmedgenet-2013-101974

Browall, M., Forsberg, C., & Wengström, Y. (2017). Assessing patient outcomes and cost-effectiveness of nurse-led follow-up for women with breast cancer - have relevant and sensitive evaluation measures been used? J Clin Nurs, 26(13-14), 1770-1786. https://doi.org/10.1111/jocn.13496

Brown, T., Cruickshank, S., & Noblet, M. (2021). Specialist breast care nurses for support of women with breast cancer. Cochrane Database Syst Rev, 2(2), CD005634. https://doi.org/10.1002/14651858.CD005634.pub3

Brufsky, A. M., Harker, W. G., Beck, J. T., Bosserman, L., Vogel, C., Seidler, C., . . . Perez, E. A. (2012). Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer, 118(5), 1192-1201. https://doi.org/10.1002/cncr.26313

Bröstcancer: Nationellt vårdprogram. (2014). Stockholm: Regionalt cancercentrum. Retrieved from http://www.swebcg.se/wp-content/uploads/2016/09/NVP-Br%C3%B6stcancer-2014.pdf

Buchanan, C. L., Dorn, P. L., Fey, J., Giron, G., Naik, A., Mendez, J., . . . Sclafani, L. M. (2006). Locoregional recurrence after mastectomy: incidence and outcomes. J Am Coll Surg., 203(4), 469-474. https://doi.org/10.1016/j.jamcollsurg.2006.06.015

Buchholz, T. A., Tucker, S. L., Masullo, L., Kuerer, H. M., Erwin, J., Salas, J., . . . Hortobagyi, G. N. (2002). Predictors of local-regional recurrence after neoadjuvant chemotherapy and mastectomy without radiation. J Clin Oncol., 20(1), 17-23. https://doi.org/10.1200/Jco.20.1.17

Burstein, H. J., Curigliano, G., Loibl, S., Dubsky, P., Gnant, M., Poortmans, P., . . . Thurlimann, B. (2019). Estimating the Benefits of Therapy for Early Stage Breast Cancer The St Gallen International Consensus Guidelines for the Primary Therapy of Early Breast Cancer 2019. Annals of oncology : official journal of the European Society for Medical Oncology, 30(10), 1541-1557. https://doi.org/10.1093/annonc/mdz235

Burstein, H. J., Curigliano, G., Thürlimann, B., Weber, W. P., Poortmans, P., Regan, M. M., . . . Gnant, M. (2021). Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Annals of oncology : official journal of the European Society for Medical Oncology, 32(10), 1216-1235. https://doi.org/10.1016/j.annonc.2021.06.023

Butt, D. A., Lock, M., Lewis, J. E., Ross, S., & Moineddin, R. (2008). Gabapentin for the treatment of menopausal hot flashes: a randomized controlled trial. Menopause, 15(2), 310-318. https://doi.org/10.1097/gme.0b013e3180dca175

Byrski, T., Huzarski, T., Dent, R., Marczyk, E., Jasiowka, M., Gronwald, J., . . . Narod, S. A. (2014). Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients. Breast cancer research and treatment, 147(2), 401-405. https://doi.org/10.1007/s10549-014-3100-x

Baak, J. P., van Diest, P. J., Janssen, E. A., Gudlaugsson, E., Voorhorst, F. J., van der Wall, E., & Vermorken, J. B. (2008). Proliferation accurately identifies the high-risk patients among small, low-grade, lymph node-negative invasive breast cancers. Annals of oncology : official journal of the European Society for Medical Oncology, 19(4), 649-654. https://doi.org/10.1093/annonc/mdm535

Baak, J. P., van Diest, P. J., Voorhorst, F. J., van der Wall, E., Beex, L. V., Vermorken, J. B., . . . Gudlaugsson, E. (2007). The prognostic value of proliferation in lymph-node-negative breast cancer patients is age dependent. Eur J Cancer, 43(3), 527-535. https://doi.org/10.1016/j.ejca.2006.10.001

Cabioglu, N., Hunt, K. K., Buchholz, T. A., Mirza, N., Singletary, S. E., Kuerer, H. M., . . . Meric-Bernstam, F. (2005). Improving local control with breast-conserving therapy: a 27-year single-institution experience. Cancer, 104(1), 20-29. https://doi.org/10.1002/cncr.21121

Cameron, D., Piccart-Gebhart, M. J., Gelber, R. D., Procter, M., Goldhirsch, A., de Azambuja, E., . . . Jackisch, C. (2017). 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet, 389(10075), 1195-1205. https://doi.org/10.1016/s0140-6736(16)32616-2

Campbell, E. J., & Romics, L. (2017). Oncological safety and cosmetic outcomes in oncoplastic breast conservation surgery, a review of the best level of evidence literature. Breast Cancer: Targets and Therapy, 9, 521-530. https://doi.org/10.2147/bctt.s113742

Cancer in Norway 2018: Cancer incidence, mortality, survival and prevalence in Norway. (2019). Oslo: Cancer Registry of Norway. Retrieved from https://www.kreftregisteret.no/globalassets/cancer-in-norway/2018/cin2018.pdf

Cancer in Norway 2020: Cancer incidence, mortality, survival and prevalence in Norway. (2021). Oslo: Cancer Registry of Norway. Retrieved from https://www.kreftregisteret.no/globalassets/cancer-in-norway/2020/cin-2020.pdf

Caplin, D. A., Calobrace, M. B., Wixtrom, R. N., Estes, M. M., & Canady, J. W. (2021). MemoryGel Breast Implants: Final Safety and Efficacy Results after 10 Years of Follow-Up. Plastic and reconstructive surgery, 147(3), 556-566. https://doi.org/10.1097/PRS.0000000000007635

Cardoso, F., van't Veer, L. J., Bogaerts, J., Slaets, L., Viale, G., Delaloge, S., . . . Piccart, M. (2016). 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. The New England journal of medicine, 375(8), 717-729. https://doi.org/10.1056/NEJMoa1602253

Carrick, S., Parker, S., Wilcken, N., Ghersi, D., Marzo, M., & Simes, J. (2009). Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev, (2), CD003372. https://doi.org/10.1002/14651858.CD003372.pub3

Casella, D., Di Taranto, G., Marcasciano, M., Lo Torto, F., Barellini, L., Sordi, S., . . . Ribuffo, D. (2019). Subcutaneous expanders and synthetic mesh for breast reconstruction: Long-term and patient-reported BREAST-Q outcomes of a single-center prospective study. Journal of plastic, reconstructive & aesthetic surgery : JPRAS, 72(5), 805-812. https://doi.org/10.1016/j.bjps.2018.12.018

Casella, D., Di Taranto, G., Onesti, M. G., Greco, M., & Ribuffo, D. (2019). A retrospective comparative analysis of risk factors and outcomes in direct-to-implant and two-stages prepectoral breast reconstruction: BMI and radiotherapy as new selection criteria of patients. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 45(8), 1357-1363. https://doi.org/10.1016/j.ejso.2019.02.009

Caudle, K. E., Sangkuhl, K., Whirl-Carrillo, M., Swen, J. J., Haidar, C. E., Klein, T. E., . . . Gaedigk, A. (2020). Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group. Clin Transl Sci, 13(1), 116-124. https://doi.org/10.1111/cts.12692

Chan, A., Martin, M., Untch, M., Gil, M. G., Guillem-Porta, V., Wojtukiewicz, M., . . . Petruzelka, L. (2006). Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial. Br J Cancer, 95(7), 788-793. https://doi.org/10.1038/sj.bjc.6603351

Chan, E. K., Woods, R., Virani, S., Speers, C., Wai, E. S., Nichol, A., . . . Tyldesley, S. (2012). Accelerated hypofractionated versus conventional whole breast radiotherapy for localised left-sided breast cancer: the effect on long-term cardiac morbidity. Cancer Res, 72(24 Suppl 3), Abstract nr PD04-02. https://doi.org/10.1158/0008-5472.Sabcs12-Pd04-02

Chan, R. J., Teleni, L., McDonald, S., Kelly, J., Mahony, J., Ernst, K., . . . Yates, P. (2020). Breast cancer nursing interventions and clinical effectiveness: a systematic review. BMJ Support Palliat Care, 10(3), 276-286. https://doi.org/10.1136/bmjspcare-2019-002120

Chan, S., Davidson, N., Juozaityte, E., Erdkamp, F., Pluzanska, A., Azarnia, N., & Lee, L. W. (2004). Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 15(10), 1527-1534. https://doi.org/10.1093/annonc/mdh393

Chan, S. W., Cheung, P. S., & Lam, S. H. (2010). Cosmetic outcome and percentage of breast volume excision in oncoplastic breast conserving surgery. World journal of surgery, 34(7), 1447-1452. https://doi.org/10.1007/s00268-009-0278-x

Chang, C. C., Elliott, T. A., Wright, G., Shapiro, D. B., Toledo, A. A., & Nagy, Z. P. (2013). Prospective controlled study to evaluate laboratory and clinical outcomes of oocyte vitrification obtained in in vitro fertilization patients aged 30 to 39 years. Fertil Steril, 99(7), 1891-1897. https://doi.org/10.1016/j.fertnstert.2013.02.008

Chao, S. T., De Salles, A., Hayashi, M., Levivier, M., Ma, L., Martinez, R., . . . Sahgal, A. (2018). Stereotactic Radiosurgery in the Management of Limited (1-4) Brain Metasteses: Systematic Review and International Stereotactic Radiosurgery Society Practice Guideline. Neurosurgery, 83(3), 345-353. https://doi.org/10.1093/neuros/nyx522

Chen, J., Zhang, X., Lu, Y., Zhang, T., Ouyang, Z., & Sun, Q. (2021). Optimal duration of endocrine therapy with extended aromatase inhibitors for postmenopausal patients with hormone receptor-positive breast cancer: a meta-analysis. Breast Cancer, 28(3), 630-643. https://doi.org/10.1007/s12282-020-01196-8

Chlebowski, R. T., Rohan, T. E., Manson, J. E., Aragaki, A. K., Kaunitz, A., Stefanick, M. L., . . . Prentice, R. L. (2015). Breast Cancer After Use of Estrogen Plus Progestin and Estrogen Alone: Analyses of Data From 2 Women's Health Initiative Randomized Clinical Trials. JAMA oncology, 1(3), 296-305. https://doi.org/10.1001/jamaoncol.2015.0494

Cintolo-Gonzalez, J. A., Braun, D., Blackford, A. L., Mazzola, E., Acar, A., Plichta, J. K., . . . Hughes, K. S. (2017). Breast cancer risk models: a comprehensive overview of existing models, validation, and clinical applications. Breast cancer research and treatment. https://doi.org/10.1007/s10549-017-4247-z

Clarke, C. N., Cortina, C. S., Fayanju, O. M., Dossett, L. A., Johnston, F. M., & Wong, S. L. (2021). Breast Cancer Risk and Screening in Transgender Persons: A Call for Inclusive Care. Ann Surg Oncol, Jun 7 [epub ahead of print]. https://doi.org/10.1245/s10434-021-10217-5

Clarke, M., Collins, R., Darby, S., Davies, C., Elphinstone, P., Evans, E., . . . Wang, Y. (2005). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet, 366(9503), 2087-2106. https://doi.org/10.1016/S0140-6736(05)67887-7

Clarke, M. J. (2002). Radiotherapy for early breast cancer. Cochrane Database Syst Rev, (2), CD003647.

Clough, K. B., Lewis, J. S., Couturaud, B., Fitoussi, A., Nos, C., & Falcou, M. C. (2003). Oncoplastic techniques allow extensive resections for breast-conserving therapy of breast carcinomas. Annals of surgery, 237(1), 26-34. https://doi.org/10.1097/01.sla.0000041230.77663.22

Cloyd, J. M., Hernandez-Boussard, T., & Wapnir, I. L. (2013). Outcomes of partial mastectomy in male breast cancer patients: analysis of SEER, 1983-2009. Ann Surg Oncol, 20(5), 1545-1550. https://doi.org/10.1245/s10434-013-2918-5

Cluze, C., Rey, D., Huiart, L., BenDiane, M. K., Bouhnik, A. D., Berenger, C., . . . Giorgi, R. (2012). Adjuvant endocrine therapy with tamoxifen in young women with breast cancer: determinants of interruptions vary over time. Annals of oncology : official journal of the European Society for Medical Oncology, 23(4), 882-890. https://doi.org/10.1093/annonc/mdr330

Coates, A. S., Keshaviah, A., Thurlimann, B., Mouridsen, H., Mauriac, L., Forbes, J. F., . . . Goldhirsch, A. (2007). Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol., 25(5), 486-492. https://doi.org/10.1200/Jco.2006.08.8617

Coates, A. S., Winer, E. P., Goldhirsch, A., Gelber, R. D., Gnant, M., Piccart-Gebhart, M., . . . Senn, H. J. (2015). Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Annals of oncology : official journal of the European Society for Medical Oncology, 26(8), 1533-1546. https://doi.org/10.1093/annonc/mdv221

Cobo, A., Garcia-Velasco, J., Domingo, J., Pellicer, A., & Remohi, J. (2018). Elective and Onco-fertility preservation: factors related to IVF outcomes. Human Reproduction, 33(12), 2222-2231. https://doi.org/10.1093/humrep/dey321

Cochrane, R. A., Valasiadou, P., Wilson, A. R., Al-Ghazal, S. K., & Macmillan, R. D. (2003). Cosmesis and satisfaction after breast-conserving surgery correlates with the percentage of breast volume excised. The British journal of surgery, 90(12), 1505-1509. https://doi.org/10.1002/bjs.4344

Cold, S., During, M., Ewertz, M., Knoop, A., & Møller, S. (2005). Does timing of adjuvant chemotherapy influence the prognosis after early breast cancer? Results of the Danish Breast Cancer Cooperative Group (DBCG). Br J Cancer, 93(6), 627-632.

Coleman, R. E., Marshall, H., Cameron, D., Dodwell, D., Burkinshaw, R., Keane, M., . . . Bell, R. (2011). Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med., 365(15), 1396-1405.

Coles, C. E., Griffin, C. L., Kirby, A. M., Titley, J., Agrawal, R. K., Alhasso, A., . . . Bliss, J. M. (2017). Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet, 390(10099), 1048-1060. https://doi.org/10.1016/s0140-6736(17)31145-5

Colleoni, M., Bonetti, M., Coates, A. S., Castiglione-Gertsch, M., Gelber, R. D., Price, K., . . . Goldhirsch, A. (2000). Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. The International Breast Cancer Study Group. J Clin Oncol., 18(3), 584-590. https://doi.org/10.1200/Jco.2000.18.3.584

Collins, L. C., Achacoso, N., Haque, R., Nekhlyudov, L., Fletcher, S. W., Quesenberry, C. P., Jr., . . . Habel, L. A. (2013). Risk factors for non-invasive and invasive local recurrence in patients with ductal carcinoma in situ. Breast Cancer Res Treat., 139(2), 453-460. https://doi.org/10.1007/s10549-013-2539-5

Colwell, A. S., & Taylor, E. M. (2020). Recent Advances in Implant-Based Breast Reconstruction. Plastic and reconstructive surgery, 145(2), 421e-432e. https://doi.org/10.1097/PRS.0000000000006510

Conte, P. F., Gennari, A., Landucci, E., & Orlandini, C. (2000). Role of epirubicin in advanced breast cancer. Clin Breast Cancer, 1(Suppl 1), S46-S51. https://doi.org/10.3816/cbc.2000.s.009

Coombes, R. C., Kilburn, L. S., Snowdon, C. F., Paridaens, R., Coleman, R. E., Jones, S. E., . . . Bliss, J. M. (2007). Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet, 369(9561), 559-570. https://doi.org/10.1016/S0140-6736(07)60200-1

Cortazar, P., Zhang, L., Untch, M., Mehta, K., Costantino, J. P., Wolmark, N., . . . von Minckwitz, G. (2014). Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet, 384(9938), 164-172. https://doi.org/10.1016/s0140-6736(13)62422-8

Cortes, J., Cescon, D. W., Rugo, H. S., Nowecki, Z., Im, S. A., Yusof, M. M., . . . Schmid, P. (2020). Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet, 396(10265), 1817-1828. https://doi.org/10.1016/s0140-6736(20)32531-9

Cortes, J., Kim, S. B., Chung, W. P., Im, S. A., Park, Y. H., Hegg, R., . . . Hurvitz, S. A. (2021). LBA1 Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study. Annals of oncology : official journal of the European Society for Medical Oncology, 32(Suppl 5), S1287-S1288. https://doi.org/10.1016/j.annonc.2021.08.2087

Cortes, J., O'Shaughnessy, J., Loesch, D., Blum, J. L., Vahdat, L. T., Petrakova, K., . . . Twelves, C. (2011). Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet, 377(9769), 914-923. https://doi.org/10.1016/S0140-6736(11)60070-6

Cramp, F., & Daniel, J. (2008). Exercise for the management of cancer-related fatigue in adults. Cochrane Database Syst Rev, (2), CD006145. https://doi.org/10.1002/14651858.CD006145.pub2

Cristofanilli, M., Turner, N. C., Bondarenko, I., Ro, J., Im, S. A., Masuda, N., . . . Slamon, D. (2016). Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. The Lancet. Oncology, 17(4), 425-439. https://doi.org/10.1016/s1470-2045(15)00613-0

Crivellari, D., Aapro, M., Leonard, R., von Minckwitz, G., Brain, E., Goldhirsch, A., . . . Muss, H. (2007). Breast cancer in the elderly. J Clin Oncol., 25(14), 1882-1890. https://doi.org/10.1200/JCO.2006.10.2079

Curigliano, G., Burstein, H. J., E, P. W., Gnant, M., Dubsky, P., Loibl, S., . . . Xu, B. (2017). De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Annals of oncology : official journal of the European Society for Medical Oncology, 28(8), 1700-1712. https://doi.org/10.1093/annonc/mdx308

Cuzick, J., Sestak, I., Baum, M., Buzdar, A., Howell, A., Dowsett, M., & Forbes, J. F. (2010). Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol., 11(12), 1135-1141. https://doi.org/10.1016/S1470-2045(10)70257-6

Darby, S., McGale, P., Correa, C., Taylor, C., Arriagada, R., Clarke, M., . . . Peto, R. (2011). Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet, 378(9804), 1707-1716. https://doi.org/10.1016/S0140-6736(11)61629-2

Darby, S. C., Ewertz, M., McGale, P., Bennet, A. M., Blom-Goldman, U., Bronnum, D., . . . Hall, P. (2013). Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med., 368(11), 987-998. https://doi.org/10.1056/NEJMoa1209825

Darby, S. C., McGale, P., Taylor, C. W., & Peto, R. (2005). Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in US SEER cancer registries. Lancet Oncol., 6(8), 557-565. https://doi.org/10.1016/S1470-2045(05)70251-5

Davies, C., Godwin, J., Gray, R., Clarke, M., Cutter, D., Darby, S., . . . Peto, R. (2011). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet, 378(9793), 771-784. https://doi.org/10.1016/S0140-6736(11)60993-8

Davies, C., Pan, H., Godwin, J., Gray, R., Arriagada, R., Raina, V., . . . Peto, R. (2013). Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet, 381(9869), 805-816.

de Blok, C. J. M., Wiepjes, C. M., Nota, N. M., van Engelen, K., Adank, M. A., Dreijerink, K. M. A., . . . den Heijer, M. (2019). Breast cancer risk in transgender people receiving hormone treatment: nationwide cohort study in the Netherlands. BMJ, 365, l1652. https://doi.org/10.1136/bmj.l1652

de Bock, G. H., Bonnema, J., van der Hage, J., Kievit, J., & van de Velde, C. J. (2004). Effectiveness of routine visits and routine tests in detecting isolated locoregional recurrences after treatment for early-stage invasive breast cancer: a meta-analysis and systematic review. J Clin Oncol, 22(19), 4010-4018. https://doi.org/10.1200/jco.2004.06.080

de Boer, R., Bundred, N., Eidtmann, H., Neven, P., von Minckwitz, G., Martin, N., . . . Coleman, R. (2011). Long-Term Survival Outcomes among Postmenopausal Women with Hormone Receptor-Positive Early Breast Cancer Receiving Adjuvant Letrozole and Zoledronic Acid: 5-Year Follow-Up of ZO-FAST. (Abstract [S1-3] fra CTRC-AACR San Antonio breast canver symposium, 7. desember 2011). San Antonio: Cancer Therapy & Research Center at UT Health Science Center. Retrieved from http://cancerres.aacrjournals.org/content/71/24_Supplement/S1-3

de Boniface, J., Szulkin, R., & Johansson, A. L. V. (2021). Survival After Breast Conservation vs Mastectomy Adjusted for Comorbidity and Socioeconomic Status: A Swedish National 6-Year Follow-up of 48 986 Women. JAMA surgery, 156(7), 628-637. https://doi.org/10.1001/jamasurg.2021.1438

De La Cruz, L., Blankenship, S. A., Chatterjee, A., Geha, R., Nocera, N., Czerniecki, B. J., . . . Fisher, C. S. (2016). Outcomes After Oncoplastic Breast-Conserving Surgery in Breast Cancer Patients: A Systematic Literature Review. Ann Surg Oncol, 23(10), 3247-3258. https://doi.org/10.1245/s10434-016-5313-1

de Mascarel, I., MacGrogan, G., Picot, V., Dougazz, A., & Mathoulin-Pelissier, S. (2006). Results of a long term follow-up study of 115 patients with flat epithelial atypia. Lab Invest, 86(Suppl), 25A.

Del Mastro, L., Boni, L., Michelotti, A., & et al. (2011). Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: A randomized trial. JAMA, 306(3), 269-276. https://doi.org/10.1001/jama.2011.991

Del Mastro, L., Bruzzi, P., Nicolo, G., Cavazzini, G., Contu, A., D'Amico, M., . . . Venturini, M. (2005). HER2 expression and efficacy of dose-dense anthracycline-containing adjuvant chemotherapy in breast cancer patients. Br J Cancer, 93(1), 7-14. https://doi.org/10.1038/sj.bjc.6602660

Del Mastro, L., Ceppi, M., Poggio, F., Bighin, C., Peccatori, F., Demeestere, I., . . . Bruzzi, P. (2014). Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: Systematic review and meta-analysis of randomized trials. Cancer Treat Rev, 40(5), 675-683. https://doi.org/10.1016/j.ctrv.2013.12.001

Del Mastro, L., De Placido, S., Bruzzi, P., De Laurentiis, M., Boni, C., Cavazzini, G., . . . Cognetti, F. (2015). Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 x 2 factorial, randomised phase 3 trial. Lancet, 385(9980), 1863-1872. https://doi.org/10.1016/s0140-6736(14)62048-1

Delanian, S., Lefaix, J. L., & Pradat, P. F. (2012). Radiation-induced neuropathy in cancer survivors. Radiother Oncol, 105(3), 273-282. https://doi.org/10.1016/j.radonc.2012.10.012

DeLong, M. R., Tandon, V. J., Bertrand, A. A., MacEachern, M., Goldberg, M., Salibian, A., . . . Wilkins, E. G. (2021). Review of Outcomes in Prepectoral Prosthetic Breast Reconstruction with and without Surgical Mesh Assistance. Plastic and reconstructive surgery, 147(2), 305-315. https://doi.org/10.1097/PRS.0000000000007586

Denduluri, N., Chavez-MacGregor, M., Telli, M. L., Eisen, A., Graff, S. L., Hassett, M. J., . . . Giordano, S. H. (2018). Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update. J Clin Oncol, 36(23), 2433-2443. https://doi.org/10.1200/JCO.2018.78.8604

Deng, G., Vickers, A., Yeung, S., D'Andrea, G. M., Xiao, H., Heerdt, A. S., . . . Cassileth, B. (2007). Randomized, controlled trial of acupuncture for the treatment of hot flashes in breast cancer patients. J Clin Oncol., 25(35), 5584-5590. https://doi.org/10.1200/JCO.2007.12.0774

Deshpande, N. A., Braun, I. M., & Meyer, F. L. (2015). Impact of fertility preservation counseling and treatment on psychological outcomes among women with cancer: A systematic review. Cancer, 121(22), 3938-3947. https://doi.org/10.1002/cncr.29637

Diaz, R., Degnim, A. C., Boughey, J. C., Nassar, A., & Jakub, J. W. (2012). A positive intramammary lymph node does not mandate a complete axillary node dissection. Am J Surg., 203(2), 151-155.

Dickler, M. N., Saura, C., Richards, D. A., Krop, I. E., Cervantes, A., Bedard, P. L., . . . Baselga, J. (2018). Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 24(18), 4380-4387. https://doi.org/10.1158/1078-0432.CCR-18-0613

Dickler, M. N., Tolaney, S. M., Rugo, H. S., Cortés, J., Diéras, V., Patt, D., . . . Baselga, J. (2017). MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR(+)/HER2(-) Metastatic Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 23(17), 5218-5224. https://doi.org/10.1158/1078-0432.Ccr-17-0754

Dieci, M. V., Griguolo, G., Bottosso, M., Tsvetkova, V., Giorgi, C. A., Vernaci, G., . . . Guarneri, V. (2021). Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant/adjuvant chemotherapy. NPJ Breast Cancer, 7(1), 101. https://doi.org/10.1038/s41523-021-00308-7

Dijkema, I. M., Hofman, P., Raaijmakers, C. P., Lagendijk, J. J., Battermann, J. J., & Hillen, B. (2004). Loco-regional conformal radiotherapy of the breast: delineation of the regional lymph node clinical target volumes in treatment position. Radiother Oncol., 71(3), 287-295. https://doi.org/10.1016/j.radonc.2004.02.017

Domchek, S., & Kaunitz, A. M. (2016). Use of systemic hormone therapy in BRCA mutation carriers. Menopause, 23(9), 1026-1027. https://doi.org/10.1097/GME.0000000000000724

Domchek, S. M., Friebel, T. M., Singer, C. F., Evans, D. G., Lynch, H. T., Isaacs, C., . . . Rebbeck, T. R. (2010). Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA, 304(9), 967-975. https://doi.org/10.1001/jama.2010.1237

Donegan, W. L., Perez-Mesa, C. M., & Watson, F. R. (1966). A biostatistical study of locally recurrent breast carcinoma. Surg Gynecol Obstet., 122(3), 529-540.

Donker, M., Litière, S., Werutsky, G., Julien, J. P., Fentiman, I. S., Agresti, R., . . . Bijker, N. (2013). Breast-conserving treatment with or without radiotherapy in ductal carcinoma In Situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial. J Clin Oncol, 31(32), 4054-4059. https://doi.org/10.1200/jco.2013.49.5077

Dowsett, M., Forbes, J. F., Bradley, R., Ingle, J., Aihara, T., Bliss, J., . . . Gray, R. (2015). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet, 386(10001), 1341-1352. https://doi.org/10.1016/s0140-6736(15)61074-1

Dowsett, M., Sestak, I., Lopez-Knowles, E., Sidhu, K., Dunbier, A. K., Cowens, J. W., . . . Cuzick, J. (2013). Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol, 31(22), 2783-2790. https://doi.org/10.1200/jco.2012.46.1558

Dowsett, M., Sestak, I., Regan, M. M., Dodson, A., Viale, G., Thurlimann, B., . . . Cuzick, J. (2018). Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5. J Clin Oncol, 36(19), 1941-1948. https://doi.org/10.1200/jco.2017.76.4258

Duane, F., Aznar, M. C., Bartlett, F., Cutter, D. J., Darby, S. C., Jagsi, R., . . . Taylor, C. W. (2017). A cardiac contouring atlas for radiotherapy. Radiother Oncol, 122(3), 416-422. https://doi.org/10.1016/j.radonc.2017.01.008

Dupont, W. D., & Page, D. L. (1985). Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med., 312(3), 146-151. https://doi.org/10.1056/NEJM198501173120303

Earl, H. M., Hiller, L., Vallier, A.-L., Loi, S., Howe, D., Higgins, H. B., . . . Investigators, P. T. (2018). PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results. Journal of Clinical Oncology, 36(15 suppl), 506. https://doi.org/10.1200/JCO.2018.36.15_suppl.506

Early Breast Cancer Trialists' Collaborative Group (EBCTCG). (2005). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet, 365(9472), 1687-1717.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG). (2019). Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. Lancet, 393(10179), 1440-1452. https://doi.org/10.1016/s0140-6736(18)33137-4

Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Correa, C., McGale, P., Taylor, C., Wang, Y., Clarke, M., . . . Darby, S. (2010). Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr, 2010(41), 162-177. https://doi.org/10.1093/jncimonographs/lgq039

Early Breast Cancer Trialists’ Collaborative group (EBCTCG). (2021). Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials. The Lancet. Oncology, 22(8), 1139-1150. https://doi.org/10.1016/s1470-2045(21)00288-6

Early detection of breast cancer by surveillance. (20. november 2019). In: Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer Clinical guideline [CG164]. [nettdokument]. London: National Institute for Health and Care Excellence. Retrieved 11. mai 2020, from https://www.nice.org.uk/guidance/cg164/ifp/chapter/Early-detection-of-breast-cancer-by-surveillance

Easton, D. F., Pharoah, P. D., Antoniou, A. C., Tischkowitz, M., Tavtigian, S. V., Nathanson, K. L., . . . Foulkes, W. D. (2015). Gene-panel sequencing and the prediction of breast-cancer risk. The New England journal of medicine, 372(23), 2243-2257. https://doi.org/10.1056/NEJMsr1501341

Eggemann, H., Ignatov, A., Smith, B. J., Altmann, U., von Minckwitz, G., Röhl, F. W., . . . Costa, S. D. (2013). Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients. Breast cancer research and treatment, 137(2), 465-470. https://doi.org/10.1007/s10549-012-2355-3

Eidtmann, H., de Boer, R., Bundred, N., Llombart-Cussac, A., Davidson, N., Neven, P., . . . Coleman, R. (2010). Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol., 21(11), 2188-2194. https://doi.org/10.1093/annonc/mdq217

Eikesdal, H. P., Løes, S., & Herlofson, B. B. (2014). Tannhelse ved bruk av bisfosfonater mot brystkreft. Tidsskr Nor Legeforen, 134(15), 1451. https://doi.org/10.4045/tidsskr.14.0717

Ejlertsen, B., Tuxen, M. K., Jakobsen, E. H., Jensen, M. B., Knoop, A. S., Højris, I., . . . Mouridsen, H. T. (2017). Adjuvant Cyclophosphamide and Docetaxel With or Without Epirubicin for Early TOP2A-Normal Breast Cancer: DBCG 07-READ, an Open-Label, Phase III, Randomized Trial. J Clin Oncol, 35(23), 2639-2646. https://doi.org/10.1200/jco.2017.72.3494

Elgindy, E., Sibai, H., Abdelghani, A., & Mostafa, M. (2015). Protecting Ovaries During Chemotherapy Through Gonad Suppression: A Systematic Review and Meta-analysis. Obstet Gynecol, 126(1), 187-195. https://doi.org/10.1097/aog.0000000000000905

Elkins, G., Marcus, J., Stearns, V., & Hasan, R. M. (2007). Pilot evaluation of hypnosis for the treatment of hot flashes in breast cancer survivors. Psychooncology., 16(5), 487-492. https://doi.org/10.1002/pon.1096

Ellis, M. J., Gao, F., Dehdashti, F., Jeffe, D. B., Marcom, P. K., Carey, L. A., . . . Siegel, B. A. (2009). Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. JAMA, 302(7), 774-780. https://doi.org/10.1001/jama.2009.1204

Elshof, L. E., Schmidt, M. K., Rutgers, E. J. T., van Leeuwen, F. E., Wesseling, J., & Schaapveld, M. (2018). Cause-specific Mortality in a Population-based Cohort of 9799 Women Treated for Ductal Carcinoma In Situ. Annals of surgery, 267(5), 952-958. https://doi.org/10.1097/sla.0000000000002239

Eniu, A., Palmieri, F. M., & Perez, E. A. (2005). Weekly administration of docetaxel and paclitaxel in metastatic or advanced breast cancer. Oncologist, 10(9), 665-685. https://doi.org/10.1634/theoncologist.10-9-665

Eriksen, E. F., Moen, M. H., & Iversen, O. E. (2018). Østrogener i menopausen – på tide å endre anbefalingene? Tidsskr Nor Legeforen, 138(6). https://doi.org/10.4045/tidsskr.17.1059

Esposito, N. N. (2012). Fibroepitelial lesions. In: D. J. Dabbs (Ed.), Breast pathology (p. 239-251). Philadelphia, PA: Elsevier (Saunders). (Reprinted from: Not in File).

Esteva, F. J., Valero, V., Pusztai, L., Boehnke-Michaud, L., Buzdar, A. U., & Hortobagyi, G. N. (2001). Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond. Oncologist, 6(2), 133-146. https://doi.org/10.1634/theoncologist.6-2-133

Evans, D. G., Baildam, A. D., Anderson, E., Brain, A., Shenton, A., Vasen, H. F., . . . Howell, A. (2009). Risk reducing mastectomy: outcomes in 10 European centres. J Med Genet., 46(4), 254-258. https://doi.org/10.1136/jmg.2008.062232

Evans, D. G., Kesavan, N., Lim, Y., Gadde, S., Hurley, E., Massat, N. J., . . . Duffy, S. W. (2014). MRI breast screening in high-risk women: cancer detection and survival analysis. Breast cancer research and treatment, 145(3), 663-672. https://doi.org/10.1007/s10549-014-2931-9

Falstie-Jensen, A. M., Esen, B., Kjærsgaard, A., Lorenzen, E. L., Jensen, J. D., Reinertsen, K. V., . . . Cronin-Fenton, D. P. (2020). Incidence of hypothyroidism after treatment for breast cancer-a Danish matched cohort study. Breast Cancer Res, 22(1), 106. https://doi.org/10.1186/s13058-020-01337-z

Faneyte, I. F., Rutgers, E. J., & Zoetmulder, F. A. (1997). Chest wall resection in the treatment of locally recurrent breast carcinoma: indications and outcome for 44 patients. Cancer, 80(5), 886-891.

Farshid, G., & Buckley, E. (2019). Meta-analysis of upgrade rates in 3163 radial scars excised after needle core biopsy diagnosis. Breast cancer research and treatment, 174(1), 165-177. https://doi.org/10.1007/s10549-018-5040-3

Feliciano, Y., Mamtani, A., Morrow, M., Stempel, M. M., Patil, S., & Jochelson, M. S. (2017). Do Calcifications Seen on Mammography After Neoadjuvant Chemotherapy for Breast Cancer Always Need to Be Excised? Ann Surg Oncol, 24(6), 1492-1498. https://doi.org/10.1245/s10434-016-5741-y

Ferguson, T., Wilcken, N., Vagg, R., Ghersi, D., & Nowak, A. K. (2007). Taxanes for adjuvant treatment of early breast cancer. Cochrane Database Syst Rev, (4), CD004421. https://doi.org/10.1002/14651858.CD004421.pub2

Fertsch, S., Hagouan, M., Munder, B., Schulz, T., Abu-Ghazaleh, A., Schaberick, J., . . . Thamm, O. C. (2017). Increased risk of recurrence associated with certain risk factors in breast cancer patients after DIEP-flap reconstruction and lipofilling-a matched cohort study with 200 patients. Gland surgery, 6(4), 315-323. https://doi.org/10.21037/gs.2017.03.11

Filipits, M., Nielsen, T. O., Rudas, M., Greil, R., Stoger, H., Jakesz, R., . . . Gnant, M. (2014). The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 20(5), 1298-1305. https://doi.org/10.1158/1078-0432.ccr-13-1845

Finch, A. P., Lubinski, J., Moller, P., Singer, C. F., Karlan, B., Senter, L., . . . Narod, S. A. (2014). Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol, 32(15), 1547-1553. https://doi.org/10.1200/JCO.2013.53.2820

Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., . . . Slamon, D. J. (2015). The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. The Lancet. Oncology, 16(1), 25-35. https://doi.org/10.1016/s1470-2045(14)71159-3

Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., . . . Slamon, D. J. (2014). Abstract CT101: Final results of a randomized Phase II study of PD 0332991, a cyclin-dependent kinase (CDK)-4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1; TRIO-18). Cancer Research, 74(19 Suppl), CT101. https://doi.org/10.1158/1538-7445.AM2014-CT101

Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S. A., Gelmon, K., . . . Slamon, D. J. (2016). Palbociclib and Letrozole in Advanced Breast Cancer. The New England journal of medicine, 375(20), 1925-1936. https://doi.org/10.1056/NEJMoa1607303

Fisher, B., Anderson, S., Bryant, J., Margolese, R. G., Deutsch, M., Fisher, E. R., . . . Wolmark, N. (2002). Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med., 347(16), 1233-1241. https://doi.org/10.1056/NEJMoa022152

Fisher, B., Dignam, J., Wolmark, N., Mamounas, E., Costantino, J., Poller, W., . . . Kavanah, M. (1998). Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol, 16(2), 441-452. https://doi.org/10.1200/jco.1998.16.2.441

Fisher, B., Land, S., Mamounas, E., Dignam, J., Fisher, E. R., & Wolmark, N. (2001). Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. Semin Oncol., 28(4), 400-418. https://doi.org/10.1016/s0093-7754(01)90133-2

Fisher, B., Ravdin, R. G., Ausman, R. K., Slack, N. H., Moore, G. E., & Noer, R. J. (1968). Surgical adjuvant chemotherapy in cancer of the breast: results of a decade of cooperative investigation. Ann Surg., 168(3), 337-356. https://doi.org/10.1097/00000658-196809000-00004

Flemming, J., Madarnas, Y., & Franek, J. A. (2009). Fulvestrant for systemic therapy of locally advanced or metastatic breast cancer in postmenopausal women: a systematic review. Breast Cancer Res Treat., 115(2), 255-268. https://doi.org/10.1007/s10549-008-0137-8

Fontein, D. B., van de Water, W., Mieog, J. S., Liefers, G. J., & Van de Velde, C. J. (2013). Timing of the sentinel lymph node biopsy in breast cancer patients receiving neoadjuvant therapy - recommendations for clinical guidance. Eur J Surg Oncol., 39(5), 417-424.

Forbes, J. F., Cuzick, J., Buzdar, A., Howell, A., Tobias, J. S., & Baum, M. (2008). Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol., 9(1), 45-53.

Forskrift om prioritering av helsetjenester, rett til nødvendig helsehjelp fra spesialisthelsetjenesten, rett til behandling i utlandet og om klagenemnd (prioriteringsforskriften). FOR-2000-12-01-1208. nr. 1208.

Fountzilas, G., Athanassiades, A., Giannakakis, T., Briasoulis, E., Bafaloukos, D., Kalogera-Fountzila, A., . . . Skarlos, D. (1997). A randomized study of epirubicin monotherapy every four or every two weeks in advanced breast cancer. A Hellenic Cooperative Oncology Group study. Ann Oncol., 8(12), 1213-1220. https://doi.org/10.1023/a:1008270307264

Francis, P., Crown, J., Di, L. A., Buyse, M., Balil, A., Andersson, M., . . . Piccart-Gebhart, M. (2008). Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. J Natl Cancer Inst., 100(2), 121-133. https://doi.org/10.1093/jnci/djm287

Francis, P. A., Pagani, O., Fleming, G. F., Walley, B. A., Colleoni, M., Lang, I., . . . Regan, M. M. (2018). Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. The New England journal of medicine, 379(2), 122-137. https://doi.org/10.1056/NEJMoa1803164

Francis, P. A., Regan, M. M., Fleming, G. F., Lang, I., Ciruelos, E., Bellet, M., . . . Gelber, R. D. (2015). Adjuvant ovarian suppression in premenopausal breast cancer. The New England journal of medicine, 372(5), 436-446. https://doi.org/10.1056/NEJMoa1412379

Franzoi, M. A., Agostinetto, E., Perachino, M., Del Mastro, L., de Azambuja, E., Vaz-Luis, I., . . . Lambertini, M. (2021). Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer. The Lancet. Oncology, 22(7), e303-e313. https://doi.org/10.1016/s1470-2045(20)30666-5

Frebourg, T., Bajalica Lagercrantz, S., Oliveira, C., Magenheim, R., & Evans, D. G. (2020). Guidelines for the Li-Fraumeni and heritable TP53-related cancer syndromes. Eur J Hum Genet, 28(10), 1379-1386. https://doi.org/10.1038/s41431-020-0638-4

Frederick, M. J., Lin, A. M., Neuman, R., Smith, B. L., Austen, W. G., Jr., & Colwell, A. S. (2015). Nipple-sparing mastectomy in patients with previous breast surgery: comparative analysis of 775 immediate breast reconstructions. Plastic and reconstructive surgery, 135(6), 954e-962e. https://doi.org/10.1097/PRS.0000000000001283

Frey, J. D., Salibian, A. A., Choi, M., & Karp, N. S. (2020). Putting Together the Pieces: Development and Validation of a Risk-Assessment Model for Nipple-Sparing Mastectomy. Plastic and reconstructive surgery, 145(2), 273e-283e. https://doi.org/10.1097/PRS.0000000000006443

Fribbens, C., O'Leary, B., Kilburn, L., Hrebien, S., Garcia-Murillas, I., Beaney, M., . . . Turner, N. C. (2016). Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer. J Clin Oncol, 34(25), 2961-2968. https://doi.org/10.1200/JCO.2016.67.3061

Fritz, H., Seely, D., Flower, G., Skidmore, B., Fernandes, R., Vadeboncoeur, S., . . . Fergusson, D. (2013). Soy, red clover, and isoflavones and breast cancer: a systematic review. PLoS ONE, 8(11), e81968. https://doi.org/10.1371/journal.pone.0081968

Froud, P. J., Mates, D., Jackson, J. S., Phillips, N., Andersen, S., Jackson, S. M., . . . Olivotto, I. A. (2000). Effect of time interval between breast-conserving surgery and radiation therapy on ipsilateral breast recurrence. Int J Radiat Oncol Biol Phys., 46(2), 363-372. https://doi.org/10.1016/S0360-3016(99)00412-5

Furet, E., Peurien, D., Fournier-Bidoz, N., Servois, V., Reyal, F., Fourquet, A., . . . Kirova, Y. M. (2014). Plastic surgery for breast conservation therapy: how to define the volume of the tumor bed for the boost? European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 40(7), 830-834. https://doi.org/10.1016/j.ejso.2014.03.009

Gale, K. L., Rakha, E. A., Ball, G., Tan, V. K., McCulley, S. J., & Macmillan, R. D. (2015). A case-controlled study of the oncologic safety of fat grafting. Plastic and reconstructive surgery, 135(5), 1263-1275. https://doi.org/10.1097/PRS.0000000000001151

Galimberti, V., Botteri, E., Chifu, C., Gentilini, O., Luini, A., Intra, M., . . . Veronesi, U. (2012). Can we avoid axillary dissection in the micrometastatic sentinel node in breast cancer? Breast Cancer Res Treat., 131(3), 819-825.

Gao, J. J., Cheng, J., Prowell, T. M., Bloomquist, E., Tang, S., Wedam, S. B., . . . Amiri-Kordestani, L. (2021). Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis. The Lancet. Oncology, 22(11), 1573-1581. https://doi.org/10.1016/s1470-2045(21)00472-1

Garreffa, E., Hughes-Davies, L., Russell, S., Lightowlers, S., & Agrawal, A. (2020). Definition of Tumor Bed Boost in Oncoplastic Breast Surgery: An Understanding and Approach. Clin Breast Cancer, S1526-8209(20)30059-8 [epub ahead of print]. https://doi.org/10.1016/j.clbc.2020.03.003

Gasparini, G., Gion, M., Mariani, L., Papaldo, P., Crivellari, D., Filippelli, G., . . . Amadori, D. (2007). Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer. Breast Cancer Res Treat., 101(3), 355-365. https://doi.org/10.1007/s10549-006-9306-9

Gentile, P., Bernini, M., Orzalesi, L., Sordi, S., Meattini, I., Lessi, F., . . . Calabrese, C. (2021). Titanium-coated polypropylene mesh as innovative bioactive material in conservatives mastectomies and pre-pectoral breast reconstruction. Bioact Mater, 6(12), 4640-4653. https://doi.org/10.1016/j.bioactmat.2021.05.002

Geyer, C. E., Forster, J., Lindquist, D., Chan, S., Romieu, C. G., Pienkowski, T., . . . Cameron, D. (2006). Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med., 355(26), 2733-2743. https://doi.org/10.1056/NEJMoa064320

Ghersi, D., Wilcken, N., Simes, J., & Donoghue, E. (2005). Taxane containing regimens for metastatic breast cancer. Cochrane Database Syst Rev, (2), CD003366.

Giannakeas, V., Sopik, V., & Narod, S. A. (2020). Association of a Diagnosis of Ductal Carcinoma In Situ With Death From Breast Cancer. JAMA Netw Open, 3(9), e2017124. https://doi.org/10.1001/jamanetworkopen.2020.17124

Gianni, L., Pienkowski, T., Im, Y. H., Tseng, L. M., Liu, M. C., Lluch, A., . . . Valagussa, P. (2016). 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. The Lancet. Oncology, 17(6), 791-800. https://doi.org/10.1016/s1470-2045(16)00163-7

Gibson, L., Lawrence, D., Dawson, C., & Bliss, J. (2009). Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane Database Syst Rev, (4), CD003370. https://doi.org/10.1002/14651858.CD003370.pub3

Gilliland, M. D., Barton, R. M., & Copeland, E. M., 3rd. (1983). The implications of local recurrence of breast cancer as the first site of therapeutic failure. Ann Surg., 197(3), 284-287.

Giltnane, J. M., Hutchinson, K. E., Stricker, T. P., Formisano, L., Young, C. D., Estrada, M. V., . . . Arteaga, C. L. (2017). Genomic profiling of ER(+) breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance. Sci Transl Med, 9(402), eaai7993. https://doi.org/10.1126/scitranslmed.aai7993

Giordano, S. H., Kuo, Y. F., Freeman, J. L., Buchholz, T. A., Hortobagyi, G. N., & Goodwin, J. S. (2005). Risk of cardiac death after adjuvant radiotherapy for breast cancer. J Natl Cancer Inst., 97(6), 419-424. https://doi.org/10.1093/jnci/dji067

Giordano, S. H., Temin, S., Kirshner, J. J., Chandarlapaty, S., Crews, J. R., Davidson, N. E., . . . Winer, E. P. (2014). Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol., 32(19), 2078-2099. https://doi.org/10.1200/jco.2013.54.0948

Giuliano, A. E., Hunt, K. K., Ballman, K. V., Beitsch, P. D., Whitworth, P. W., Blumencranz, P. W., . . . Morrow, M. (2011). Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA, 305(6), 569-575.

Giuliano, A. E., McCall, L., Beitsch, P., Whitworth, P. W., Blumencranz, P., Leitch, A. M., . . . Ballman, K. (2010). Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg., 252(3), 426-432. https://doi.org/10.1097/SLA.0b013e3181f08f32

Glaser, R., & Dimitrakakis, C. (2015). Testosterone and breast cancer prevention. Maturitas, 82(3), 291-295. https://doi.org/10.1016/j.maturitas.2015.06.002

Gluz, O., Nitz, U. A., Christgen, M., Kates, R. E., Shak, S., Clemens, M., . . . Harbeck, N. (2016). West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment. J Clin Oncol, 34(20), 2341-2349. https://doi.org/10.1200/jco.2015.63.5383

Gnant, M., Dueck, A. C., Frantal, S., Martin, M., Burstein, H. J., Greil, R., . . . Mayer, E. L. (2022). Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03). J Clin Oncol, 40(3), 282-293. https://doi.org/10.1200/jco.21.02554

Gnant, M., Fitzal, F., Rinnerthaler, G., Steger, G. G., Greil-Ressler, S., Balic, M., . . . Greil, R. (2021). Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer. The New England journal of medicine, 385(5), 395-405. https://doi.org/10.1056/NEJMoa2104162

Gnant, M., Mlineritsch, B., Luschin-Ebengreuth, G., Stoeger, H., Dubsky, P., Jakesz, R., . . . Greil, R. (2011). Long-Term Follow-Up in ABCSG-12: Significantly Improved Overall Survival with Adjuvant Zoledronic Acid in Premenopausal Patients with Endocrine-Receptor-Positive Early Breast Cancer. (Abstract [S1-2] fra CTRC-AACR San Antonio breast canver symposium, 7. desember 2011). San Antonio: Cancer Therapy & Research Center at UT Health Science Center. Retrieved from http://cancerres.aacrjournals.org/content/71/24_Supplement/S1-2

Gnant, M., Mlineritsch, B., Schippinger, W., Luschin-Ebengreuth, G., Postlberger, S., Menzel, C., . . . Marth, C. (2009). Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med., 360(7), 679-691. https://doi.org/10.1056/NEJMoa0806285

Gnant, M., Mlineritsch, B., Stoeger, H., Luschin-Ebengreuth, G., Heck, D., Menzel, C., . . . Greil, R. (2011). Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol., 12(7), 631-641. https://doi.org/10.1016/S1470-2045(11)70122-X

Gnant, M., Sestak, I., Filipits, M., Dowsett, M., Balic, M., Lopez-Knowles, E., . . . Cuzick, J. (2015). Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype. Annals of oncology : official journal of the European Society for Medical Oncology, 26(8), 1685-1691. https://doi.org/10.1093/annonc/mdv215

Goetz, M. P., Knox, S. K., Suman, V. J., Rae, J. M., Safgren, S. L., Ames, M. M., . . . Ingle, J. N. (2007). The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat., 101(1), 113-121. https://doi.org/10.1007/s10549-006-9428-0

Goetz, M. P., Toi, M., Campone, M., Sohn, J., Paluch-Shimon, S., Huober, J., . . . Di Leo, A. (2017). MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol, 35(32), 3638-3646. https://doi.org/10.1200/jco.2017.75.6155

Goldgar, D. E., Healey, S., Dowty, J. G., Da Silva, L., Chen, X., Spurdle, A. B., . . . Chenevix-Trench, G. (2011). Rare variants in the ATM gene and risk of breast cancer. Breast Cancer Res, 13(4), R73. https://doi.org/10.1186/bcr2919

Goldhirsch, A., Gelber, R. D., Piccart-Gebhart, M. J., de Azambuja, E., Procter, M., Suter, T. M., . . . Baselga, J. (2013). 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet, 382(9897), 1021-1028. https://doi.org/10.1016/s0140-6736(13)61094-6

Goldhirsch, A., Glick, J. H., Gelber, R. D., Coates, A. S., Thurlimann, B., & Senn, H. J. (2005). Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol., 16(10), 1569-1583. https://doi.org/10.1093/annonc/mdi326

Goldhirsch, A., Ingle, J. N., Gelber, R. D., Coates, A. S., Thurlimann, B., & Senn, H. J. (2009). Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol., 20(8), 1319-1329. https://doi.org/10.1093/annonc/mdp322

Goldhirsch, A., Winer, E. P., Coates, A. S., Gelber, R. D., Piccart-Gebhart, M., Thurlimann, B., & Senn, H. J. (2013). Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol., 24(9), 2206-2223. https://doi.org/10.1093/annonc/mdt303

Goldhirsch, A., Wood, W. C., Coates, A. S., Gelber, R. D., Thurlimann, B., & Senn, H. J. (2011). Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol., 22(8), 1736-1747. https://doi.org/10.1093/annonc/mdr304

Goldhirsch, A., Wood, W. C., Gelber, R. D., Coates, A. S., Thurlimann, B., & Senn, H. J. (2007). Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol., 18(7), 1133-1144. https://doi.org/10.1093/annonc/mdm271

Gompel, A., Sirmoachkova, M., Lombet, A., Thevenin, D., Mimoun, M., & Poitout, P. (1997). The effect of tibolone on proliferation, differentiation and apoptosis in normal breast cells. Gynecological Endocrinology, 11(Suppl 1), 77-79.

Gonzalez, V., Sandelin, K., Karlsson, A., Aberg, W., Lofgren, L., Iliescu, G., . . . Arver, B. (2014). Preoperative MRI of the breast (POMB) influences primary treatment in breast cancer: a prospective, randomized, multicenter study. World journal of surgery, 38(7), 1685-1693. https://doi.org/10.1007/s00268-014-2605-0

Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Livingston, R. B., . . . Tu, D. (2013). Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole. Ann Oncol., 24(2), 355-361. https://doi.org/10.1093/annonc/mds330

Goss, P. E., Ingle, J. N., Pritchard, K. I., Robert, N. J., Muss, H., Gralow, J., . . . Parulekar, W. R. (2016). Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. The New England journal of medicine, 375(3), 209-219. https://doi.org/10.1056/NEJMoa1604700

Gradishar, W. J., Krasnojon, D., Cheporov, S., Makhson, A. N., Manikhas, G. M., Clawson, A., & Bhar, P. (2009). Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol., 27(22), 3611-3619. https://doi.org/10.1200/Jco.2008.18.5397

Gradishar, W. J., Tjulandin, S., Davidson, N., Shaw, H., Desai, N., Bhar, P., . . . O'Shaughnessy, J. (2005). Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol, 23(31), 7794-7803. https://doi.org/10.1200/jco.2005.04.937

Gravina, P. R., Pettit, R. W., Davis, M. J., Winocour, S. J., & Selber, J. C. (2019). Evidence for the Use of Acellular Dermal Matrix in Implant-Based Breast Reconstruction. Semin Plast Surg, 33(4), 229-235. https://doi.org/10.1055/s-0039-1696986

Gray, R., Rea, D., Handley, K., Bowden, S. J., Perry, P., Earl, H. M., . . . al., e. (2013). aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. ASCO Annual meeting, abstract.no 05.

Gregory, W., Marshall, H., Bell, R., Cameron, D. A., & Coleman, R. E. (2012). Adjuvant zoledronic acid (ZOL) in postmenopausal women with breast cancer and those rendered postmenopausal: Results of a meta-analysis. J Clin Oncol., 30(15 Supplement), 513.

Griepsma, M., de Roy van Zuidewijn, D. B., Grond, A. J., Siesling, S., Groen, H., & de Bock, G. H. (2014). Residual breast tissue after mastectomy: how often and where is it located? Ann Surg Oncol, 21(4), 1260-1266. https://doi.org/10.1245/s10434-013-3383-x

Grogan, M., Tabar, L., Chua, B., Chen, H. H., & Boyages, J. (2001). Estimating the benefits of adjuvant systemic therapy for women with early breast cancer. Br J Surg., 88(11), 1513-1518. https://doi.org/10.1046/j.0007-1323.2001.01902.x

Gundersen, S., Hannisdal, E., Lundgren, S., & Wist, E. (1994). Weekly doxorubicin with or without high-dose medroxyprogesterone acetate in hormone-resistant advanced breast cancer. A randomised study. The Norwegian Breast Cancer Group. Eur J Cancer, 30A(12), 1775-1778. https://doi.org/Doi 10.1016/0959-8049(94)00213-O

Gundersen, S., Kvinnsland, S., Klepp, O., Kvaloy, S., Lund, E., & Host, H. (1986). Weekly adriamycin versus VAC in advanced breast cancer. A randomized trial. Eur J Cancer Clin Oncol., 22(12), 1431-1434. https://doi.org/10.1016/0277-5379(86)90075-1

Gøtzsche, P. C., & Nielsen, M. (2011). Screening for breast cancer with mammography. Cochrane Database Syst Rev, (1), CD001877.

Habberstad, R., Frøseth, T. C. S., Aass, N., Bjerkeset, E., Abramova, T., Garcia-Alonso, E., . . . Klepstad, P. (2021). Clinical Predictors for Analgesic Response to Radiotherapy in Patients with Painful Bone Metastases. Journal of pain and symptom management, 62(4), 681-690. https://doi.org/10.1016/j.jpainsymman.2021.03.022

Hagen, A. I., Tretli, S., Maehle, L., Apold, J., Veda, N., & Moller, P. (2009). Survival in Norwegian BRCA1 mutation carriers with breast cancer. Hered Cancer Clin Pract., 7(1), 7. https://doi.org/10.1186/1897-4287-7-7

Halverson, K. J., Perez, C. A., Kuske, R. R., Garcia, D. M., Simpson, J. R., & Fineberg, B. (1990). Isolated local-regional recurrence of breast cancer following mastectomy: radiotherapeutic management. Int J Radiat Oncol Biol Phys., 19(4), 851-858. https://doi.org/10.1016/0360-3016(90)90004-4

Hamdi, M., Spano, A., Van Landuyt, K., D'Herde, K., Blondeel, P., & Monstrey, S. (2008). The lateral intercostal artery perforators: anatomical study and clinical application in breast surgery. Plastic and reconstructive surgery, 121(2), 389-396. https://doi.org/10.1097/01.prs.0000298317.65296.cf

Hancock, S. L., Cox, R. S., & McDougall, I. R. (1991). Thyroid diseases after treatment of Hodgkin's disease. N Engl J Med., 325(9), 599-605. https://doi.org/10.1056/NEJM199108293250902

Hannoun-Levi, J. M., Resch, A., Gal, J., Kauer-Dorner, D., Strnad, V., Niehoff, P., . . . Polgár, C. (2013). Accelerated partial breast irradiation with interstitial brachytherapy as second conservative treatment for ipsilateral breast tumour recurrence: multicentric study of the GEC-ESTRO Breast Cancer Working Group. Radiother Oncol, 108(2), 226-231. https://doi.org/10.1016/j.radonc.2013.03.026

Hanrahan, E. O., Valero, V., Gonzalez-Angulo, A. M., & Hortobagyi, G. N. (2006). Prognosis and management of patients with node-negative invasive breast carcinoma that is 1 cm or smaller in size (stage 1; T1a,bN0M0): a review of the literature. J Clin Oncol., 24(13), 2113-2122.

Harbeck, N., Rastogi, P., Martin, M., Tolaney, S. M., Shao, Z. M., Fasching, P. A., . . . O'Shaughnessy, J. (2021). Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study. Annals of oncology : official journal of the European Society for Medical Oncology, 32(12), 1571-1581. https://doi.org/10.1016/j.annonc.2021.09.015

Harris, L., Batist, G., Belt, R., Rovira, D., Navari, R., Azarnia, N., . . . Winer, E. (2002). Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer, 94(1), 25-36. https://doi.org/10.1002/cncr.10201

Harris, L. N., Ismaila, N., McShane, L. M., Andre, F., Collyar, D. E., Gonzalez-Angulo, A. M., . . . Hayes, D. F. (2016). Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol, 34(10), 1134-1150. https://doi.org/10.1200/jco.2015.65.2289

Hartmann, L. C., Sellers, T. A., Schaid, D. J., Frank, T. S., Soderberg, C. L., Sitta, D. L., . . . Jenkins, R. B. (2001). Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. Journal of the National Cancer Institute, 93(21), 1633-1637. https://doi.org/10.1093/jnci/93.21.1633

Harvey, J. A., Mahoney, M. C., Newell, M. S., Bailey, L., Barke, L. D., D'Orsi, C., . . . Haffty, B. G. (2016). ACR Appropriateness Criteria Palpable Breast Masses. Journal of the American College of Radiology : JACR, 13(11s), e31-e42. https://doi.org/10.1016/j.jacr.2016.09.022

Haviland, J. S., Owen, J. R., Dewar, J. A., Agrawal, R. K., Barrett, J., Barrett-Lee, P. J., . . . Yarnold, J. R. (2013). The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol., 14(11), 1086-1094. https://doi.org/10.1016/S1470-2045(13)70386-3

Hayes, D. F., & Rae, J. M. (2020). Pharmacogenomics and Endocrine Therapy in Breast Cancer. J Clin Oncol, 38(6), 525-528. https://doi.org/10.1200/JCO.19.03119

Hayes, D. F., Thor, A. D., Dressler, L. G., Weaver, D., Edgerton, S., Cowan, D., . . . Berry, D. A. (2007). HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med., 357(15), 1496-1506. https://doi.org/10.1056/NEJMoa071167

Haylock, B. J., Coppin, C. M., Jackson, J., Basco, V. E., & Wilson, K. S. (2000). Locoregional first recurrence after mastectomy: prospective cohort studies with and without immediate chemotherapy. Int J Radiat Oncol Biol Phys., 46(2), 355-362. https://doi.org/Doi 10.1016/S0360-3016(99)00428-9

He, W., Grassmann, F., Eriksson, M., Eliasson, E., Margolin, S., Thoren, L., . . . Czene, K. (2020). CYP2D6 Genotype Predicts Tamoxifen Discontinuation and Prognosis in Patients With Breast Cancer. J Clin Oncol, 38(6), 548-557. https://doi.org/10.1200/JCO.19.01535

Heemskerk-Gerritsen, B. A., Brekelmans, C. T., Menke-Pluymers, M. B., van Geel, A. N., Tilanus-Linthorst, M. M., Bartels, C. C., . . . Seynaeve, C. (2007). Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic. Ann Surg Oncol., 14(12), 3335-3344. https://doi.org/10.1245/s10434-007-9449-x

Heemskerk-Gerritsen, B. A., Menke-Pluijmers, M. B., Jager, A., Tilanus-Linthorst, M. M., Koppert, L. B., Obdeijn, I. M., . . . Hooning, M. J. (2013). Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy BRCA1 and BRCA2 mutation carriers: a prospective analysis. Ann Oncol., 24(8), 2029-2035. https://doi.org/10.1093/annonc/mdt134

Heemskerk-Gerritsen, B. A., Rookus, M. A., Aalfs, C. M., Ausems, M. G., Collee, J. M., Jansen, L., . . . Seynaeve, C. (2015). Improved overall survival after contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis. Int J Cancer, 136(3), 668-677. https://doi.org/10.1002/ijc.29032

Helsedirektoratet. (2016). Nasjonalt handlingsprogram med retningslinjer for gynekologisk kreft. Oslo: Helsedirektoratet. Retrieved from http://helsebiblioteket.no/retningslinjer/gynekologisk-kreft/forord

Helsten, T., Elkin, S., Arthur, E., Tomson, B. N., Carter, J., & Kurzrock, R. (2016). The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing. Clinical cancer research : an official journal of the American Association for Cancer Research, 22(1), 259-267. https://doi.org/10.1158/1078-0432.CCR-14-3212

Hennequin, C., Bossard, N., Servagi-Vernat, S., Maingon, P., Dubois, J. B., Datchary, J., . . . Romestaing, P. (2013). Ten-year survival results of a randomized trial of irradiation of internal mammary nodes after mastectomy. International journal of radiation oncology, biology, physics, 86(5), 860-866. https://doi.org/10.1016/j.ijrobp.2013.03.021

Henry, N. L., Unger, J. M., Schott, A. F., Fehrenbacher, L., Flynn, P. J., Prow, D. M., . . . Wade, J. L., 3rd. (2018). Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202. J Clin Oncol, 36(4), 326-332. https://doi.org/10.1200/jco.2017.74.6651

Hershman, D. L., Kushi, L. H., Shao, T., Buono, D., Kershenbaum, A., Tsai, W. Y., . . . Neugut, A. I. (2010). Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol, 28(27), 4120-4128. https://doi.org/10.1200/jco.2009.25.9655

Hickey, B. E., Francis, D., & Lehman, M. H. (2006). Sequencing of chemotherapy and radiation therapy for early breast cancer. Cochrane Database Syst Rev, (4), CD005212. https://doi.org/10.1002/14651858.CD005212.pub2

Hickey, M., Saunders, C., Partridge, A., Santoro, N., Joffe, H., & Stearns, V. (2008). Practical clinical guidelines for assessing and managing menopausal symptoms after breast cancer. Ann Oncol., 19(10), 1669-1680. https://doi.org/10.1093/annonc/mdn353

Hillner, B. E., Ingle, J. N., Berenson, J. R., Janjan, N. A., Albain, K. S., Lipton, A., . . . Pfister, D. G. (2000). American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel. J Clin Oncol., 18(6), 1378-1391. https://doi.org/10.1200/JCO.2000.18.6.1378

Himelstein, A. L., Qin, R., Novotny, P. J., Seisler, D. K., Khatcheressian, J. L., Roberts, J. D., & Grubbs, S. S. (2015). A randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer. J Clin Oncol., 33(15 suppl), abstract 9501.

Hoberg-Vetti, H., Bjorvatn, C., Fiane, B. E., Aas, T., Woie, K., Espelid, H., . . . Hoogerbrugge, N. (2016). BRCA1/2 testing in newly diagnosed breast and ovarian cancer patients without prior genetic counselling: the DNA-BONus study. Eur J Hum Genet, 24(6), 881-888. https://doi.org/10.1038/ejhg.2015.196

Hofvind, S., Ursin, G., Tretli, S., Sebuødegård, S., & Møller, B. (2013). Breast cancer mortality in participants of the Norwegian Breast Cancer Screening Program. Cancer, 119(17), 3106-3112. https://doi.org/10.1002/cncr.28174

Holmberg, L., Garmo, H., Granstrand, B., Ringberg, A., Arnesson, L. G., Sandelin, K., . . . Emdin, S. (2008). Absolute risk reductions for local recurrence after postoperative radiotherapy after sector resection for ductal carcinoma in situ of the breast. J Clin Oncol, 26(8), 1247-1252. https://doi.org/10.1200/jco.2007.12.7969

Holmberg, L., Iversen, O. E., Rudenstam, C. M., Hammar, M., Kumpulainen, E., Jaskiewicz, J., . . . Maenpaa, J. (2008). Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst., 100(7), 475-482. https://doi.org/10.1093/jnci/djn058

Hoogstraten, B., Gad-el-Mawla, N., Maloney, T. R., Fletcher, W. S., Vaughn, C. B., Tranum, B. L., . . . Foulkes, M. (1984). Combined modality therapy for first recurrence of breast cancer. A Southwest Oncology Group study. Cancer, 54(10), 2248-2256. https://doi.org/10.1002/1097-0142(19841115)54:10<2248::aid-cncr2820541031>3.0.co;2-d

Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y. S., Sonke, G. S., Hart, L., . . . O'Shaughnessy, J. (2021). LBA17 Overall survival (OS) results from the phase III MONALEESA-2 (ML-2) trial of postmenopausal patients (pts) with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) advanced breast cancer (ABC) treated with endocrine therapy (ET) +/- ribociclib (RIB). Annals of oncology : official journal of the European Society for Medical Oncology, 32(Suppl 5), S1290-S1291. https://doi.org/10.1016/j.annonc.2021.08.2090

Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y. S., Sonke, G. S., Paluch-Shimon, S., . . . O'Shaughnessy, J. (2016). Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. The New England journal of medicine, 375(18), 1738-1748. https://doi.org/10.1056/NEJMoa1609709

Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y. S., Sonke, G. S., Paluch-Shimon, S., . . . O'Shaughnessy, J. (2018). Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 29(7), 1541-1547. https://doi.org/10.1093/annonc/mdy155

Hortobagyi, G. N., Theriault, R. L., Porter, L., Blayney, D., Lipton, A., Sinoff, C., . . . Knight, R. D. (1996). Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med., 335(24), 1785-1791. https://doi.org/10.1056/NEJM199612123352401

Houghton, J., George, W. D., Cuzick, J., Duggan, C., Fentiman, I. S., & Spittle, M. (2003). Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet, 362(9378), 95-102. https://doi.org/10.1016/s0140-6736(03)13859-7

Houssami, N., Macaskill, P., Marinovich, M. L., Dixon, J. M., Irwig, L., Brennan, M. E., & Solin, L. J. (2010). Meta-analysis of the impact of surgical margins on local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapy. Eur J Cancer, 46(18), 3219-3232. https://doi.org/10.1016/j.ejca.2010.07.043

Houssami, N., Macaskill, P., von Minckwitz, G., Marinovich, M. L., & Mamounas, E. (2012). Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur J Cancer, 48(18), 3342-3354. https://doi.org/10.1016/j.ejca.2012.05.023

Houssami, N., Turner, R., & Morrow, M. (2013). Preoperative magnetic resonance imaging in breast cancer: meta-analysis of surgical outcomes. Annals of surgery, 257(2), 249-255. https://doi.org/10.1097/SLA.0b013e31827a8d17

Hu, C., Hart, S. N., Gnanaolivu, R., Huang, H., Lee, K. Y., Na, J., . . . Couch, F. J. (2021). A Population-Based Study of Genes Previously Implicated in Breast Cancer. The New England journal of medicine, 384(5), 440-451. https://doi.org/10.1056/NEJMoa2005936

Huang, E. H., Tucker, S. L., Strom, E. A., McNeese, M. D., Kuerer, H. M., Buzdar, A. U., . . . Buchholz, T. A. (2004). Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. J Clin Oncol., 22(23), 4691-4699. https://doi.org/10.1200/JCO.2004.11.129

Hugh, J., Hanson, J., Cheang, M. C., Nielsen, T. O., Perou, C. M., Dumontet, C., . . . Vogel, C. (2009). Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol., 27(8), 1168-1176.

Hughes, R. T., Masters, A. H., McTyre, E. R., Farris, M. K., Chung, C., Page, B. R., . . . Chan, M. D. (2019). Initial SRS for Patients With 5 to 15 Brain Metastases: Results of a Multi-Institutional Experience. International journal of radiation oncology, biology, physics, 104(5), 1091-1098. https://doi.org/10.1016/j.ijrobp.2019.03.052

Hunt, K. K., Yi, M., Mittendorf, E. A., Guerrero, C., Babiera, G. V., Bedrosian, I., . . . Meric-Bernstam, F. (2009). Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients. Ann Surg., 250(4), 558-566. https://doi.org/10.1097/SLA.0b013e3181b8fd5e

Hurvitz, S., Kim, S.-B., Chung, W.-P., Im, S.-A., Park, Y. H., Hegg, R., . . . Cortés, J. (2022). Abstract GS3-01: Trastuzumab deruxtecan (T-DXd; DS-8201a) vs. trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): subgroup analyses from the randomized phase 3 study DESTINY-Breast03. Cancer Research, 82(4 Suppl), GS3-01. https://doi.org/10.1158/1538-7445.Sabcs21-gs3-01

Højris, I., Overgaard, M., Christensen, J. J., & Overgaard, J. (1999). Morbidity and mortality of ischaemic heart disease in high-risk breast-cancer patients after adjuvant postmastectomy systemic treatment with or without radiotherapy: analysis of DBCG 82b and 82c randomised trials. Radiotherapy Committee of the Danish Breast Cancer Cooperative Group. Lancet, 354(9188), 1425-1430.

Ignatov, A., Eggemann, H., Burger, E., & Ignatov, T. (2018). Patterns of breast cancer relapse in accordance to biological subtype. J Cancer Res Clin Oncol, 144(7), 1347-1355. https://doi.org/10.1007/s00432-018-2644-2

Im, S. A., Lu, Y. S., Bardia, A., Harbeck, N., Colleoni, M., Franke, F., . . . Tripathy, D. (2019). Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. The New England journal of medicine, 381(4), 307-316. https://doi.org/10.1056/NEJMoa1903765

Independent, U. K. P. o. B. C. S. (2012). The benefits and harms of breast cancer screening: an independent review. Lancet, 380(9855), 1778-1786. https://doi.org/10.1016/S0140-6736(12)61611-0

Iodice, S., Barile, M., Rotmensz, N., Feroce, I., Bonanni, B., Radice, P., . . . Gandini, S. (2010). Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis. Eur J Cancer, 46(12), 2275-2284. https://doi.org/10.1016/j.ejca.2010.04.018

Jakesz, R., Jonat, W., Gnant, M., Mittlboeck, M., Greil, R., Tausch, C., . . . Wolfgang, J. (2005). Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet, 366(9484), 455-462. https://doi.org/10.1016/S0140-6736(05)67059-6

Jensen, A. K., Kristensen, S. G., Macklon, K. T., Jeppesen, J. V., Fedder, J., Ernst, E., & Andersen, C. Y. (2015). Outcomes of transplantations of cryopreserved ovarian tissue to 41 women in Denmark. Hum Reprod, 30(12), 2838-2845. https://doi.org/10.1093/humrep/dev230

Jereczek-Fossa, B. A., Alterio, D., Jassem, J., Gibelli, B., Tradati, N., & Orecchia, R. (2004). Radiotherapy-induced thyroid disorders. Cancer Treat Rev, 30(4), 369-384. https://doi.org/10.1016/j.ctrv.2003.12.003

Joensuu, H., Bono, P., Kataja, V., Alanko, T., Kokko, R., Asola, R., . . . Kellokumpu-Lehtinen, P. L. (2009). Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. J Clin Oncol, 27(34), 5685-5692. https://doi.org/10.1200/jco.2008.21.4577

Joensuu, H., Fraser, J., Wildiers, H., Huovinen, R., Auvinen, P., Utriainen, M., . . . Lindman, H. (2018). Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The SOLD Randomized Clinical Trial. JAMA oncology, 4(9), 1199-1206. https://doi.org/10.1001/jamaoncol.2018.1380

Joensuu, H., Kellokumpu-Lehtinen, P. L., Bono, P., Alanko, T., Kataja, V., Asola, R., . . . Isola, J. (2006). Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. The New England journal of medicine, 354(8), 809-820. https://doi.org/10.1056/NEJMoa053028

Joensuu, H., Kellokumpu-Lehtinen, P. L., Huovinen, R., Jukkola-Vuorinen, A., Tanner, M., Kokko, R., . . . Lindman, H. (2012). Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial. J Clin Oncol, 30(1), 11-18. https://doi.org/10.1200/jco.2011.35.4639

Joensuu, H., & Viikari, J. (1986). Thyroid function after postoperative radiation therapy in patients with breast cancer. Acta Radiol Oncol., 25(3), 167-170. https://doi.org/10.3109/02841868609136397

Johansen, K., Lønning, P. E., Naume, B., Norderhaug, I., Norum, J., Olsen, J. A., & Wist, E. (2006). Ny medikamentell behandling av brystkreft - adjuvant behandling med trastuzumab ved tidlig stadium av brystkreft (Rapport fra Kunnskapssenteret nr 02-2006). Oslo: Kunnskapssenteret. Retrieved from https://www.fhi.no/publ/eldre/ny-medikamentell-behandling-av-brystkreft.--adjuvant-behandling-med-trastuz/

Johansson, S., Svensson, H., & Denekamp, J. (2002). Dose response and latency for radiation-induced fibrosis, edema, and neuropathy in breast cancer patients. International journal of radiation oncology, biology, physics, 52(5), 1207-1219. https://doi.org/10.1016/s0360-3016(01)02743-2

Johnson, D. J. (2021). Discussion: MemoryGel Breast Implants: Final Safety and Efficacy Results after 10 Years of Follow-Up. Plastic and reconstructive surgery, 147(3), 567-568. https://doi.org/10.1097/PRS.0000000000007691

Johnston, S., Pippen, J., Jr., Pivot, X., Lichinitser, M., Sadeghi, S., Dieras, V., . . . Pegram, M. (2009). Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol., 27(33), 5538-5546. https://doi.org/10.1200/Jco.2009.23.3734

Johnston, S. R. D., Harbeck, N., Hegg, R., Toi, M., Martin, M., Shao, Z. M., . . . Rastogi, P. (2020). Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE). J Clin Oncol, 38(34), 3987-3998. https://doi.org/10.1200/jco.20.02514

Jones, S. E., Savin, M. A., Holmes, F. A., O'Shaughnessy, J. A., Blum, J. L., Vukelja, S., . . . Asmar, L. (2006). Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol, 24(34), 5381-5387. https://doi.org/10.1200/jco.2006.06.5391

Kaidar-Person, O., Dahn, H. M., Nichol, A. M., Boersma, L. J., de Ruysscher, D., Meattini, I., . . . Offersen, B. V. (2021). A Delphi study and International Consensus Recommendations: The use of bolus in the setting of postmastectomy radiation therapy for early breast cancer. Radiother Oncol, 164, 115-121. https://doi.org/10.1016/j.radonc.2021.09.012

Kaidar-Person, O., Oldenborg, S., & Poortmans, P. (2018). Re-irradiation and Hyperthermia in Breast Cancer. Clin Oncol (R Coll Radiol), 30(2), 73-84. https://doi.org/10.1016/j.clon.2017.11.004

Kaidar-Person, O., Vrou Offersen, B., Hol, S., Arenas, M., Aristei, C., Bourgier, C., . . . Poortmans, P. (2019). ESTRO ACROP consensus guideline for target volume delineation in the setting of postmastectomy radiation therapy after implant-based immediate reconstruction for early stage breast cancer. Radiother Oncol, 137, 159-166. https://doi.org/10.1016/j.radonc.2019.04.010

Kalinsky, K., Barlow, W. E., Gralow, J. R., Meric-Bernstam, F., Albain, K. S., Hayes, D. F., . . . Hortobagyi, G. N. (2021). 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. The New England journal of medicine, 385(25), 2336-2347. https://doi.org/10.1056/NEJMoa2108873

Kamby, C., & Sengelov, L. (1997). Pattern of dissemination and survival following isolated locoregional recurrence of breast cancer. A prospective study with more than 10 years of follow up. Breast Cancer Res Treat., 45(2), 181-192. https://doi.org/Doi 10.1023/A:1005845100512

Karlsson, P., Cole, B. F., Colleoni, M., Roncadin, M., Chua, B. H., Murray, E., . . . Gruber, G. (2011). Timing of radiotherapy and outcome in patients receiving adjuvant endocrine therapy. Int J Radiat Oncol Biol Phys., 80(2), 398-402. https://doi.org/10.1016/j.ijrobp.2010.02.042

Kaufman, B., Mackey, J. R., Clemens, M. R., Bapsy, P. P., Vaid, A., Wardley, A., . . . Jones, A. (2009). Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol., 27(33), 5529-5537. https://doi.org/10.1200/JCO.2008.20.6847

Kaufman, P. A., Awada, A., Twelves, C., Yelle, L., Perez, E. A., Velikova, G., . . . Cortes, J. (2015). Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol, 33(6), 594-601. https://doi.org/10.1200/jco.2013.52.4892

Kaufmann, M., Karn, T., & Ruckhaberle, E. (2012). Controversies concerning the use of neoadjuvant systemic therapy for primary breast cancer. World J Surg., 36(7), 1480-1485. https://doi.org/10.1007/s00268-012-1424-4

Kelly, B. N., Faulkner, H. R., Smith, B. L., Korotkin, J. E., Lanahan, C. R., Brown, C., . . . Coopey, S. B. (2022). Nipple-Sparing Mastectomy versus Skin-Sparing Mastectomy: Does Saving the Nipple Impact Short- and Long-Term Patient Satisfaction? Ann Surg Oncol, 29(2), 1033-1040. https://doi.org/10.1245/s10434-021-10767-8

Kelly, C. M., Juurlink, D. N., Gomes, T., Duong-Hua, M., Pritchard, K. I., Austin, P. C., & Paszat, L. F. (2010). Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ, 340, c693. https://doi.org/10.1136/bmj.c693

Kendall, A., Dowsett, M., Folkerd, E., & Smith, I. (2006). Caution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol., 17(4), 584-587. https://doi.org/10.1093/annonc/mdj127

Kenemans, P., Bundred, N. J., Foidart, J. M., Kubista, E., von Schoultz, B., Sismondi, P., . . . Beckmann, M. W. (2009). Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncol., 10(2), 135-146. https://doi.org/10.1016/S1470-2045(08)70341-3

Kerlikowske, K., Molinaro, A., Cha, I., Ljung, B. M., Ernster, V. L., Stewart, K., . . . Waldman, F. (2003). Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy. J Natl Cancer Inst., 95(22), 1692-1702. https://doi.org/10.1093/jnci/djg097

Khatcheressian, J. L., Wolff, A. C., Smith, T. J., Grunfeld, E., Muss, H. B., Vogel, V. G., . . . Davidson, N. E. (2006). American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol., 24(31), 5091-5097. https://doi.org/10.1200/JCO.2006.08.8575

Kim, S. B., Dent, R., Im, S. A., Espie, M., Blau, S., Tan, A. R., . . . investigators, L. (2017). Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet. Oncology, 18(10), 1360-1372. https://doi.org/10.1016/S1470-2045(17)30450-3

Kim, T., Giuliano, A. E., & Lyman, G. H. (2006). Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. Cancer, 106(1), 4-16. https://doi.org/10.1002/cncr.21568

Kisqali. (4. mai.2020). Felleskatalogen [database]. Oslo: Felleskatalogen AS. Retrieved 11. mai 2020, from https://www.felleskatalogen.no/medisin/kisqali-novartis-642779

Klintman, M., Strand, C., Ahlin, C., Beglerbegovic, S., Fjällskog, M. L., Grabau, D., . . . Ferno, M. (2013). The prognostic value of mitotic activity index (MAI), phosphohistone H3 (PPH3), cyclin B1, cyclin A, and Ki67, alone and in combinations, in node-negative premenopausal breast cancer. PLoS ONE, 8(12), e81902. https://doi.org/10.1371/journal.pone.0081902

Kollias, J., Murphy, C. A., Elston, C. W., Ellis, I. O., Robertson, J. F., & Blamey, R. W. (1999). The prognosis of small primary breast cancers. Eur J Cancer, 35(6), 908-912. https://doi.org/10.1016/s0959-8049(99)00056-8

Kopans, D. B. (2007). Breast Imaging (3. ed.). Philadelphia Lippincott Williams and Wilkins.

Koyama, H., Wada, T., Nishizawa, Y., Iwanaga, T., & Aoki, Y. (1977). Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer. Cancer, 39(4), 1403-1409. https://doi.org/10.1002/1097-0142(197704)39:4<1403::aid-cncr2820390408>3.0.co;2-8

Krastev, T., van Turnhout, A., Vriens, E., Smits, L., & van der Hulst, R. (2019). Long-term Follow-up of Autologous Fat Transfer vs Conventional Breast Reconstruction and Association With Cancer Relapse in Patients With Breast Cancer. JAMA surgery, 154(1), 56-63. https://doi.org/10.1001/jamasurg.2018.3744

Krastev, T. K., Schop, S. J., Hommes, J., Piatkowski, A. A., Heuts, E. M., & van der Hulst, R. (2018). Meta-analysis of the oncological safety of autologous fat transfer after breast cancer. The British journal of surgery, 105(9), 1082-1097. https://doi.org/10.1002/bjs.10887

Kreftregisteret. (2018). Årsrapport 2017 med resultater og forbedringstiltak fra Nasjonalt kvalitetsregister for brystkreft. Oslo: Kreftregisteret. Retrieved from https://www.kvalitetsregistre.no/sites/default/files/13_arsrapport_2017_brystkreft.pdf

Kronowitz, S. J., Mandujano, C. C., Liu, J., Kuerer, H. M., Smith, B., Garvey, P., . . . Valero, V. (2016). Lipofilling of the Breast Does Not Increase the Risk of Recurrence of Breast Cancer: A Matched Controlled Study. Plastic and reconstructive surgery, 137(2), 385-393. https://doi.org/10.1097/01.prs.0000475741.32563.50

Krop, I., Ismaila, N., Andre, F., Bast, R. C., Barlow, W., Collyar, D. E., . . . Stearns, V. (2017). Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. J Clin Oncol, 35(24), 2838-2847. https://doi.org/10.1200/jco.2017.74.0472

Krop, I. E., Kim, S. B., Gonzalez-Martin, A., LoRusso, P. M., Ferrero, J. M., Smitt, M., . . . Wildiers, H. (2014). Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. The Lancet. Oncology, 15(7), 689-699. https://doi.org/10.1016/s1470-2045(14)70178-0

Kuchenbaecker, K. B., Hopper, J. L., Barnes, D. R., Phillips, K. A., Mooij, T. M., Roos-Blom, M. J., . . . Olsson, H. (2017). Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA, 317(23), 2402-2416. https://doi.org/10.1001/jama.2017.7112

Kucuk, O. (2017). Soy foods, isoflavones, and breast cancer. Cancer, 123(11), 1901-1903. https://doi.org/10.1002/cncr.30614

Kuo, S. H., Huang, C. S., Kuo, W. H., Cheng, A. L., Chang, K. J., & Chia-Hsien, C. J. (2008). Comprehensive locoregional treatment and systemic therapy for postmastectomy isolated locoregional recurrence. Int J Radiat Oncol Biol Phys., 72(5), 1456-1464. https://doi.org/10.1016/j.ijrobp.2008.03.042

Kurata, K., Kubo, M., Kai, M., Mori, H., Kawaji, H., Kaneshiro, K., . . . Nakamura, M. (2020). Microsatellite instability in Japanese female patients with triple-negative breast cancer. Breast Cancer, 27(3), 490-498. https://doi.org/10.1007/s12282-019-01043-5

Kurian, A. W., Sigal, B. M., & Plevritis, S. K. (2010). Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers. J Clin Oncol, 28(2), 222-231. https://doi.org/10.1200/JCO.2009.22.7991

Lakhani, S. R., Schnitt, S., O'Malley, F., Van de Vijver, M. J., Simpson, P. T., & Palacios, J. (2019). Lobular neoplasia. In: WHO Classification of Tumours Editorial Board (Ed.), WHO classification of Tumours of the Breast, Volume 2 (5. ed., p. 71-74). Lyan: IARC.

Lambertini, M., Ceppi, M., Poggio, F., Peccatori, F. A., Azim, H. A., Jr., Ugolini, D., . . . Del Mastro, L. (2015). Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies. Annals of oncology : official journal of the European Society for Medical Oncology, 26(12), 2408-2419. https://doi.org/10.1093/annonc/mdv374

Landercasper, J., Attai, D., Atisha, D., Beitsch, P., Bosserman, L., Boughey, J., . . . Cody, H., 3rd. (2015). Toolbox to Reduce Lumpectomy Reoperations and Improve Cosmetic Outcome in Breast Cancer Patients: The American Society of Breast Surgeons Consensus Conference. Ann Surg Oncol, 22(10), 3174-3183. https://doi.org/10.1245/s10434-015-4759-x

Larson, K. E., Grobmyer, S. R., & Valente, S. A. (2018). Evaluation of recurrence patterns and survival in modern series of young women with breast cancer. The breast journal, 24(5), 749-754. https://doi.org/10.1111/tbj.13041

Lawenda, B. D., Mondry, T. E., & Johnstone, P. A. (2009). Lymphedema: a primer on the identification and management of a chronic condition in oncologic treatment. CA Cancer J Clin., 59(1), 8-24. https://doi.org/10.3322/caac.20001

Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., . . . Diaz, L. A., Jr. (2017). Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science, 357(6349), 409-413. https://doi.org/10.1126/science.aan6733

Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., . . . Diaz, L. A., Jr. (2015). PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. The New England journal of medicine, 372(26), 2509-2520. https://doi.org/10.1056/NEJMoa1500596

Lee, L. A., Silverstein, M. J., Chung, C. T., Macdonald, H., Sanghavi, P., Epstein, M., . . . Lagios, M. D. (2006). Breast cancer-specific mortality after invasive local recurrence in patients with ductal carcinoma-in-situ of the breast. Am J Surg., 192(4), 416-419. https://doi.org/10.1016/j.amjsurg.2006.06.005

Lee, S. H., Lee, J., Park, J., Park, S. H., Lee, K. E., Lee, S. I., . . . Im, Y. H. (2004). Capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Med Oncol., 21(3), 223-231. https://doi.org/10.1385/MO:21:3:223

Lehman, C. D., Lee, A. Y., & Lee, C. I. (2014). Imaging management of palpable breast abnormalities. AJR. American journal of roentgenology, 203(5), 1142-1153. https://doi.org/10.2214/ajr.14.12725

Leidenius, M. H., Krogerus, L. A., Toivonen, T. S., Leppanen, E. A., & von Smitten, K. A. (2006). The clinical value of parasternal sentinel node biopsy in breast cancer. Ann Surg Oncol., 13(3), 321-326. https://doi.org/10.1245/ASO.2006.02.022

Lende, T. H., Janssen, E. A., Gudlaugsson, E., Voorhorst, F., Smaaland, R., van Diest, P., . . . Baak, J. P. (2011). In patients younger than age 55 years with lymph node-negative breast cancer, proliferation by mitotic activity index is prognostically superior to adjuvant! J Clin Oncol, 29(7), 852-858. https://doi.org/10.1200/jco.2009.25.0407

Leon-Ferre, R. A., Novotny, P. J., Wolfe, E. G., Faubion, S. S., Ruddy, K. J., Flora, D., . . . Loprinzi, C. L. (2020). Oxybutynin vs Placebo for Hot Flashes in Women With or Without Breast Cancer: A Randomized, Double-Blind Clinical Trial (ACCRU SC-1603). JNCI Cancer Spectr, 4(1), pkz088. https://doi.org/10.1093/jncics/pkz088

Leve med kreft: nasjonal kreftstrategi 2018–2022. (2018). Oslo: Helse- og omsorgsdepartementet. Retrieved from https://www.regjeringen.no/contentassets/266bf1eec38940888a589ec86d79da20/regjeringens_kreftstrategi_180418.pdf

Li, J., Yu, K., Pang, D., Wang, C., Jiang, J., Yang, S., . . . Shao, Z. (2020). Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial. J Clin Oncol, 38(16), 1774-1784. https://doi.org/10.1200/jco.19.02474

Lind, P. A., Wennberg, B., Gagliardi, G., & Fornander, T. (2001). Pulmonary complications following different radiotherapy techniques for breast cancer, and the association to irradiated lung volume and dose. Breast Cancer Res Treat., 68(3), 199-210. https://doi.org/10.1023/a:1012292019599

Litiere, S., Werutsky, G., Fentiman, I. S., Rutgers, E., Christiaens, M. R., Van Limbergen, E., . . . Bartelink, H. (2012). Breast conserving therapy versus mastectomy for stage I-II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial. Lancet Oncol., 13(4), 412-419. https://doi.org/10.1016/S1470-2045(12)70042-6

Litton, J. K., Rugo, H. S., Ettl, J., Hurvitz, S. A., Gonçalves, A., Lee, K. H., . . . Blum, J. L. (2018). Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. The New England journal of medicine, 379(8), 753-763. https://doi.org/10.1056/NEJMoa1802905

Liu, Y., Malin, J. L., Diamant, A. L., Thind, A., & Maly, R. C. (2013). Adherence to adjuvant hormone therapy in low-income women with breast cancer: the role of provider-patient communication. Breast cancer research and treatment, 137(3), 829-836. https://doi.org/10.1007/s10549-012-2387-8

Lluch, A., Barrios, C. H., Torrecillas, L., Ruiz-Borrego, M., Bines, J., Segalla, J., . . . Martín, M. (2020). Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01). J Clin Oncol, 38(3), 203-213. https://doi.org/10.1200/jco.19.00904

Loesch, D., Asmar, L., McIntyre, K., Doane, L., Monticelli, M., Paul, D., . . . O'Shaughnessy, J. A. (2008). Phase II trial of gemcitabine/carboplatin (plus trastuzumab in HER2-positive disease) in patients with metastatic breast cancer. Clin Breast Cancer, 8(2), 178-186. https://doi.org/10.3816/CBC.2008.n.019

Lohrisch, C., Paltiel, C., Gelmon, K., Speers, C., Taylor, S., Barnett, J., & Olivotto, I. A. (2006). Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol., 24(30), 4888-4894. https://doi.org/10.1200/JCO.2005.01.6089

Loibl, S., Han, S. N., von Minckwitz, G., Bontenbal, M., Ring, A., Giermek, J., . . . Amant, F. (2012). Treatment of breast cancer during pregnancy: an observational study. The Lancet. Oncology, 13(9), 887-896. https://doi.org/10.1016/s1470-2045(12)70261-9

Loibl, S., Marmé, F., Martin, M., Untch, M., Bonnefoi, H., Kim, S. B., . . . von Minckwitz, G. (2021). Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial. J Clin Oncol, 39(14), 1518-1530. https://doi.org/10.1200/jco.20.03639

Loibl, S., O'Shaughnessy, J., Untch, M., Sikov, W. M., Rugo, H. S., McKee, M. D., . . . Geyer, C. E., Jr. (2018). Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. The Lancet. Oncology, 19(4), 497-509. https://doi.org/10.1016/s1470-2045(18)30111-6

Loibl, S., Schmidt, A., Gentilini, O., Kaufman, B., Kuhl, C., Denkert, C., . . . Amant, F. (2015). Breast Cancer Diagnosed During Pregnancy: Adapting Recent Advances in Breast Cancer Care for Pregnant Patients. JAMA oncology, 1(8), 1145-1153. https://doi.org/10.1001/jamaoncol.2015.2413

Loibl, S., Turner, N. C., Ro, J., Cristofanilli, M., Iwata, H., Im, S. A., . . . Dowsett, M. (2017). Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results. Oncologist, 22(9), 1028-1038. https://doi.org/10.1634/theoncologist.2017-0072

Lopez, M., Papaldo, P., Di Lauro, L., Vici, P., Carpano, S., & Conti, E. M. (1989). 5-Fluorouracil, adriamycin, cyclophosphamide (FAC) vs. 5-fluorouracil, epirubicin, cyclophosphamide (FEC) in metastatic breast cancer. Oncology, 46(1), 1-5. https://doi.org/10.1159/000226671

Loprinzi, C. L. (1994). It is now the age to define the appropriate follow-up of primary breast cancer patients. J Clin Oncol., 12(5), 881-883. https://doi.org/Doi 10.1200/Jco.1994.12.5.881

Loprinzi, C. L., Kugler, J. W., Barton, D. L., Dueck, A. C., Tschetter, L. K., Nelimark, R. A., . . . Jaslowski, A. J. (2007). Phase III trial of gabapentin alone or in conjunction with an antidepressant in the management of hot flashes in women who have inadequate control with an antidepressant alone: NCCTG N03C5. J Clin Oncol., 25(3), 308-312. https://doi.org/10.1200/Jco.2006.07.5390

Lord, S., Ghersi, D., Gattellari, M., Wortley, S., Wilcken, N., & Simes, J. (2004). Antitumour antibiotic containing regimens for metastatic breast cancer. Cochrane Database Syst Rev, (4), CD003367. https://doi.org/10.1002/14651858.CD003367.pub2

Lov om kommunale helse- og omsorgstjenester m.m. (helse- og omsorgstjenesteloven). LOV-2011-06-24-30. Last update in LOV-2021-06-18-118 fra 01.09.2021, LOV-2021-06-18-127 fra 01.07.2021.

Lov om pasient- og brukerrettigheter (pasient- og brukerrettighetsloven). LOV-1999-07-02-63.

Lu, W. L., Jansen, L., Post, W. J., Bonnema, J., Van de Velde, J. C., & De Bock, G. H. (2009). Impact on survival of early detection of isolated breast recurrences after the primary treatment for breast cancer: a meta-analysis. Breast cancer research and treatment, 114(3), 403-412. https://doi.org/10.1007/s10549-008-0023-4

Luck, H. J., & Roche, H. (2002). Weekly paclitaxel: an effective and well-tolerated treatment in patients with advanced breast cancer. Crit Rev Oncol Hematol., 44(Suppl), S15-S30. https://doi.org/10.1016/s1040-8428(02)00105-1

Ludwig, K. K., Neuner, J., Butler, A., Geurts, J. L., & Kong, A. L. (2016). Risk reduction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic review. Am J Surg, 212(4), 660-669. https://doi.org/10.1016/j.amjsurg.2016.06.010

Lyman, G. H., Giuliano, A. E., Somerfield, M. R., Benson, A. B., III, Bodurka, D. C., Burstein, H. J., . . . Winer, E. P. (2005). American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol., 23(30), 7703-7720. https://doi.org/10.1200/JCO.2005.08.001

Lænkholm, A. V., Jensen, M. B., Eriksen, J. O., Rasmussen, B. B., Knoop, A. S., Buckingham, W., . . . Ejlertsen, B. (2018). PAM50 Risk of Recurrence Score Predicts 10-Year Distant Recurrence in a Comprehensive Danish Cohort of Postmenopausal Women Allocated to 5 Years of Endocrine Therapy for Hormone Receptor-Positive Early Breast Cancer. J Clin Oncol, 36(8), 735-740. https://doi.org/10.1200/jco.2017.74.6586

Lønning, P. E., & Eikesdal, H. P. (2013). Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved. Endocrine-related cancer, 20(4), R183-201. https://doi.org/10.1530/erc-13-0099

Lønning, P. E., Taylor, P. D., Anker, G., Iddon, J., Wie, L., Jørgensen, L. M., . . . Howell, A. (2001). High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Res Treat., 67(2), 111-116. https://doi.org/10.1023/a:1010619225209

MacDonald, H. R., Silverstein, M. J., Mabry, H., Moorthy, B., Ye, W., Epstein, M. S., . . . Lagios, M. (2005). Local control in ductal carcinoma in situ treated by excision alone: incremental benefit of larger margins. Am J Surg., 190(4), 521-525. https://doi.org/10.1016/j.amjsurg.2005.06.005

Madorsky-Feldman, D., Sklair-Levy, M., Perri, T., Laitman, Y., Paluch-Shimon, S., Schmutzler, R., . . . Friedman, E. (2016). An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers. Breast cancer research and treatment, 157(2), 319-327. https://doi.org/10.1007/s10549-016-3805-0

Madsen, S. (2009). Planteøstrogener og overgangsplager hos kvinner. Tidsskr Nor Lægeforen, 129(21), 2238-2239.

Major, P., Lortholary, A., Hon, J., Abdi, E., Mills, G., Menssen, H. D., . . . Seaman, J. (2001). Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol., 19(2), 558-567. https://doi.org/Doi 10.1200/Jco.2001.19.2.558

Mamounas, E. P., Bandos, H., Lembersky, B. C., Jeong, J. H., Geyer, C. E., Jr., Rastogi, P., . . . Wolmark, N. (2019). Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. Oncology, 20(1), 88-99. https://doi.org/10.1016/s1470-2045(18)30621-1

Mamounas, E. P., Bandos, H., Lembersky, B. C., Jeong, J. H., Geyer, C. E., Rastogi, P., . . . Wolmark, N. (2020). Abstract GS4-01: Ten-year results from NRG Oncology/NSABP B-42: A randomized, double-blinded, placebo-controlled clinical trial of extended adjuvant endocrine therapy with letrozole (L) in postmenopausal women with hormone-receptor+ breast cancer (BC) who have completed previous adjuvant therapy with an aromatase inhibitor (AI). Cancer Research, 80(4 Suppl), GS4-01. https://doi.org/10.1158/1538-7445.SABCS19-GS4-01

Mann, R. M., Balleyguier, C., Baltzer, P. A., Bick, U., Colin, C., Cornford, E., . . . Sardanelli, F. (2015). Breast MRI: EUSOBI recommendations for women's information. European radiology, 25(12), 3669-3678. https://doi.org/10.1007/s00330-015-3807-z

Mann, R. M., Loo, C. E., Wobbes, T., Bult, P., Barentsz, J. O., Gilhuijs, K. G., & Boetes, C. (2010). The impact of preoperative breast MRI on the re-excision rate in invasive lobular carcinoma of the breast. Breast cancer research and treatment, 119(2), 415-422. https://doi.org/10.1007/s10549-009-0616-6

Mannu, G. S., Wang, Z., Broggio, J., Charman, J., Cheung, S., Kearins, O., . . . Darby, S. C. (2020). Invasive breast cancer and breast cancer mortality after ductal carcinoma in situ in women attending for breast screening in England, 1988-2014: population based observational cohort study. BMJ, 369, m1570. https://doi.org/10.1136/bmj.m1570

Mansell, J., Weiler-Mithoff, E., Stallard, S., Doughty, J. C., Mallon, E., & Romics, L. (2017). Oncoplastic breast conservation surgery is oncologically safe when compared to wide local excision and mastectomy. Breast, 32, 179-185. https://doi.org/10.1016/j.breast.2017.02.006

Manson, J. E., Aragaki, A. K., Rossouw, J. E., Anderson, G. L., Prentice, R. L., LaCroix, A. Z., . . . Wactawski-Wende, J. (2017). Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials. JAMA, 318(10), 927-938. https://doi.org/10.1001/jama.2017.11217

Marinovich, M. L., Houssami, N., Macaskill, P., Sardanelli, F., Irwig, L., Mamounas, E. P., . . . Ciatto, S. (2013). Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy. Journal of the National Cancer Institute, 105(5), 321-333. https://doi.org/10.1093/jnci/djs528

Marinovich, M. L., Macaskill, P., Irwig, L., Sardanelli, F., von Minckwitz, G., Mamounas, E., . . . Houssami, N. (2013). Meta-analysis of agreement between MRI and pathologic breast tumour size after neoadjuvant chemotherapy. Br J Cancer, 109(6), 1528-1536. https://doi.org/10.1038/bjc.2013.473

Marinovich, M. L., Sardanelli, F., Ciatto, S., Mamounas, E., Brennan, M., Macaskill, P., . . . Houssami, N. (2012). Early prediction of pathologic response to neoadjuvant therapy in breast cancer: systematic review of the accuracy of MRI. Breast, 21(5), 669-677. https://doi.org/10.1016/j.breast.2012.07.006

Martaindale, S., Omofoye, T. S., Teichgraeber, D. C., Hess, K. R., & Whitman, G. J. (2020). Imaging Follow-up Versus Surgical Excision for Radial Scars Identified on Tomosynthesis-Guided Core Needle Biopsy. Acad Radiol, 27(3), 389-394. https://doi.org/10.1016/j.acra.2019.05.012

Martin, M., Holmes, F. A., Ejlertsen, B., Delaloge, S., Moy, B., Iwata, H., . . . Chan, A. (2017). Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. Oncology, 18(12), 1688-1700. https://doi.org/10.1016/s1470-2045(17)30717-9

Martin, M., Pienkowski, T., Mackey, J., Pawlicki, M., Guastalla, J. P., Weaver, C., . . . Vogel, C. (2005). Adjuvant docetaxel for node-positive breast cancer. N Engl J Med., 352(22), 2302-2313. https://doi.org/10.1056/NEJMoa043681

Martín, M., Ruiz Simón, A., Ruiz Borrego, M., Ribelles, N., Rodríguez-Lescure, Á., Muñoz-Mateu, M., . . . Lluch, A. (2015). Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study. J Clin Oncol, 33(32), 3788-3795. https://doi.org/10.1200/jco.2015.61.9510

Marty, M., Cognetti, F., Maraninchi, D., Snyder, R., Mauriac, L., Tubiana-Hulin, M., . . . Extra, J. M. (2005). Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol., 23(19), 4265-4274. https://doi.org/10.1200/Jco.2005.04.173

Masannat, Y. A., Bains, S. K., Pinder, S. E., & Purushotham, A. D. (2013). Challenges in the management of pleomorphic lobular carcinoma in situ of the breast. Breast, 22(2), 194-196. https://doi.org/10.1016/j.breast.2013.01.003

Masuda, N., Lee, S. J., Ohtani, S., Im, Y. H., Lee, E. S., Yokota, I., . . . Toi, M. (2017). Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. The New England journal of medicine, 376(22), 2147-2159. https://doi.org/10.1056/NEJMoa1612645

Mateo, J., Porta, N., Bianchini, D., McGovern, U., Elliott, T., Jones, R., . . . de Bono, J. S. (2020). Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. The Lancet. Oncology, 21(1), 162-174. https://doi.org/10.1016/s1470-2045(19)30684-9

Mavaddat, N., Peock, S., Frost, D., Ellis, S., Platte, R., Fineberg, E., . . . Embrace. (2013). Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. Journal of the National Cancer Institute, 105(11), 812-822. https://doi.org/10.1093/jnci/djt095

Mayer, I. A., Zhao, F., Arteaga, C. L., Symmans, W. F., Park, B. H., Burnette, B. L., . . . Miller, K. D. (2021). Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131. J Clin Oncol, 39(23), 2539-2551. https://doi.org/10.1200/jco.21.00976

McCormack, P. M., Bains, M. S., Burt, M. E., Martini, N., Chaglassian, T., & Hidalgo, D. A. (1989). Local recurrent mammary carcinoma failing multimodality therapy. A solution. Arch Surg., 124(2), 158-161. https://doi.org/10.1001/archsurg.1989.01410020028003

McCulley, S. J., Schaverien, M. V., Tan, V. K., & Macmillan, R. D. (2015). Lateral thoracic artery perforator (LTAP) flap in partial breast reconstruction. Journal of plastic, reconstructive & aesthetic surgery : JPRAS, 68(5), 686-691. https://doi.org/10.1016/j.bjps.2015.01.008

McGale, P., Taylor, C., Correa, C., Cutter, D., Duane, F., Ewertz, M., . . . Darby, S. (2014). Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet, 383(9935), 2127-2135. https://doi.org/10.1016/s0140-6736(14)60488-8

McGuire, S. E., Gonzalez-Angulo, A. M., Huang, E. H., Tucker, S. L., Kau, S. W., Yu, T. K., . . . Buchholz, T. A. (2007). Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys., 68(4), 1004-1009. https://doi.org/10.1016/j.ijrobp.2007.01.023

McNeely, M. L., Campbell, K., Ospina, M., Rowe, B. H., Dabbs, K., Klassen, T. P., . . . Courneya, K. (2010). Exercise interventions for upper-limb dysfunction due to breast cancer treatment. Cochrane Database Syst Rev, (6), CD005211. https://doi.org/ARTN CD005211

10.1002/14651858.CD005211.pub2

McNeely, M. L., Magee, D. J., Lees, A. W., Bagnall, K. M., Haykowsky, M., & Hanson, J. (2004). The addition of manual lymph drainage to compression therapy for breast cancer related lymphedema: a randomized controlled trial. Breast Cancer Res Treat., 86(2), 95-106. https://doi.org/10.1023/B:BREA.0000032978.67677.9f

Meattini, I., Marrazzo, L., Saieva, C., Desideri, I., Scotti, V., Simontacchi, G., . . . Livi, L. (2020). Accelerated Partial-Breast Irradiation Compared With Whole-Breast Irradiation for Early Breast Cancer: Long-Term Results of the Randomized Phase III APBI-IMRT-Florence Trial. J Clin Oncol, 38(35), 4175-4183. https://doi.org/10.1200/jco.20.00650

Mehta, R. S., Barlow, W. E., Albain, K. S., Vandenberg, T. A., Dakhil, S. R., Tirumali, N. R., . . . Hortobagyi, G. N. (2019). Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer. The New England journal of medicine, 380(13), 1226-1234. https://doi.org/10.1056/NEJMoa1811714

Meijers-Heijboer, H., van, G. B., van Putten, W. L., Henzen-Logmans, S. C., Seynaeve, C., Menke-Pluymers, M. B., . . . Klijn, J. G. (2001). Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med., 345(3), 159-164. https://doi.org/10.1056/NEJM200107193450301

Mendenhall, N. P., Devine, J. W., Mendenhall, W. M., Bland, K. I., Million, R. R., & Copeland, E. M., III. (1988). Isolated local-regional recurrence following mastectomy for adenocarcinoma of the breast treated with radiation therapy alone or combined with surgery and/or chemotherapy. Radiother Oncol., 12(3), 177-185.

Menes, T. S., Tartter, P. I., Bleiweiss, I., Godbold, J. H., Estabrook, A., & Smith, S. R. (2005). The consequence of multiple re-excisions to obtain clear lumpectomy margins in breast cancer patients. Ann Surg Oncol., 12(11), 881-885. https://doi.org/10.1245/ASO.2005.03.021

Metcalfe, K., Gershman, S., Ghadirian, P., Lynch, H. T., Snyder, C., Tung, N., . . . Narod, S. A. (2014). Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. BMJ, 348, g226. https://doi.org/10.1136/bmj.g226

Metcalfe, K., Lynch, H. T., Foulkes, W. D., Tung, N., Kim-Sing, C., Olopade, O. I., . . . Narod, S. A. (2015). Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers. JAMA oncology, 1(3), 306-313. https://doi.org/10.1001/jamaoncol.2015.0658

Metcalfe, K., Lynch, H. T., Ghadirian, P., Tung, N., Olivotto, I., Warner, E., . . . Narod, S. A. (2004). Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol, 22(12), 2328-2335. https://doi.org/10.1200/JCO.2004.04.033

Mieog, J. S., van der Hage, J. A., & van de Velde, C. J. (2007). Neoadjuvant chemotherapy for operable breast cancer. The British journal of surgery, 94(10), 1189-1200. https://doi.org/10.1002/bjs.5894

Miles, D. W., Gligorov, J., Andre, F., Cameron, D., Schneeweiss, A., Barrios, C. H., . . . O'Shaughnessy, J. (2020). Primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first-line paclitaxel (PAC) +/- atezolizumab (atezo) for unresectable locally advanced/metastatic triple-negative breast cancer (mTNBC). Annals of Oncology, 31(Suppl 4), S1147-S1148. https://doi.org/10.1016/j.annonc.2020.08.2243

Mittendorf, E. A., Jeruss, J. S., Tucker, S. L., Kolli, A., Newman, L. A., Gonzalez-Angulo, A. M., . . . Hunt, K. K. (2011). Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy. J Clin Oncol, 29(15), 1956-1962. https://doi.org/10.1200/jco.2010.31.8469

Modi, S., Saura, C., Yamashita, T., Park, Y. H., Kim, S. B., Tamura, K., . . . Krop, I. (2020). Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. The New England journal of medicine, 382(7), 610-621. https://doi.org/10.1056/NEJMoa1914510

Moinfar, F., Man, Y. G., Bratthauer, G. L., Ratschek, M., & Tavassoli, F. A. (2000). Genetic abnormalities in mammary ductal intraepithelial neoplasia-flat type ("clinging ductal carcinoma in situ"): a simulator of normal mammary epithelium. Cancer, 88(9), 2072-2081. https://doi.org/Doi 10.1002/(Sici)1097-0142(20000501)88:9<2072::Aid-Cncr13>3.3.Co;2-8

Mokbel, K., & Cutuli, B. (2006). Heterogeneity of ductal carcinoma in situ and its effects on management. Lancet Oncol., 7(9), 756-765. https://doi.org/10.1016/S1470-2045(06)70861-0

Molina-Montes, E., Perez-Nevot, B., Pollan, M., Sanchez-Cantalejo, E., Espin, J., & Sanchez, M. J. (2014). Cumulative risk of second primary contralateral breast cancer in BRCA1/BRCA2 mutation carriers with a first breast cancer: A systematic review and meta-analysis. Breast, 23(6), 721-742. https://doi.org/10.1016/j.breast.2014.10.005

Moller, P., Evans, D. G., Reis, M. M., Gregory, H., Anderson, E., Maehle, L., . . . Steel, C. M. (2007). Surveillance for familial breast cancer: Differences in outcome according to BRCA mutation status. Int J Cancer, 121(5), 1017-1020. https://doi.org/10.1002/ijc.22789

Montgomery, D. A., Krupa, K., & Cooke, T. G. (2007). Follow-up in breast cancer: does routine clinical examination improve outcome? A systematic review of the literature. Br J Cancer, 97(12), 1632-1641. https://doi.org/10.1038/sj.bjc.6604065

Moore, H. C. F., Unger, J. M., Phillips, K.-A., Boyle, F., Hitre, E., Porter, D., . . . Albain, K. S. (2015). Goserelin for Ovarian Protection during Breast-Cancer Adjuvant Chemotherapy. The New England journal of medicine, 372(10), 923-932. https://doi.org/10.1056/NEJMoa1413204

Moore, K. N., Secord, A. A., Geller, M. A., Miller, D. S., Cloven, N., Fleming, G. F., . . . Monk, B. J. (2019). Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. The Lancet. Oncology, 20(5), 636-648. https://doi.org/10.1016/S1470-2045(19)30029-4

Moorman, P. G., Havrilesky, L. J., Gierisch, J. M., Coeytaux, R. R., Lowery, W. J., Peragallo Urrutia, R., . . . Myers, E. R. (2013). Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. J Clin Oncol, 31(33), 4188-4198. https://doi.org/10.1200/jco.2013.48.9021

Moran, M. S., Schnitt, S. J., Giuliano, A. E., Harris, J. R., Khan, S. A., Horton, J., . . . Morrow, M. (2014). Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. Ann Surg Oncol, 21(3), 704-716. https://doi.org/10.1245/s10434-014-3481-4

Morante, Z., Ruiz, R., De la Cruz - Ku, G., Namuche, F., Mantilla, R., Lujan, M. G., . . . Gomez, H. (2019). Abstract GS2-05: Impact of the delayed initiation of adjuvant chemotherapy in the outcomes of triple negative breast cancer. Cancer Research, 79(4 Suppl), GS2-05. https://doi.org/10.1158/1538-7445.SABCS18-GS2-05

Moravek, M. B., Confino, R., Smith, K. N., Kazer, R. R., Klock, S. C., Lawson, A. K., . . . Pavone, M. E. (2018). Long-term outcomes in cancer patients who did or did not pursue fertility preservation. Fertility and Sterility, 109(2), 349-355. https://doi.org/10.1016/j.fertnstert.2017.10.029

Morrow, M., Schnitt, S. J., & Norton, L. (2015). Current management of lesions associated with an increased risk of breast cancer. Nature reviews. Clinical oncology, 12(4), 227-238. https://doi.org/10.1038/nrclinonc.2015.8

Morrow, M., Van Zee, K. J., Solin, L. J., Houssami, N., Chavez-MacGregor, M., Harris, J. R., . . . Moran, M. S. (2016). Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma In Situ. J Clin Oncol, 34(33), 4040-4046. https://doi.org/10.1200/jco.2016.68.3573

Moschetti, I., Cinquini, M., Lambertini, M., Levaggi, A., & Liberati, A. (2016). Follow-up strategies for women treated for early breast cancer. Cochrane Database Syst Rev, 2016(5), CD001768. https://doi.org/10.1002/14651858.CD001768.pub3

Mouridsen, H., Giobbie-Hurder, A., Goldhirsch, A., Thurlimann, B., Paridaens, R., Smith, I., . . . Coates, A. S. (2009). Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med., 361(8), 766-776. https://doi.org/10.1056/NEJMoa0810818

Mulder, R. L., Hudson, M. M., Bhatia, S., Landier, W., Levitt, G., Constine, L. S., . . . Oeffinger, K. C. (2020). Updated Breast Cancer Surveillance Recommendations for Female Survivors of Childhood, Adolescent, and Young Adult Cancer From the International Guideline Harmonization Group. J Clin Oncol, 38(35), 4194-4207. https://doi.org/10.1200/jco.20.00562

Murphy, C., Anderson, P. R., Li, T., Bleicher, R. J., Sigurdson, E. R., Goldstein, L. J., . . . Freedman, G. M. (2011). Impact of the radiation boost on outcomes after breast-conserving surgery and radiation. International journal of radiation oncology, biology, physics, 81(1), 69-76. https://doi.org/10.1016/j.ijrobp.2010.04.067

Murray Brunt, A., Haviland, J. S., Wheatley, D. A., Sydenham, M. A., Alhasso, A., Bloomfield, D. J., . . . Yarnold, J. R. (2020). Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Lancet, 395(10237), 1613-1626. https://doi.org/10.1016/s0140-6736(20)30932-6

Murthy, R. K., Loi, S., Okines, A., Paplomata, E., Hamilton, E., Hurvitz, S. A., . . . Winer, E. P. (2020). Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. The New England journal of medicine, 382(7), 597-609. https://doi.org/10.1056/NEJMoa1914609

Muscolino, G., Valente, M., Lequaglie, C., & Ravasi, G. (1992). Correlation between first disease-free interval from mastectomy to second disease-free interval from chest wall resection. Eur J Surg Oncol., 18(1), 49-52.

Musolino, A., Campone, M., Neven, P., Denduluri, N., Barrios, C. H., Cortes, J., . . . Andre, F. (2017). Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2- breast cancer that had progressed during or after prior endocrine therapy. Breast Cancer Res, 19(1), 18. https://doi.org/10.1186/s13058-017-0807-8

Muss, H. B., Biganzoli, L., Sargent, D. J., & Aapro, M. (2007). Adjuvant therapy in the elderly: making the right decision. J Clin Oncol., 25(14), 1870-1875. https://doi.org/10.1200/JCO.2006.10.3457

Muss, H. B., Tu, D., Ingle, J. N., Martino, S., Robert, N. J., Pater, J. L., . . . Goss, P. E. (2008). Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17. J Clin Oncol., 26(12), 1956-1964. https://doi.org/10.1200/JCO.2007.12.6334

Myckatyn, T. M., Wagner, I. J., Mehrara, B. J., Crosby, M. A., Park, J. E., Qaqish, B. F., . . . Lee, C. N. (2017). Cancer Risk after Fat Transfer: A Multicenter Case-Cohort Study. Plastic and reconstructive surgery, 139(1), 11-18. https://doi.org/10.1097/PRS.0000000000002838

Möbus, V., Diel, I. J., Elling, D., Harbeck, N., Jackisch, C., Thomssen, C., . . . al., e. (2011). GAIN Study: A Phase III Trial To Compare ETC vs. EC-TX and Ibandronate vs. Observation in Patients with Node-Positive Primary Breast Cancer – 1st Interim Efficacy Analysis. (Abstract [S2-4] fra CTRC-AACR San Antonio breast canver symposium, 7. desember 2011). San Antonio: Cancer Therapy & Research Center at UT Health Science Center. Retrieved from http://cancerres.aacrjournals.org/content/71/24_Supplement/S2-4

Møller, P., Hagen, A. I., Apold, J., Maehle, L., Clark, N., Fiane, B., . . . Vabo, A. (2007). Genetic epidemiology of BRCA mutations--family history detects less than 50% of the mutation carriers. Eur J Cancer, 43(11), 1713-1717. https://doi.org/10.1016/j.ejca.2007.04.023

Møller, P., Stormorken, A., Holmen, M. M., Hagen, A. I., Vabø, A., & Mæhle, L. (2014). The clinical utility of genetic testing in breast cancer kindreds: a prospective study in families without a demonstrable BRCA mutation. Breast cancer research and treatment, 144(3), 607-614. https://doi.org/10.1007/s10549-014-2902-1

Møller, P., Stormorken, A., Jonsrud, C., Holmen, M. M., Hagen, A. I., Clark, N., . . . Mæhle, L. (2013). Survival of patients with BRCA1-associated breast cancer diagnosed in an MRI-based surveillance program. Breast Cancer Res Treat., 139(1), 155-161. https://doi.org/10.1007/s10549-013-2540-z

Nabholtz, J. M., Senn, H. J., Bezwoda, W. R., Melnychuk, D., Deschenes, L., Douma, J., . . . Aapro, M. (1999). Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol., 17(5), 1413-1424. https://doi.org/10.1200/JCO.1999.17.5.1413

Nagaraja, V., Edirimanne, S., & Eslick, G. D. (2016). Is Sentinel Lymph Node Biopsy Necessary in Patients Undergoing Prophylactic Mastectomy? A Systematic Review and Meta-Analysis. The breast journal, 22(2), 158-165. https://doi.org/10.1111/tbj.12549

Nasjonal strategi for kreftområdet 2006-2009. (2006). Oslo: Helse- og omsorgsdepartementet. Retrieved from https://www.regjeringen.no/globalassets/upload/hod/sykehus/kreftstrategi-2006-2009.pdf

Natori, A., Ethier, J. L., Amir, E., & Cescon, D. W. (2017). Capecitabine in early breast cancer: A meta-analysis of randomised controlled trials. Eur J Cancer, 77, 40-47. https://doi.org/10.1016/j.ejca.2017.02.024

Nayar, U., Cohen, O., Kapstad, C., Cuoco, M. S., Waks, A. G., Wander, S. A., . . . Wagle, N. (2018). Acquired HER2 mutations in ER(+) metastatic breast cancer confer resistance to estrogen receptor-directed therapies. Nat Genet, 51(2), 207-216. https://doi.org/10.1038/s41588-018-0287-5

NCCN clinical practice guidelines in oncology (NCCN Guidelines): breast cancer. Version 1.2018. (2018). Fort Washington, PA: National Comprehensive Cancer Network.

NCCN clinical practice guidelines in oncology (NCCN Guidelines): breast cancer. Version 2.2022. (2022). Fort Washington, PA: National Comprehensive Cancer Network.

NCCN Clinical Practice Guidelines in Oncology (NCCN guidelines): Genetic/Familial High-Risk assessment: breast and ovarian. Version 1.2016. (2016). Fort Washington, PA: National Coprehensive Cancer Network.

Nelson, H. D., Vesco, K. K., Haney, E., Fu, R., Nedrow, A., Miller, J., . . . Humphrey, L. (2006). Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA, 295(17), 2057-2071. https://doi.org/10.1001/jama.295.17.2057

Nelson, J. A., Allen, R. J., Jr., Polanco, T., Shamsunder, M., Patel, A. R., McCarthy, C. M., . . . Pusic, A. L. (2019). Long-term Patient-reported Outcomes Following Postmastectomy Breast Reconstruction: An 8-year Examination of 3268 Patients. Annals of surgery, 270(3), 473-483. https://doi.org/10.1097/sla.0000000000003467

Nichol, A., Narinesingh, D., Raman, S., Germain, F., Chan, E. K., Tran, E., . . . Truong, P. (2021). The Effect of Bolus on Local Control for Patients Treated With Mastectomy and Radiation Therapy. International journal of radiation oncology, biology, physics, 110(5), 1360-1369. https://doi.org/10.1016/j.ijrobp.2021.01.019

Nichols, H. B., Berrington de González, A., Lacey, J. V., Jr., Rosenberg, P. S., & Anderson, W. F. (2011). Declining incidence of contralateral breast cancer in the United States from 1975 to 2006. J Clin Oncol, 29(12), 1564-1569. https://doi.org/10.1200/jco.2010.32.7395

Nielsen, T. O., Parker, J. S., Leung, S., Voduc, D., Ebbert, M., Vickery, T., . . . Ellis, M. J. (2010). A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 16(21), 5222-5232. https://doi.org/10.1158/1078-0432.ccr-10-1282

Nieweg, O. E., & Bartelink, H. (2004). Implications of lymphatic mapping for staging and adjuvant treatment of patients with breast cancer. Eur J Cancer, 40(2), 179-181. https://doi.org/10.1016/j.ejca.2003.09.026

Nilsson, C., & Valachis, A. (2015). The role of boost and hypofractionation as adjuvant radiotherapy in patients with DCIS: a meta-analysis of observational studies. Radiother Oncol, 114(1), 50-55. https://doi.org/10.1016/j.radonc.2015.01.001

Nilsson, M. P., Hartman, L., Kristoffersson, U., Johannsson, O. T., Borg, A., Henriksson, K., . . . Loman, N. (2014). High risk of in-breast tumor recurrence after BRCA1/2-associated breast cancer. Breast cancer research and treatment, 147(3), 571-578. https://doi.org/10.1007/s10549-014-3115-3

Nitz, U., Gluz, O., Clemens, M., Malter, W., Reimer, T., Nuding, B., . . . Harbeck, N. (2019). West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer. J Clin Oncol, 37(10), 799-808. https://doi.org/10.1200/jco.18.00028

Njor, S., Nystrom, L., Moss, S., Paci, E., Broeders, M., Segnan, N., & Lynge, E. (2012). Breast cancer mortality in mammographic screening in Europe: a review of incidence-based mortality studies. J Med Screen., 19 Suppl 1, 33-41. https://doi.org/10.1258/jms.2012.012080

Norsk bryst cancer gruppe. (2011). NBCGs hehandlingsanbefalinger "Blåboka". [nettdokument]. Retrieved 13. feb. 2013

Nystrom, L., Andersson, I., Bjurstam, N., Frisell, J., Nordenskjold, B., & Rutqvist, L. E. (2002). Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet, 359(9310), 909-919. https://doi.org/10.1016/S0140-6736(02)08020-0

O'Brien, M. E., Wigler, N., Inbar, M., Rosso, R., Grischke, E., Santoro, A., . . . Tendler, C. (2004). Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol., 15(3), 440-449. https://doi.org/10.1093/annonc/mdh097

O'Shaughnessy, J., Osborne, C., Pippen, J. E., Yoffe, M., Patt, D., Rocha, C., . . . Bradley, C. (2011). Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med., 364(3), 205-214. https://doi.org/10.1056/NEJMoa1011418

O'Shaughnessy, J., Petrakova, K., Sonke, G. S., Conte, P., Arteaga, C. L., Cameron, D. A., . . . Hortobagyi, G. N. (2018). Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial. Breast cancer research and treatment, 168(1), 127-134. https://doi.org/10.1007/s10549-017-4518-8

Offersen, B., Nielsen, H. M., Jacobsen, E. H., Nielsen, M. H., Krause, M., Stenbygaard, L., . . . Overgaard, J. (2018). OC-0596: Hypo- vs normofractionated radiation of early breast cancer in the randomized DBCG HYPO trial. Radiotherapy and Oncology, 127(Suppl 1), S312. https://doi.org/10.1016/S0167-8140(18)30906-X

Offersen, B. V., Alsner, J., Nielsen, H. M., Jakobsen, E. H., Nielsen, M. H., Krause, M., . . . Overgaard, J. (2020). Hypofractionated Versus Standard Fractionated Radiotherapy in Patients With Early Breast Cancer or Ductal Carcinoma In Situ in a Randomized Phase III Trial: The DBCG HYPO Trial. J Clin Oncol, 38(31), 3615-3625. https://doi.org/10.1200/jco.20.01363

Offersen, B. V., Boersma, L. J., Kirkove, C., Hol, S., Aznar, M. C., Biete Sola, A., . . . Poortmans, P. (2015). ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer. Radiother Oncol, 114(1), 3-10. https://doi.org/10.1016/j.radonc.2014.11.030

Offersen, B. V., Boersma, L. J., Kirkove, C., Hol, S., Aznar, M. C., Sola, A. B., . . . Poortmans, P. (2016). ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer, version 1.1. Radiother Oncol, 118(1), 205-208. https://doi.org/10.1016/j.radonc.2015.12.027

Offersen, B. V., Overgaard, M., Kroman, N., & Overgaard, J. (2009). Accelerated partial breast irradiation as part of breast conserving therapy of early breast carcinoma: a systematic review. Radiother Oncol, 90(1), 1-13. https://doi.org/10.1016/j.radonc.2008.08.005

Olinger, T. A., Berlin, N. L., Qi, J., Hamill, J. B., Kim, H. M., Pusic, A. L., . . . Momoh, A. O. (2020). Outcomes of Immediate Implant-Based Mastectomy Reconstruction in Women with Previous Breast Radiotherapy. Plastic and reconstructive surgery, 145(6), 1029e-1036e. https://doi.org/10.1097/PRS.0000000000006811

Olivotto, I. A., Lesperance, M. L., Truong, P. T., Nichol, A., Berrang, T., Tyldesley, S., . . . Kennecke, H. (2009). Intervals longer than 20 weeks from breast-conserving surgery to radiation therapy are associated with inferior outcome for women with early-stage breast cancer who are not receiving chemotherapy. J Clin Oncol., 27(1), 16-23.

Orecchia, R., Veronesi, U., Maisonneuve, P., Galimberti, V. E., Lazzari, R., Veronesi, P., . . . Intra, M. (2021). Intraoperative irradiation for early breast cancer (ELIOT): long-term recurrence and survival outcomes from a single-centre, randomised, phase 3 equivalence trial. The Lancet. Oncology, 22(5), 597-608. https://doi.org/10.1016/s1470-2045(21)00080-2

Osswald, R., Boss, A., Lindenblatt, N., Vorburger, D., & Dedes, K. (2020). Does lipofilling after oncologic breast surgery increase the amount of suspicious imaging and required biopsies?-A systematic meta-analysis. The breast journal, 26(5), 847-859. https://doi.org/10.1111/tbj.13514

Ottesen, G. L., Graversen, H. P., Blichert-Toft, M., Christensen, I. J., & Andersen, J. A. (2000). Carcinoma in situ of the female breast. 10 year follow-up results of a prospective nationwide study. Breast Cancer Res Treat., 62(3), 197-210. https://doi.org/10.1023/a:1006453915590

Overgaard, M., Hansen, P. S., Overgaard, J., Rose, C., Andersson, M., Bach, F., . . . Zedeler, K. (1997). Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med., 337(14), 949-955. https://doi.org/10.1056/NEJM199710023371401

Overgaard, M., Jensen, M. B., Overgaard, J., Hansen, P. S., Rose, C., Andersson, M., . . . Mouridsen, H. T. (1999). Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet, 353(9165), 1641-1648. https://doi.org/10.1016/S0140-6736(98)09201-0

Pagani, O., Francis, P. A., Fleming, G. F., Walley, B. A., Viale, G., Colleoni, M., . . . Regan, M. M. (2020). Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT. J Clin Oncol, 38(12), 1293-1303. https://doi.org/10.1200/jco.18.01967

Pagani, O., Regan, M. M., Walley, B. A., Fleming, G. F., Colleoni, M., Lang, I., . . . Francis, P. A. (2014). Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. The New England journal of medicine, 371(2), 107-118. https://doi.org/10.1056/NEJMoa1404037

Paik, S., Tang, G., Shak, S., Kim, C., Baker, J., Kim, W., . . . Wolmark, N. (2006). Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol, 24(23), 3726-3734. https://doi.org/10.1200/jco.2005.04.7985

Palli, D., Russo, A., Saieva, C., Ciatto, S., Rosselli Del, T. M., Distante, V., & Pacini, P. (1999). Intensive vs clinical follow-up after treatment of primary breast cancer: 10-year update of a randomized trial. National Research Council Project on Breast Cancer Follow-up. JAMA, 281(17), 1586. https://doi.org/10.1001/jama.281.17.1586

Pan, H., Gray, R., Braybrooke, J., Davies, C., Taylor, C., McGale, P., . . . Hayes, D. F. (2017). 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. The New England journal of medicine, 377(19), 1836-1846. https://doi.org/10.1056/NEJMoa1701830

Pandya, K. J., Raubertas, R. F., Flynn, P. J., Hynes, H. E., Rosenbluth, R. J., Kirshner, J. J., . . . Morrow, G. R. (2000). Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology Program study. Ann Intern Med., 132(10), 788-793. https://doi.org/10.7326/0003-4819-132-10-200005160-00004

Papaldo, P., Fabi, A., Ferretti, G., Mottolese, M., Cianciulli, A. M., Di, C. B., . . . Cognetti, F. (2006). A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease. Ann Oncol., 17(4), 630-636. https://doi.org/10.1093/annonc/mdj110

Parazzini, F., Colli, E., Scatigna, M., & Tozzi, L. (1993). Treatment with tamoxifen and progestins for metastatic breast cancer in postmenopausal women: a quantitative review of published randomized clinical trials. Oncology, 50(6), 483-489. https://doi.org/10.1159/000227233

Park, Y. H., Kim, T. Y., Kim, G. M., Kang, S. Y., Park, I. H., Kim, J. H., . . . Im, S. A. (2019). Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial. The Lancet. Oncology, 20(12), 1750-1759. https://doi.org/10.1016/s1470-2045(19)30565-0

Partridge, A. H., Rumble, R. B., Carey, L. A., Come, S. E., Davidson, N. E., Di Leo, A., . . . Smith, I. E. (2014). Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol, 32(29), 3307-3329. https://doi.org/10.1200/jco.2014.56.7479

Partridge, A. H., Wang, P. S., Winer, E. P., & Avorn, J. (2003). Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol, 21(4), 602-606. https://doi.org/10.1200/jco.2003.07.071

Paterson, A. H. G., Anderson, S. J., Lembersky, B. C., Fehrenbacher, L., Falkson, C. I., King, K. M., . . . al., e. (2011). NSABP Protocol B-34: A Clinical Trial Comparing Adjuvant Clodronate vs. Placebo in Early Stage Breast Cancer Patients Receiving Systemic Chemotherapy and/or Tamoxifen or No Therapy – Final Analysis. (Abstract [S2-3] fra CTRC-AACR San Antonio breast canver symposium, 7. desember 2011). San Antonio: Cancer Therapy & Research Center at UT Health Science Center. Retrieved from http://cancerres.aacrjournals.org/content/71/24_Supplement/S2-3

Peccatori, F. A., Azim, H. A., Jr., Orecchia, R., Hoekstra, H. J., Pavlidis, N., Kesic, V., & Pentheroudakis, G. (2013). Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology : official journal of the European Society for Medical Oncology, 24 Suppl 6, vi160-170. https://doi.org/10.1093/annonc/mdt199

Peled, A. W., Irwin, C. S., Hwang, E. S., Ewing, C. A., Alvarado, M., & Esserman, L. J. (2014). Total skin-sparing mastectomy in BRCA mutation carriers. Ann Surg Oncol, 21(1), 37-41. https://doi.org/10.1245/s10434-013-3230-0

Penault-Llorca, F., Andre, F., Sagan, C., Lacroix-Triki, M., Denoux, Y., Verriele, V., . . . Roche, H. (2009). Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer. J Clin Oncol., 27(17), 2809-2815. https://doi.org/10.1200/JCO.2008.18.2808

Perez, E. A., Romond, E. H., Suman, V. J., Jeong, J. H., Sledge, G., Geyer, C. E., Jr., . . . Wolmark, N. (2014). Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol, 32(33), 3744-3752. https://doi.org/10.1200/jco.2014.55.5730

Perez, E. A., Suman, V. J., Davidson, N. E., Gralow, J. R., Kaufman, P. A., Visscher, D. W., . . . Jenkins, R. B. (2011). Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol., 29(34), 4491-4497. https://doi.org/10.1200/JCO.2011.36.7045

Peters, N. H., van Esser, S., van den Bosch, M. A., Storm, R. K., Plaisier, P. W., van Dalen, T., . . . Peeters, P. H. (2011). Preoperative MRI and surgical management in patients with nonpalpable breast cancer: the MONET - randomised controlled trial. Eur J Cancer, 47(6), 879-886. https://doi.org/10.1016/j.ejca.2010.11.035

Petit, J. Y., Botteri, E., Lohsiriwat, V., Rietjens, M., De Lorenzi, F., Garusi, C., . . . Rotmensz, N. (2012). Locoregional recurrence risk after lipofilling in breast cancer patients. Annals of oncology : official journal of the European Society for Medical Oncology, 23(3), 582-588. https://doi.org/10.1093/annonc/mdr158

Petit, J. Y., Maisonneuve, P., Rotmensz, N., Bertolini, F., & Rietjens, M. (2017). Fat Grafting after Invasive Breast Cancer: A Matched Case-Control Study. Plastic and reconstructive surgery, 139(6), 1292-1296. https://doi.org/10.1097/PRS.0000000000003339

Petit, J. Y., Rietjens, M., Botteri, E., Rotmensz, N., Bertolini, F., Curigliano, G., . . . Lohsiriwat, V. (2013). Evaluation of fat grafting safety in patients with intraepithelial neoplasia: a matched-cohort study. Annals of oncology : official journal of the European Society for Medical Oncology, 24(6), 1479-1484. https://doi.org/10.1093/annonc/mds660

Peto, R., Davies, C., Godwin, J., Gray, R., Pan, H. C., Clarke, M., . . . Pritchard, K. (2012). Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet, 379(9814), 432-444. https://doi.org/10.1016/S0140-6736(11)61625-5

Petruolo, O. A., Pilewskie, M., Patil, S., Barrio, A. V., Stempel, M., Wen, H. Y., & Morrow, M. (2017). Standard Pathologic Features Can Be Used to Identify a Subset of Estrogen Receptor-Positive, HER2 Negative Patients Likely to Benefit from Neoadjuvant Chemotherapy. Ann Surg Oncol, 24(9), 2556-2562. https://doi.org/10.1245/s10434-017-5898-z

Phi, X. A., Houssami, N., Obdeijn, I. M., Warner, E., Sardanelli, F., Leach, M. O., . . . de Bock, G. H. (2015). Magnetic resonance imaging improves breast screening sensitivity in BRCA mutation carriers age >/= 50 years: evidence from an individual patient data meta-analysis. J Clin Oncol, 33(4), 349-356. https://doi.org/10.1200/JCO.2014.56.6232

Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., . . . Gelber, R. D. (2005). Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med., 353(16), 1659-1672. https://doi.org/10.1056/NEJMoa052306

Piccart, M., Hortobagyi, G. N., Campone, M., Pritchard, K. I., Lebrun, F., Ito, Y., . . . Baselga, J. (2014). Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2dagger. Annals of oncology : official journal of the European Society for Medical Oncology, 25(12), 2357-2362. https://doi.org/10.1093/annonc/mdu456

Piccart, M., Procter, M., Fumagalli, D., de Azambuja, E., Clark, E., Ewer, M. S., . . . Thomssen, C. (2020). Abstract GS1-04: Interim overall survival analysis of APHINITY (BIG 4-11): A randomized multicenter, double-blind, placebo-controlled trial comparing chemotherapy plus trastuzumab plus pertuzumab versus chemotherapy plus trastuzumab plus placebo as adjuvant therapy in patients with operable HER2-positive early breast cancer. Cancer Research, 80(4 Suppl), GS1-04. https://doi.org/10.1158/1538-7445.SABCS19-GS1-04

Piccart, M., van 't Veer, L. J., Poncet, C., Lopes Cardozo, J. M. N., Delaloge, S., Pierga, J. Y., . . . Rutgers, E. J. T. (2021). 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. The Lancet. Oncology, 22(4), 476-488. https://doi.org/10.1016/s1470-2045(21)00007-3

Piccart, M. J., de Valeriola, D., Dal Lago, L., de Azambuja, E., Demonty, G., Lebrun, F., . . . Cufer, T. (2005). Adjuvant chemotherapy in 2005: standards and beyond. Breast, 14(6), 439-445. https://doi.org/10.1016/j.breast.2005.08.004

Piper, M., Peled, A. W., Sbitany, H., Foster, R. D., Esserman, L. J., & Price, E. R. (2016). Comparison of Mammographic Findings Following Oncoplastic Mammoplasty and Lumpectomy Without Reconstruction. Ann Surg Oncol, 23(1), 65-71. https://doi.org/10.1245/s10434-015-4611-3

Pivot, X., Romieu, G., Debled, M., Pierga, J. Y., Kerbrat, P., Bachelot, T., . . . Kramar, A. (2013). 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. The Lancet. Oncology, 14(8), 741-748. https://doi.org/10.1016/s1470-2045(13)70225-0

Poggio, F., Bruzzone, M., Ceppi, M., Ponde, N. F., La Valle, G., Del Mastro, L., . . . Lambertini, M. (2018). Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis. Annals of oncology : official journal of the European Society for Medical Oncology, 29(7), 1497-1508. https://doi.org/10.1093/annonc/mdy127

Poortmans, P. M., Collette, S., Kirkove, C., Van Limbergen, E., Budach, V., Struikmans, H., . . . Van den Bogaert, W. (2015). Internal Mammary and Medial Supraclavicular Irradiation in Breast Cancer. The New England journal of medicine, 373(4), 317-327. https://doi.org/10.1056/NEJMoa1415369

Potter, S., Conroy, E. J., Cutress, R. I., Williamson, P. R., Whisker, L., Thrush, S., . . . Holcombe, C. (2019). Short-term safety outcomes of mastectomy and immediate implant-based breast reconstruction with and without mesh (iBRA): a multicentre, prospective cohort study. The Lancet. Oncology, 20(2), 254-266. https://doi.org/10.1016/s1470-2045(18)30781-2

Prat, A., Saura, C., Pascual, T., Hernando, C., Muñoz, M., Paré, L., . . . Gavilá, J. (2020). Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial. The Lancet. Oncology, 21(1), 33-43. https://doi.org/10.1016/s1470-2045(19)30786-7

Pronzato, P., Campora, E., Amoroso, D., Bertelli, G., Botto, F., Conte, P. F., . . . Rosso, R. (1989). Impact of administration-related factors on outcome of adjuvant chemotherapy for primary breast cancer. Am J Clin Oncol., 12(6), 481-485. https://doi.org/10.1097/00000421-198912000-00004

Quiet, C. A., Ferguson, D. J., Weichselbaum, R. R., & Hellman, S. (1995). Natural history of node-negative breast cancer: a study of 826 patients with long-term follow-up. J Clin Oncol., 13(5), 1144-1151. https://doi.org/10.1200/JCO.1995.13.5.1144

Radovanovic, Z., Ranisavljevic, M., Radovanovic, D., Vicko, F., Ivkovic-Kapicl, T., & Solajic, N. (2018). Nipple-Sparing Mastectomy with Primary Implant Reconstruction: Surgical and Oncological Outcome of 435 Breast Cancer Patients. Breast Care (Basel), 13(5), 373-378. https://doi.org/10.1159/000489317

Ragaz, J., Jackson, S. M., Le, N., Plenderleith, I. H., Spinelli, J. J., Basco, V. E., . . . Olivotto, I. A. (1997). Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med., 337(14), 956-962. https://doi.org/10.1056/NEJM199710023371402

Ragaz, J., Olivotto, I. A., Spinelli, J. J., Phillips, N., Jackson, S. M., Wilson, K. S., . . . Manji, M. (2005). Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst., 97(2), 116-126. https://doi.org/10.1093/jnci/djh297

Rageth, C. J., O'Flynn, E. A. M., Pinker, K., Kubik-Huch, R. A., Mundinger, A., Decker, T., . . . Varga, Z. (2019). Second International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions). Breast cancer research and treatment, 174(2), 279-296. https://doi.org/10.1007/s10549-018-05071-1

Rakha, E. A., Pinder, S. E., Bartlett, J. M., Ibrahim, M., Starczynski, J., Carder, P. J., . . . Ellis, I. O. (2015). Updated UK Recommendations for HER2 assessment in breast cancer. Journal of clinical pathology, 68(2), 93-99. https://doi.org/10.1136/jclinpath-2014-202571

Rakovitch, E., Nofech-Mozes, S., Narod, S. A., Hanna, W., Thiruchelvam, D., Saskin, R., . . . Paszat, L. (2013). Can we select individuals with low risk ductal carcinoma in situ (DCIS)? A population-based outcomes analysis. Breast Cancer Res Treat., 138(2), 581-590. https://doi.org/10.1007/s10549-013-2455-8

Ramakrishna, N., Temin, S., Chandarlapaty, S., Crews, J. R., Davidson, N. E., Esteva, F. J., . . . Lin, N. U. (2018). Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update. J Clin Oncol, 36(27), 2804-2807. https://doi.org/10.1200/jco.2018.79.2713

Rastogi, P., Anderson, S. J., Bear, H. D., Geyer, C. E., Kahlenberg, M. S., Robidoux, A., . . . Wolmark, N. (2008). Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol., 26(5), 778-785. https://doi.org/10.1200/JCO.2007.15.0235

Razavi, P., Chang, M. T., Xu, G., Bandlamudi, C., Ross, D. S., Vasan, N., . . . Baselga, J. (2018). The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. Cancer Cell, 34(3), 427-438 e426. https://doi.org/10.1016/j.ccell.2018.08.008

Rebbeck, T. R., Friebel, T., Lynch, H. T., Neuhausen, S. L., van, t., V, Garber, J. E., . . . Weber, B. L. (2004). Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol., 22(6), 1055-1062. https://doi.org/10.1200/JCO.2004.04.188

Rebbeck, T. R., Kauff, N. D., & Domchek, S. M. (2009). Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. Journal of the National Cancer Institute, 101(2), 80-87. https://doi.org/10.1093/jnci/djn442

Recht, A., Comen, E. A., Fine, R. E., Fleming, G. F., Hardenbergh, P. H., Ho, A. Y., . . . Edge, S. B. (2016). Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update. Practical radiation oncology, 6(6), e219-e234. https://doi.org/10.1016/j.prro.2016.08.009

Recht, A., Edge, S. B., Solin, L. J., Robinson, D. S., Estabrook, A., Fine, R. E., . . . Pfister, D. G. (2001). Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol., 19(5), 1539-1569. https://doi.org/10.1200/JCO.2001.19.5.1539

Reed, W., Hannisdal, E., Boehler, P. J., Gundersen, S., Host, H., & Marthin, J. (2000). The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years. Cancer, 88(4), 804-813. https://doi.org/Doi 10.1002/(Sici)1097-0142(20000215)88:4<804::Aid-Cncr11>3.0.Co;2-Y

Refusjonsrapport: denosumab (Xgenva) til forebygging av skjelett-realterte hendelser hos voksne med benmetastaser fra solide tumorer: vurdering av søknad om forhåndsgodkjent refusjon §2. (2012). Oslo: Statens legemiddelverk. Retrieved from https://legemiddelverket.no/Documents/Offentlig%20finansiering%20og%20pris/Metodevurderinger/X/Xgeva_forebygging%20av%20SRE%20ved%20benmetastaser_2012.pdf

Regan, M. M., Neven, P., Giobbie-Hurder, A., Goldhirsch, A., Ejlertsen, B., Mauriac, L., . . . Thurlimann, B. (2011). Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up. Lancet Oncol., 12(12), 1101-1108. https://doi.org/10.1016/S1470-2045(11)70270-4

Regan, M. M., Pagani, O., Francis, P. A., Fleming, G. F., Walley, B. A., Kammler, R., . . . Viale, G. (2015). Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials. Breast cancer research and treatment, 154(2), 275-286. https://doi.org/10.1007/s10549-015-3612-z

Reinertsen, K. V., Cvancarova, M., Wist, E., Bjøro, T., Dahl, A. A., Danielsen, T., & Fossa, S. D. (2009). Thyroid function in women after multimodal treatment for breast cancer stage II/III: comparison with controls from a population sample. Int J Radiat Oncol Biol Phys., 75(3), 764-770. https://doi.org/10.1016/j.ijrobp.2008.11.037

Research based evaluation of the Norwegian Breast Cancer Screening Program: final report. (2015). Oslo: Research Council of Norway. Retrieved from https://www.regjeringen.no/contentassets/444d08daf15e48aca5321f2cefaac511/mammografirapport-til-web.pdf

Rigakos, G., & Razis, E. (2012). BRCAness: finding the Achilles heel in ovarian cancer. Oncologist, 17(7), 956-962. https://doi.org/10.1634/theoncologist.2012-0028

Rimawi, M., Ferrero, J. M., de la Haba-Rodriguez, J., Poole, C., De Placido, S., Osborne, C. K., . . . Arpino, G. (2018). First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial. J Clin Oncol, 36(28), 2826-2835. https://doi.org/10.1200/jco.2017.76.7863

Robert, N. J., Vogel, C. L., Henderson, I. C., Sparano, J. A., Moore, M. R., Silverman, P., . . . Gabizon, A. A. (2004). The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer. Semin Oncol., 31(6 Suppl 13), 106-146. https://doi.org/10.1053/j.seminoncol.2004.09.018

Robertson, J. F. R., Bondarenko, I. M., Trishkina, E., Dvorkin, M., Panasci, L., Manikhas, A., . . . Ellis, M. J. (2016). Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet, 388(10063), 2997-3005. https://doi.org/10.1016/s0140-6736(16)32389-3

Robertson, S. A., Rusby, J. E., & Cutress, R. I. (2014). Determinants of optimal mastectomy skin flap thickness. The British journal of surgery, 101(8), 899-911. https://doi.org/10.1002/bjs.9470

Robson, M., Im, S. A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., . . . Conte, P. (2017). Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. The New England journal of medicine, 377(6), 523-533. https://doi.org/10.1056/NEJMoa1706450

Robson, M. E., Tung, N., Conte, P., Im, S. A., Senkus, E., Xu, B., . . . Domchek, S. M. (2019). OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 30(4), 558-566. https://doi.org/10.1093/annonc/mdz012

Rojas, M. P., Telaro, E., Russo, A., Moschetti, I., Coe, L., Fossati, R., . . . Liberati, A. (2005). Follow-up strategies for women treated for early breast cancer. Cochrane Database Syst Rev, (1), CD001768. https://doi.org/10.1002/14651858.CD001768.pub2

Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Jr., Davidson, N. E., . . . Wolmark, N. (2005). Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med., 353(16), 1673-1684. https://doi.org/10.1056/NEJMoa052122

Rosen, L. S., Gordon, D., Kaminski, M., Howell, A., Belch, A., Mackey, J., . . . Ambros, Y. (2001). Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J, 7(5), 377-387.

Rosen, L. S., Gordon, D., Kaminski, M., Howell, A., Belch, A., Mackey, J., . . . Seaman, J. J. (2003). Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer, 98(8), 1735-1744. https://doi.org/10.1002/cncr.11701

Rosen, P. P., Groshen, S., Saigo, P. E., Kinne, D. W., & Hellman, S. (1989). Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with median follow-up of 18 years. J Clin Oncol, 7(9), 1239-1251. https://doi.org/10.1200/jco.1989.7.9.1239

Rosen, P. R., Groshen, S., Saigo, P. E., Kinne, D. W., & Hellman, S. (1989). A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma. J Clin Oncol, 7(3), 355-366. https://doi.org/10.1200/jco.1989.7.3.355

Rossouw, J. E., Anderson, G. L., Prentice, R. L., LaCroix, A. Z., Kooperberg, C., Stefanick, M. L., . . . Ockene, J. (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA, 288(3), 321-333. https://doi.org/10.1001/jama.288.3.321

Rubino, C., Arriagada, R., Delaloge, S., & Lê, M. G. (2010). Relation of risk of contralateral breast cancer to the interval since the first primary tumour. Br J Cancer, 102(1), 213-219. https://doi.org/10.1038/sj.bjc.6605434

Rugo, H. S., Barry, W. T., Moreno-Aspitia, A., Lyss, A. P., Cirrincione, C., Leung, E., . . . Winer, E. P. (2015). Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance). J Clin Oncol, 33(21), 2361-2369. https://doi.org/10.1200/jco.2014.59.5298

Rugo, H. S., Finn, R. S., Diéras, V., Ettl, J., Lipatov, O., Joy, A. A., . . . Slamon, D. J. (2019). Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. Breast cancer research and treatment, 174(3), 719-729. https://doi.org/10.1007/s10549-018-05125-4

Rugo, H. S., Lerebours, F., Ciruelos, E., Drullinsky, P., Borrego, M. R., Neven, P., . . . Chia, S. K. L. (2020). Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with PIK3CA-mutated (mut) hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDKi) + aromatase inhibitor (AI): BYLieve study results. Journal of Clinical Oncology, 38(15_suppl), 1006. https://doi.org/10.1200/JCO.2020.38.15_suppl.1006

Ruhstaller, T., Giobbie-Hurder, A., Colleoni, M., Jensen, M. B., Ejlertsen, B., de Azambuja, E., . . . Regan, M. M. (2019). Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial. J Clin Oncol, 37(2), 105-114. https://doi.org/10.1200/jco.18.00440

Rusby, J. E., Paramanathan, N., Laws, S. A., & Rainsbury, R. M. (2008). Immediate latissimus dorsi miniflap volume replacement for partial mastectomy: use of intra-operative frozen sections to confirm negative margins. Am J Surg, 196(4), 512-518. https://doi.org/10.1016/j.amjsurg.2008.06.026

Ryberg, M., Nielsen, D., Cortese, G., Nielsen, G., Skovsgaard, T., & Andersen, P. K. (2008). New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients. J Natl Cancer Inst., 100(15), 1058-1067. https://doi.org/10.1093/jnci/djn206

Sabate, J. M., Clotet, M., Torrubia, S., Gomez, A., Guerrero, R., de las Heras, P., & Lerma, E. (2007). Radiologic evaluation of breast disorders related to pregnancy and lactation. Radiographics, 27 Suppl 1, S101-124. https://doi.org/10.1148/rg.27si075505

Safra, T., Muggia, F., Jeffers, S., Tsao-Wei, D. D., Groshen, S., Lyass, O., . . . Gabizon, A. (2000). Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann Oncol., 11(8), 1029-1033. https://doi.org/10.1023/a:1008365716693

Safran, T., Al-Halabi, B., Viezel-Mathieu, A., Boileau, J. F., & Dionisopoulos, T. (2021). Skin-Reducing Mastectomy with Immediate Prepectoral Reconstruction: Surgical, Aesthetic, and Patient-Reported Outcomes with and without Dermal Matrices. Plastic and reconstructive surgery, 147(5), 1046-1057. https://doi.org/10.1097/PRS.0000000000007899

Sagen, A., Kåresen, R., & Risberg, M. A. (2009). Influence of physical activity on the development on arm lymphedema after breast cancer surgery. A prospective randomized controlled trial with two years follow-up. Acta Oncol, 48(4), 1102-1110.

Sakakibara, M., Nagashima, T., Sangai, T., Nakamura, R., Fujimoto, H., Arai, M., . . . Miyazaki, M. (2008). Breast-conserving surgery using projection and reproduction techniques of surgical-position breast MRI in patients with ductal carcinoma in situ of the breast. Journal of the American College of Surgeons, 207(1), 62-68. https://doi.org/10.1016/j.jamcollsurg.2007.12.034

Salibian, A. A., Bekisz, J. M., Kussie, H. C., Thanik, V. D., Levine, J. P., Choi, M., & Karp, N. S. (2021). Do We Need Support in Prepectoral Breast Reconstruction? Comparing Outcomes with and without ADM. Plastic and reconstructive surgery. Global open, 9(8), e3745. https://doi.org/10.1097/GOX.0000000000003745

Salibian, A. A., Frey, J. D., Bekisz, J. M., Karp, N. S., & Choi, M. (2019). Ischemic Complications after Nipple-sparing Mastectomy: Predictors of Reconstructive Failure in Implant-based Reconstruction and Implications for Decision-making. Plastic and reconstructive surgery. Global open, 7(5), e2280. https://doi.org/10.1097/GOX.0000000000002280

Salibian, A. A., Frey, J. D., Karp, N. S., & Choi, M. (2019). Does Staged Breast Reduction before Nipple-Sparing Mastectomy Decrease Complications? A Matched Cohort Study between Staged and Nonstaged Techniques. Plastic and reconstructive surgery, 144(5), 1023-1032. https://doi.org/10.1097/PRS.0000000000006121

Salvadori, B., Rovini, D., Squicciarini, P., Conti, R., Cusumano, F., & Grassi, M. (1992). Surgery for local recurrences following deficient radical mastectomy for breast cancer: a selected series of 39 cases. Eur J Surg Oncol., 18(5), 438-441.

Sammen – mot kreft: nasjonal kreftstrategi 2013–2017. (2013). Oslo: Helse- og omsorgsdepartementet.

Samuel, J. A., Wilson, J. W., Bandos, H., Ellede, R. M., Robidoux, A., Fehrenbacher, L., . . . Brufsky, A. M. (2014). NSABP B-36: A randomized phase III trial comparing six cycles of 5-fluorouracil (5-FU), epirubicin, and cyclophosphamide (FEC) to four cycles of adriamycin and cyclophosphamide (AC) in patients (pts) with node-negative breast cancer. at The 2014 San Antonio Breast Cancer Symposium, Abstrakt nummer S3-02. Hentet fra https://www.sabcs.org/Portals/SABCS/Documents/2014SABCSCall4Abstracts.pdf

Sardanelli, F., Boetes, C., Borisch, B., Decker, T., Federico, M., Gilbert, F. J., . . . Wilson, R. (2010). Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group. Eur J Cancer, 46(8), 1296-1316. https://doi.org/10.1016/j.ejca.2010.02.015

Saura, C., Oliveira, M., Feng, Y. H., Dai, M. S., Chen, S. W., Hurvitz, S. A., . . . Investigators, N. (2020). Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With >/= 2 HER2-Directed Regimens: Phase III NALA Trial. J Clin Oncol, 38(27), 3138-3149. https://doi.org/10.1200/JCO.20.00147

Scaltriti, M., Rojo, F., Ocana, A., Anido, J., Guzman, M., Cortes, J., . . . Baselga, J. (2007). Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. Journal of the National Cancer Institute, 99(8), 628-638. https://doi.org/99/8/628 [pii]

10.1093/jnci/djk134

Schaverien, M. V., Stallard, S., Dodwell, D., & Doughty, J. C. (2013). Use of boost radiotherapy in oncoplastic breast-conserving surgery - a systematic review. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 39(11), 1179-1185. https://doi.org/10.1016/j.ejso.2013.07.240

Schettini, F., Giudici, F., Giuliano, M., Cristofanilli, M., Arpino, G., Del Mastro, L., . . . Generali, D. (2020). Overall Survival of CDK4/6-Inhibitor-Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis. Journal of the National Cancer Institute, 112(11), 1089-1097. https://doi.org/10.1093/jnci/djaa071

Schmid, P., Abraham, J., Chan, S., Wheatley, D., Brunt, A. M., Nemsadze, G., . . . Turner, N. C. (2020). Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial. J Clin Oncol, 38(5), 423-433. https://doi.org/10.1200/JCO.19.00368

Schmid, P., Rugo, H. S., Adams, S., Schneeweiss, A., Barrios, C. H., Iwata, H., . . . Emens, L. A. (2020). Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. Oncology, 21(1), 44-59. https://doi.org/10.1016/s1470-2045(19)30689-8

Schmid, P., Zaiss, M., Harper-Wynne, C., Ferreira, M., Dubey, S., Chan, S., . . . Cortés, J. (2019). Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor-Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial. JAMA oncology, 5(11), 1556-1563. https://doi.org/10.1001/jamaoncol.2019.2526

Schmitz, K. H., Courneya, K. S., Matthews, C., Demark-Wahnefried, W., Galvao, D. A., Pinto, B. M., . . . Schwartz, A. L. (2010). American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. Med Sci Sports Exerc., 42(7), 1409-1426. https://doi.org/10.1249/MSS.0b013e3181e0c112

Schnitt, S., Collins, L. C., Lakhani, S. R., & Simpson, P. (2019). Flat epithelial atypi. In: WHO Classification of Tumours Editorial Board (Ed.), WHO classification of tumours of the Breast, Volume 2 (5 ed., p. 15-17). Lyon: IARC Press. (Reprinted from: In File).

Schnitt, S. J., & Collins, L. C. (2005). Columnar Cell Lesions and Flat Epithelial Atypia of the Breast. Seminars in Breast Disease, 8(2), 100-111. https://doi.org/10.1053/j.sembd.2006.06.007

Schnitt, S. J., & Vincent-Salomon, A. (2003). Columnar cell lesions of the breast. Adv Anat Pathol., 10(3), 113-124. https://doi.org/10.1097/00125480-200305000-00001

Schou Bredal, I., Smeby, N. A., Ottesen, S., Warncke, T., & Schlichting, E. (2014). Chronic pain in breast cancer survivors: comparison of psychosocial, surgical, and medical characteristics between survivors with and without pain. Journal of pain and symptom management, 48(5), 852-862. https://doi.org/10.1016/j.jpainsymman.2013.12.239

Schouten van der Velden, A. P., Peeters, P. H., Koot, V. C., & Hennipman, A. (2006). Local recurrences after conservative treatment of ductal carcinoma-in-situ of the breast without radiotherapy: the effect of age. Ann Surg Oncol, 13(7), 990-998.

Schroth, W., Goetz, M. P., Hamann, U., Fasching, P. A., Schmidt, M., Winter, S., . . . Brauch, H. (2009). Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA, 302(13), 1429-1436. https://doi.org/DOI 10.1001/jama.2009.1420

Schuck, A., Konemann, S., Heinen, K., Rube, C. E., Hesselmann, S., Reinartz, G., . . . Willich, N. (2002). Microscopic residual disease is a risk factor in the primary treatment of breast cancer. Strahlenther Onkol., 178(6), 307-313. https://doi.org/10.1007/s00066-002-0950-7

Schwaibold, F., Fowble, B. L., Solin, L. J., Schultz, D. J., & Goodman, R. L. (1991). The results of radiation therapy for isolated local regional recurrence after mastectomy. Int J Radiat Oncol Biol Phys., 21(2), 299-310. https://doi.org/10.1016/0360-3016(91)90775-y

Schwartz, G. F., Solin, L. J., Olivotto, I. A., Ernster, V. L., & Pressman, P. I. (2000). Consensus Conference on the Treatment of In Situ Ductal Carcinoma of the Breast, April 22-25, 1999. Cancer, 88(4), 946-954.

Schwartz, J. D. (2019). Toward a More Definitive Goldilocks Mastectomy: Simultaneous Addition of the Lateral Intercostal Perforator Flap. Plastic and reconstructive surgery. Global open, 7(3), e2132. https://doi.org/10.1097/GOX.0000000000002132

Sechopoulos, I., Suryanarayanan, S., Vedantham, S., D'Orsi, C. J., & Karellas, A. (2008). Radiation dose to organs and tissues from mammography: Monte Carlo and phantom study. Radiology, 246(2), 434-443. https://doi.org/10.1148/radiol.2462070256

Sestak, I., Dowsett, M., Zabaglo, L., Lopez-Knowles, E., Ferree, S., Cowens, J. W., & Cuzick, J. (2013). Factors predicting late recurrence for estrogen receptor-positive breast cancer. Journal of the National Cancer Institute, 105(19), 1504-1511. https://doi.org/10.1093/jnci/djt244

Seth, A. K., & Cordeiro, P. G. (2020). Stability of Long-Term Outcomes in Implant-Based Breast Reconstruction: An Evaluation of 12-Year Surgeon- and Patient-Reported Outcomes in 3489 Nonirradiated and Irradiated Implants. Plastic and reconstructive surgery, 146(3), 474-484. https://doi.org/10.1097/PRS.0000000000007117

Sewart, E., Turner, N. L., Conroy, E. J., Cutress, R. I., Skillman, J., Whisker, L., . . . Potter, S. (2020). The Impact of Radiotherapy on Patient-reported Outcomes of Immediate Implant-based Breast Reconstruction With and Without Mesh. Annals of surgery, Jul 9 [Epub ahead of print]. https://doi.org/10.1097/sla.0000000000004245

Sewart, E., Turner, N. L., Conroy, E. J., Cutress, R. I., Skillman, J., Whisker, L., . . . the Breast Reconstruction Research, C. (2021). Patient-reported outcomes of immediate implant-based breast reconstruction with and without biological or synthetic mesh. BJS Open, 5(1). https://doi.org/10.1093/bjsopen/zraa063

Shannon, C., Ashley, S., & Smith, I. E. (2003). Does timing of adjuvant chemotherapy for early breast cancer influence survival? J Clin Oncol., 21(20), 3792-3797.

Sikov, W. M., Berry, D. A., Perou, C. M., Singh, B., Cirrincione, C. T., Tolaney, S. M., . . . Winer, E. P. (2015). Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol, 33(1), 13-21. https://doi.org/10.1200/jco.2014.57.0572

Silver, D. P., Richardson, A. L., Eklund, A. C., Wang, Z. C., Szallasi, Z., Li, Q., . . . Garber, J. E. (2010). Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol, 28(7), 1145-1153. https://doi.org/10.1200/jco.2009.22.4725

Silverstein, M. J., Poller, D. N., Waisman, J. R., Colburn, W. J., Barth, A., Gierson, E. D., . . . Slamon, D. J. (1995). Prognostic classification of breast ductal carcinoma-in-situ. Lancet, 345(8958), 1154-1157. https://doi.org/10.1016/s0140-6736(95)90982-6

Simon, J. A., Gaines, T., & LaGuardia, K. D. (2016). Extended-release oxybutynin therapy for vasomotor symptoms in women: a randomized clinical trial. Menopause, 23(11), 1214-1221. https://doi.org/10.1097/gme.0000000000000773

Simpson, J. F., & Page, D. L. (1997). Pathology of preinvasive and excellent-prognosis breast cancer. Curr Opin Oncol., 9(6), 512-519. https://doi.org/10.1097/00001622-199711000-00004

Simpson, P. T., Gale, T., Reis-Filho, J. S., Jones, C., Parry, S., Sloane, J. P., . . . Lakhani, S. R. (2005). Columnar cell lesions of the breast: the missing link in breast cancer progression? A morphological and molecular analysis. Am J Surg Pathol., 29(6), 734-746. https://doi.org/10.1097/01.pas.0000157295.93914.3b

Sjöstrom, J., Blomqvist, C., Mouridsen, H., Pluzanska, A., Ottosson-Lönn, S., Bengtsson, N. O., . . . Bergh, J. (1999). Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer, 35(8), 1194-1201. https://doi.org/10.1016/s0959-8049(99)00122-7

Skytte, A. B., Cruger, D., Gerster, M., Laenkholm, A. V., Lang, C., Brondum-Nielsen, K., . . . Gerdes, A. M. (2011). Breast cancer after bilateral risk-reducing mastectomy. Clin Genet., 79(5), 431-437. https://doi.org/10.1111/j.1399-0004.2010.01604.x

Slamon, D., Eiermann, W., Robert, N., Giermek, J., Martin, M., Jasiowka, M., . . . Investigators, O. B. o. t. B.-. (2016). Abstract S5-04: Ten year follow-up of BCIRG-006 comparing doxorubicin plus cyclophosphamide followed by docetaxel (AC→T) with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2+ early breast cancer. Cancer Research, 76(4_Suppl), S5-04. https://doi.org/10.1158/1538-7445.Sabcs15-s5-04

Slamon, D., Eiermann, W., Robert, N., Pienkowski, T., Martin, M., Press, M., . . . Crown, J. (2011). Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med., 365(14), 1273-1283. https://doi.org/10.1056/NEJMoa0910383

Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 235(4785), 177-182. https://doi.org/10.1126/science.3798106

Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., . . . Ullrich, A. (1989). Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science, 244(4905), 707-712. https://doi.org/10.1126/science.2470152

Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., . . . Norton, L. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med., 344(11), 783-792. https://doi.org/Doi 10.1056/Nejm200103153441101

Slamon, D. J., Neven, P., Chia, S., Fasching, P. A., De Laurentiis, M., Im, S. A., . . . Jerusalem, G. (2020). Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. The New England journal of medicine, 382(6), 514-524. https://doi.org/10.1056/NEJMoa1911149

Slamon, D. J., Neven, P., Chia, S., Fasching, P. A., De Laurentiis, M., Im, S. A., . . . Jerusalem, G. (2018). Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. J Clin Oncol, 36(24), 2465-2472. https://doi.org/10.1200/jco.2018.78.9909

Sledge, G. W., Jr., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., . . . Llombart-Cussac, A. (2020). The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial. JAMA oncology, 6(1), 116-124. https://doi.org/10.1001/jamaoncol.2019.4782

Sledge, G. W., Jr., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., . . . Llombart-Cussac, A. (2017). MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. J Clin Oncol, 35(25), 2875-2884. https://doi.org/10.1200/jco.2017.73.7585

Sobti, N., Weitzman, R. E., Nealon, K. P., Jimenez, R. B., Gfrerer, L., Mattos, D., . . . Liao, E. C. (2020). Evaluation of capsular contracture following immediate prepectoral versus subpectoral direct-to-implant breast reconstruction. Scientific reports, 10(1), 1137. https://doi.org/10.1038/s41598-020-58094-4

Sorrentino, L., Regolo, L., Scoccia, E., Petrolo, G., Bossi, D., Albasini, S., . . . Corsi, F. (2019). Autologous fat transfer after breast cancer surgery: An exact-matching study on the long-term oncological safety. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. https://doi.org/10.1016/j.ejso.2019.05.013

Sotiriou, C., Lacroix, M., Lespagnard, L., Larsimont, D., Paesmans, M., & Body, J. J. (2001). Interleukins-6 and -11 expression in primary breast cancer and subsequent development of bone metastases. Cancer Lett., 169(1), 87-95. https://doi.org/10.1016/s0304-3835(01)00524-9

Southey, M. C., Goldgar, D. E., Winqvist, R., Pylkäs, K., Couch, F., Tischkowitz, M., . . . Milne, R. L. (2016). PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. J Med Genet, 53(12), 800-811. https://doi.org/10.1136/jmedgenet-2016-103839

Sparano, J. A., Gray, R. J., Makower, D. F., Pritchard, K. I., Albain, K. S., Hayes, D. F., . . . Sledge, G. W., Jr. (2018). Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. The New England journal of medicine, 379(2), 111-121. https://doi.org/10.1056/NEJMoa1804710

Sparano, J. A., Gray, R. J., Makower, D. F., Pritchard, K. I., Albain, K. S., Hayes, D. F., . . . Sledge, G. W. (2015). Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. The New England journal of medicine, 373(21), 2005-2014. https://doi.org/10.1056/NEJMoa1510764

Sparano, J. A., Gray, R. J., Ravdin, P. M., Makower, D. F., Pritchard, K. I., Albain, K. S., . . . Sledge, G. W., Jr. (2019). Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer. The New England journal of medicine, 380(25), 2395-2405. https://doi.org/10.1056/NEJMoa1904819

Sparano, J. A., Wang, M., Martino, S., Jones, V., Perez, E. A., Saphner, T., . . . Davidson, N. E. (2008). Weekly paclitaxel in the adjuvant treatment of breast cancer. The New England journal of medicine, 358(16), 1663-1671. https://doi.org/10.1056/NEJMoa0707056

Spear, S. L., Coles, C. N., Leung, B. K., Gitlin, M., Parekh, M., & Macarios, D. (2016). The Safety, Effectiveness, and Efficiency of Autologous Fat Grafting in Breast Surgery. Plastic and reconstructive surgery. Global open, 4(8), e827. https://doi.org/10.1097/GOX.0000000000000842

Speck, R. M., Courneya, K. S., Masse, L. C., Duval, S., & Schmitz, K. H. (2010). An update of controlled physical activity trials in cancer survivors: a systematic review and meta-analysis. J Cancer Surviv., 4(2), 87-100. https://doi.org/10.1007/s11764-009-0110-5

Spring, L. M., Gupta, A., Reynolds, K. L., Gadd, M. A., Ellisen, L. W., Isakoff, S. J., . . . Bardia, A. (2016). Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-analysis. JAMA oncology, 2(11), 1477-1486. https://doi.org/10.1001/jamaoncol.2016.1897

Spronk, I., Schellevis, F. G., Burgers, J. S., de Bock, G. H., & Korevaar, J. C. (2018). Incidence of isolated local breast cancer recurrence and contralateral breast cancer: A systematic review. Breast, 39, 70-79. https://doi.org/10.1016/j.breast.2018.03.011

Stark, B., Magneli, M., van Heijningen, I., Parreira, C., Bosch, U., Rouif, M., & Halle, M. (2021). Considerations on the Demography of BIA-ALCL in European Countries Based on an E(A)SAPS Survey. Aesthetic Plast Surg, 45(6), 2639-2644. https://doi.org/10.1007/s00266-021-02411-3

Stensheim, H., Cvancarova, M., Møller, B., & Fosså, S. D. (2011). Pregnancy after adolescent and adult cancer: A population-based matched cohort study. International Journal of Cancer, 129(5), 1225-1236. https://doi.org/10.1002/ijc.26045

Stokes, E. L., Tyldesley, S., Woods, R., Wai, E., & Olivotto, I. A. (2011). Effect of nodal irradiation and fraction size on cardiac and cerebrovascular mortality in women with breast cancer treated with local and locoregional radiotherapy. Int J Radiat Oncol Biol Phys., 80(2), 403-409. https://doi.org/10.1016/j.ijrobp.2010.02.041

Stopeck, A. T., Lipton, A., Body, J. J., Steger, G. G., Tonkin, K., de Boer, R. H., . . . Braun, A. (2010). Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol., 28(35), 5132-5139. https://doi.org/10.1200/JCO.2010.29.7101

Strnad, V., Ott, O. J., Hildebrandt, G., Kauer-Dorner, D., Knauerhase, H., Major, T., . . . Polgar, C. (2016). 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet, 387(10015), 229-238. https://doi.org/10.1016/s0140-6736(15)00471-7

Stuart, K. E., Houssami, N., Taylor, R., Hayen, A., & Boyages, J. (2015). Long-term outcomes of ductal carcinoma in situ of the breast: a systematic review, meta-analysis and meta-regression analysis. BMC Cancer, 15, 890. https://doi.org/10.1186/s12885-015-1904-7

Staaf, J., Glodzik, D., Bosch, A., Vallon-Christersson, J., Reutersward, C., Hakkinen, J., . . . Nik-Zainal, S. (2019). Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study. Nat Med, 25(10), 1526-1153. https://doi.org/10.1038/s41591-019-0582-4

Swain, S. M., Baselga, J., Kim, S. B., Ro, J., Semiglazov, V., Campone, M., . . . Cortes, J. (2015). Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. The New England journal of medicine, 372(8), 724-734. https://doi.org/10.1056/NEJMoa1413513

Swain, S. M., Jeong, J. H., Geyer, C. E., Jr., Costantino, J. P., Pajon, E. R., Fehrenbacher, L., . . . Wolmark, N. (2010). Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. The New England journal of medicine, 362(22), 2053-2065. https://doi.org/10.1056/NEJMoa0909638

Swain, S. M., Kim, S. B., Cortes, J., Ro, J., Semiglazov, V., Campone, M., . . . Baselga, J. (2013). Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol., 14(6), 461-471. https://doi.org/10.1016/S1470-2045(13)70130-X

Tabar, L., Vitak, B., Chen, H. H., Yen, M. F., Duffy, S. W., & Smith, R. A. (2001). Beyond randomized controlled trials: organized mammographic screening substantially reduces breast carcinoma mortality. Cancer, 91(9), 1724-1731. https://doi.org/10.1002/1097-0142(20010501)91:9<1724::aid-cncr1190>3.0.co;2-v

Takeda, A., Shigematsu, N., Kondo, M., Amemiya, A., Kawaguchi, O., Sato, M., . . . Kubo, A. (2000). The modified tangential irradiation technique for breast cancer: how to cover the entire axillary region. Int J Radiat Oncol Biol Phys., 46(4), 815-822. https://doi.org/Doi 10.1016/S0360-3016(99)00463-0

Tamoxifen and Uterine Cancer. (2014). (Committee Opinion Number 601, June 2014). Washington, DC: The American College of Obstetricians and Gynecologists, Committee on Gynecologic Practice. Retrieved from https://www.acog.org/~/media/Committee%20Opinions/Committee%20on%20Gynecologic%20Practice/co601.pdf?dmc=1&ts=20140628T0809550147

Tamura, K., Imamura, C. K., Takano, T., Saji, S., Yamanaka, T., Yonemori, K., . . . Tanigawara, Y. (2020). CYP2D6 Genotype-Guided Tamoxifen Dosing in Hormone Receptor-Positive Metastatic Breast Cancer (TARGET-1): A Randomized, Open-Label, Phase II Study. J Clin Oncol, 38(6), 558-566. https://doi.org/10.1200/JCO.19.01412

Tan, A. R., Im, S. A., Mattar, A., Colomer, R., Stroyakovskii, D., Nowecki, Z., . . . Jackisch, C. (2021). Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study. The Lancet. Oncology, 22(1), 85-97. https://doi.org/10.1016/s1470-2045(20)30536-2

Tan, P. H., Thike, A. A., Tan, W. J., Thu, M. M., Busmanis, I., Li, H., . . . Tan, M. H. (2012). Predicting clinical behaviour of breast phyllodes tumours: a nomogram based on histological criteria and surgical margins. Journal of clinical pathology, 65(1), 69-76. https://doi.org/10.1136/jclinpath-2011-200368

Tanbo, T., Greggains, G., Storeng, R., Busund, B., Langebrekke, A., & Fedorcsak, P. (2015). Autotransplantation of cryopreserved ovarian tissue after treatment for malignant disease – the first Norwegian results. Acta Obstet Gynecol Scand, 94(9), 937-941. https://doi.org/10.1111/aogs.12700

Tang, R., Coopey, S. B., Colwell, A. S., Specht, M. C., Gadd, M. A., Kansal, K., . . . Smith, B. L. (2015). Nipple-Sparing Mastectomy in Irradiated Breasts: Selecting Patients to Minimize Complications. Ann Surg Oncol, 22(10), 3331-3337. https://doi.org/10.1245/s10434-015-4669-y

Taylor, C., Correa, C., Duane, F. K., Aznar, M. C., Anderson, S. J., Bergh, J., . . . McGale, P. (2017). Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials. J Clin Oncol, 35(15), 1641-1649. https://doi.org/10.1200/jco.2016.72.0722

Taylor, C., McGale, P., Bronnum, D., Correa, C., Cutter, D., Duane, F. K., . . . Ewertz, M. (2018). Cardiac Structure Injury After Radiotherapy for Breast Cancer: Cross-Sectional Study With Individual Patient Data. J Clin Oncol, 36(22), 2288-2296. https://doi.org/10.1200/jco.2017.77.6351

Taylor, C. W., Brønnum, D., Darby, S. C., Gagliardi, G., Hall, P., Jensen, M. B., . . . Ewertz, M. (2011). Cardiac dose estimates from Danish and Swedish breast cancer radiotherapy during 1977-2001. Radiother Oncol, 100(2), 176-183. https://doi.org/10.1016/j.radonc.2011.01.020

Telli, M. L., Timms, K. M., Reid, J., Hennessy, B., Mills, G. B., Jensen, K. C., . . . Richardson, A. L. (2016). Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 22(15), 3764-3773. https://doi.org/10.1158/1078-0432.CCR-15-2477

Thamm, O. C., & Andree, C. (2018). Immediate Versus Delayed Breast Reconstruction: Evolving Concepts and Evidence Base. Clinics in plastic surgery, 45(1), 119-127. https://doi.org/10.1016/j.cps.2017.08.010

The American Society of Breast surgeons. (2018). Consensus Guideline on Concordance Assessment of Image-Guided Breast Biopsies and Management of Borderline or High-Risk Lesions. Columbia, MD: The American Society of Breast surgeons. Retrieved from https://www.breastsurgeons.org/docs/statements/Consensus-Guideline-on-Concordance-Assessment-of-Image-Guided-Breast-Biopsies.pdf

Theriault, R. L., Lipton, A., Hortobagyi, G. N., Leff, R., Gluck, S., Stewart, J. F., . . . Reitsma, D. J. (1999). Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol., 17(3), 846-854. https://doi.org/10.1200/JCO.1999.17.3.846

Theriault, R. L., & Litton, J. K. (2013). Pregnancy during or after breast cancer diagnosis: what do we know and what do we need to know? J Clin Oncol, 31(20), 2521-2522. https://doi.org/10.1200/jco.2013.49.7347

Thor, A. D., Berry, D. A., Budman, D. R., Muss, H. B., Kute, T., Henderson, I. C., . . . Liu, E. T. (1998). erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst., 90(18), 1346-1360. https://doi.org/10.1093/jnci/90.18.1346

Thorarinsson, A., Frojd, V., Kolby, L., Ljungdal, J., Taft, C., & Mark, H. (2017). Long-Term Health-Related Quality of Life after Breast Reconstruction: Comparing 4 Different Methods of Reconstruction. Plastic and reconstructive surgery. Global open, 5(6), e1316. https://doi.org/10.1097/GOX.0000000000001316

Thorsen, L. B., Offersen, B. V., Danø, H., Berg, M., Jensen, I., Pedersen, A. N., . . . Overgaard, J. (2016). DBCG-IMN: A Population-Based Cohort Study on the Effect of Internal Mammary Node Irradiation in Early Node-Positive Breast Cancer. J Clin Oncol, 34(4), 314-320. https://doi.org/10.1200/jco.2015.63.6456

Thune, I. (2008). Kreft. In: R. Bahr (Ed.), Aktivitetshåndboken: fysisk aktivitet i forebygging og behandling (p. 359-370). Oslo: Helsedirektoratet. (Reprinted from: Not in File).

Timbrell, S., Al-Himdani, S., Shaw, O., Tan, K., Morris, J., & Bundred, N. (2017). Comparison of Local Recurrence After Simple and Skin-Sparing Mastectomy Performed in Patients with Ductal Carcinoma In Situ. Ann Surg Oncol, 24(4), 1071-1076. https://doi.org/10.1245/s10434-016-5673-6

Tjan-Heijnen, V. C. G., van Hellemond, I. E. G., Peer, P. G. M., Swinkels, A. C. P., Smorenburg, C. H., van der Sangen, M. J. C., . . . Seynaeve, C. M. (2017). Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial. The Lancet. Oncology, 18(11), 1502-1511. https://doi.org/10.1016/s1470-2045(17)30600-9

TNM: classification of malignant tumours. (2017). (8. ed.). Oxford; Hoboken, NJ: John Wiley & Sons.

Tolaney, S. M., Barry, W. T., Dang, C. T., Yardley, D. A., Moy, B., Marcom, P. K., . . . Winer, E. P. (2015). Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. The New England journal of medicine, 372(2), 134-141. https://doi.org/10.1056/NEJMoa1406281

Tolaney, S. M., Barry, W. T., Guo, H., Dillon, D., Dang, C. T., Yardley, D. A., . . . Winer, E. P. (2017). Seven-year (yr) follow-up of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC). Journal of Clinical Oncology, 35(15 suppl), 511. https://doi.org/10.1200/JCO.2017.35.15_suppl.511

Tolaney, S. M., Guo, H., Pernas, S., Barry, W. T., Dillon, D. A., Ritterhouse, L., . . . Winer, E. P. (2019). Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. J Clin Oncol, 37(22), 1868-1875. https://doi.org/10.1200/jco.19.00066

Tolaney, S. M., Wardley, A. M., Zambelli, S., Hilton, J. F., Troso-Sandoval, T. A., Ricci, F., . . . Andre, F. (2020). Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial. The Lancet. Oncology, 21(6), 763-775. https://doi.org/10.1016/S1470-2045(20)30112-1

Torres, L. M., Yuste Sanchez, M. J., Zapico, G. A., Prieto, M. D., Mayoral del, M. O., Cerezo, T. E., & Minayo, M. E. (2010). Effectiveness of early physiotherapy to prevent lymphoedema after surgery for breast cancer: randomised, single blinded, clinical trial. BMJ, 340, b5396.

Toulis, K. A., Tzellos, T., Kouvelas, D., & Goulis, D. G. (2009). Gabapentin for the treatment of hot flashes in women with natural or tamoxifen-induced menopause: a systematic review and meta-analysis. Clin Ther, 31(2), 221-235. https://doi.org/10.1016/j.clinthera.2009.02.006

Trainer, A. H., Lewis, C. R., Tucker, K., Meiser, B., Friedlander, M., & Ward, R. L. (2010). The role of BRCA mutation testing in determining breast cancer therapy. Nature reviews. Clinical oncology, 7(12), 708-717. https://doi.org/10.1038/nrclinonc.2010.175

Tripathy, D., Im, S. A., Colleoni, M., Franke, F., Bardia, A., Harbeck, N., . . . Lu, Y. S. (2018). Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. The Lancet. Oncology, 19(7), 904-915. https://doi.org/10.1016/s1470-2045(18)30292-4

Trudeau, M., Charbonneau, F., Gelmon, K., Laing, K., Latreille, J., Mackey, J., . . . Verma, S. (2005). Selection of adjuvant chemotherapy for treatment of node-positive breast cancer. Lancet Oncol., 6(11), 886-898. https://doi.org/10.1016/S1470-2045(05)70424-1

Tsao, M. N., Rades, D., Wirth, A., Lo, S. S., Danielson, B. L., Gaspar, L. E., . . . Chang, E. L. (2012). Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): An American Society for Radiation Oncology evidence-based guideline. Practical radiation oncology, 2(3), 210-225. https://doi.org/10.1016/j.prro.2011.12.004

Tsoutsou, P. G., Koukourakis, M. I., Azria, D., & Belkacemi, Y. (2009). Optimal timing for adjuvant radiation therapy in breast cancer: a comprehensive review and perspectives. Crit Rev Oncol Hematol., 71(2), 102-116. https://doi.org/10.1016/j.critrevonc.2008.09.002

Tung, N., Domchek, S. M., Stadler, Z., Nathanson, K. L., Couch, F., Garber, J. E., . . . Robson, M. E. (2016). Counselling framework for moderate-penetrance cancer-susceptibility mutations. Nature reviews. Clinical oncology, 13(9), 581-588. https://doi.org/10.1038/nrclinonc.2016.90

Tung, N. M., Boughey, J. C., Pierce, L. J., Robson, M. E., Bedrosian, I., Dietz, J. R., . . . Zakalik, D. (2020). Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline. J Clin Oncol, 38(18), 2080-2106. https://doi.org/10.1200/jco.20.00299

Turnbull, L., Brown, S., Harvey, I., Olivier, C., Drew, P., Napp, V., . . . Brown, J. (2010). Comparative effectiveness of MRI in breast cancer (COMICE) trial: a randomised controlled trial. Lancet, 375(9714), 563-571. https://doi.org/10.1016/s0140-6736(09)62070-5

Turner, N., Lambros, M. B., Horlings, H. M., Pearson, A., Sharpe, R., Natrajan, R., . . . Reis-Filho, J. S. (2010). Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene, 29(14), 2013-2023. https://doi.org/10.1038/onc.2009.489

Turner, N., Tutt, A., & Ashworth, A. (2004). Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer, 4(10), 814-819. https://doi.org/10.1038/nrc1457

Turner, N. C., Ro, J., André, F., Loi, S., Verma, S., Iwata, H., . . . Cristofanilli, M. (2015). Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. The New England journal of medicine, 373(3), 209-219. https://doi.org/10.1056/NEJMoa1505270

Turner, N. C., Slamon, D. J., Ro, J., Bondarenko, I., Im, S. A., Masuda, N., . . . Cristofanilli, M. (2018). Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. The New England journal of medicine, 379(20), 1926-1936. https://doi.org/10.1056/NEJMoa1810527

Turton, P., El-Sharkawi, D., Lyburn, I., Sharma, B., Mahalingam, P., Turner, S. D., . . . Mercer, N. (2021). UK Guidelines on the Diagnosis and Treatment of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) on behalf of the Medicines and Healthcare products Regulatory Agency (MHRA) Plastic, Reconstructive and Aesthetic Surgery Expert Advisory Group (PRASEAG). Journal of plastic, reconstructive & aesthetic surgery : JPRAS, 74(1), 13-29. https://doi.org/10.1016/j.bjps.2020.10.064

Tutt, A., Tovey, H., Cheang, M. C. U., Kernaghan, S., Kilburn, L., Gazinska, P., . . . Bliss, J. M. (2018). Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nat Med, 24(5), 628-637. https://doi.org/10.1038/s41591-018-0009-7

Tutt, A. N. J., Garber, J. E., Kaufman, B., Viale, G., Fumagalli, D., Rastogi, P., . . . Geyer, C. E., Jr. (2021). Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. The New England journal of medicine, 384(25), 2394-2405. https://doi.org/10.1056/NEJMoa2105215

Untch, M., Harbeck, N., Huober, J., von Minckwitz, G., Gerber, B., Kreipe, H. H., . . . Loibl, S. (2015). Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: Opinions of German Specialists to the 14th St. Gallen International Breast Cancer Conference 2015 (Vienna 2015). Geburtshilfe und Frauenheilkunde, 75(6), 556-565. https://doi.org/10.1055/s-0035-1546120

Uusitalo, E., Rantanen, M., Kallionpaa, R. A., Poyhonen, M., Leppavirta, J., Yla-Outinen, H., . . . Peltonen, J. (2016). Distinctive Cancer Associations in Patients With Neurofibromatosis Type 1. J Clin Oncol, 34(17), 1978-1986. https://doi.org/10.1200/JCO.2015.65.3576

Vaidya, J. S., Bulsara, M., Baum, M., Wenz, F., Massarut, S., Pigorsch, S., . . . Tobias, J. S. (2020). Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. BMJ, 370, m2836. https://doi.org/10.1136/bmj.m2836

Vaidya, J. S., Joseph, D. J., Tobias, J. S., Bulsara, M., Wenz, F., Saunders, C., . . . Baum, M. (2010). Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet, 376(9735), 91-102. https://doi.org/10.1016/s0140-6736(10)60837-9

Valachis, A., Nearchou, A. D., & Lind, P. (2014). Surgical management of breast cancer in BRCA-mutation carriers: a systematic review and meta-analysis. Breast cancer research and treatment, 144(3), 443-455. https://doi.org/10.1007/s10549-014-2890-1

Van Calsteren, K., Heyns, L., De Smet, F., Van Eycken, L., Gziri, M. M., Van Gemert, W., . . . Amant, F. (2010). Cancer during pregnancy: an analysis of 215 patients emphasizing the obstetrical and the neonatal outcomes. J Clin Oncol, 28(4), 683-689. https://doi.org/10.1200/jco.2009.23.2801

van Dalen, E. C., Michiels, E. M., Caron, H. N., & Kremer, L. C. (2010). Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev, (5), CD005006. https://doi.org/10.1002/14651858.CD005006.pub4

van der Voort, A., van Ramshorst, M. S., van Werkhoven, E. D., Mandjes, I. A., Kemper, I., Vulink, A. J., . . . Sonke, G. S. (2021). Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual ERBB2 Blockade in Patients With ERBB2-Positive Breast Cancer: A Secondary Analysis of the TRAIN-2 Randomized, Phase 3 Trial. JAMA oncology, 7(7), 978-984. https://doi.org/10.1001/jamaoncol.2021.1371

van Hellemond, I. E. G., Vriens, I. J. H., Peer, P. G. M., Swinkels, A. C. P., Smorenburg, C. H., Seynaeve, C. M., . . . Tjan-Heijnen, V. C. G. (2017). Ovarian Function Recovery During Anastrozole in Breast Cancer Patients With Chemotherapy-Induced Ovarian Function Failure. Journal of the National Cancer Institute, 109(12). https://doi.org/10.1093/jnci/djx074

van Mackelenbergh, M., Seither, F., Möbus, V., Shaugnessy, J., Martin, M., Joenssuu, H., . . . Loibl, S. (2020). Abstract GS1-07: Effects of capecitabine as part of neo-/adjuvant chemotherapy. A meta-analysis of individual patient data from 12 randomized trials including 15,457 patients. Cancer Research, 80(4 Suppl), GS1-07. https://doi.org/10.1158/1538-7445.SABCS19-GS1-07

van Tienhoven, G., Voogd, A. C., Peterse, J. L., Nielsen, M., Andersen, K. W., Mignolet, F., . . . van Dongen, J. A. (1999). Prognosis after treatment for loco-regional recurrence after mastectomy or breast conserving therapy in two randomised trials (EORTC 10801 and DBCG-82TM). EORTC Breast Cancer Cooperative Group and the Danish Breast Cancer Cooperative Group. Eur J Cancer, 35(1), 32-38. https://doi.org/10.1016/s0959-8049(98)00301-3

Varghese, J., Gohari, S. S., Rizki, H., Faheem, M., Langridge, B., Kummel, S., . . . Schmid, P. (2021). A systematic review and meta-analysis on the effect of neoadjuvant chemotherapy on complications following immediate breast reconstruction. Breast, 55, 55-62. https://doi.org/10.1016/j.breast.2020.11.023

Varshavsky-Yanovsky, A. N., & Goldstein, L. J. (2020). Role of Capecitabine in Early Breast Cancer. J Clin Oncol, 38(3), 179-182. https://doi.org/10.1200/jco.19.02946

Venturini, M., Del Mastro, L., Aitini, E., Baldini, E., Caroti, C., Contu, A., . . . Bruzzi, P. (2005). Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial. J Natl Cancer Inst., 97(23), 1724-1733. https://doi.org/10.1093/jnci/dji398

Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., . . . Blackwell, K. (2012). Trastuzumab emtansine for HER2-positive advanced breast cancer. The New England journal of medicine, 367(19), 1783-1791. https://doi.org/10.1056/NEJMoa1209124

Veronesi, U., Cascinelli, N., Mariani, L., Greco, M., Saccozzi, R., Luini, A., . . . Marubini, E. (2002). Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med., 347(16), 1227-1232. https://doi.org/10.1056/NEJMoa020989

Veronesi, U., Marubini, E., Del Vecchio, M., Manzari, A., Andreola, S., Greco, M., . . . Rilke, F. (1995). Local recurrences and distant metastases after conservative breast cancer treatments: partly independent events. J Natl Cancer Inst., 87(1), 19-27. https://doi.org/10.1093/jnci/87.1.19

Veronesi, U., Paganelli, G., Viale, G., Luini, A., Zurrida, S., Galimberti, V., . . . Gennari, R. (2003). A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med., 349(6), 546-553. https://doi.org/10.1056/NEJMoa012782

Vicini, F. A., Cecchini, R. S., White, J. R., Arthur, D. W., Julian, T. B., Rabinovitch, R. A., . . . Wolmark, N. (2019). Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. Lancet, 394(10215), 2155-2164. https://doi.org/10.1016/s0140-6736(19)32514-0

Vidal, L., Ben-Aharon, I., Shulamith, R., Yerushalmi, R., Sulkes, A., & Stemmer, S. M. (2012). Bisphosphonates in the adjuvant setting of breast cancer therapy: Effect on survival--A systematic review and meta-analysis. J Clin Oncol., 30(15 Supplement), 548.

Virnig, B. A., Tuttle, T. M., Shamliyan, T., & Kane, R. L. (2010). Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. J Natl Cancer Inst., 102(3), 170-178. https://doi.org/10.1093/jnci/djp482

Vitek, W. S., Shayne, M., Hoeger, K., Han, Y., Messing, S., & Fung, C. (2014). Gonadotropin-releasing hormone agonists for the preservation of ovarian function among women with breast cancer who did not use tamoxifen after chemotherapy: a systematic review and meta-analysis. Fertil Steril, 102(3), 808-815.e801. https://doi.org/10.1016/j.fertnstert.2014.06.003

Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., . . . Press, M. (2002). Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol., 20(3), 719-726. https://doi.org/Doi 10.1200/Jco.20.3.719

Volum og doser ved strålebehandling: definisjoner, retningslinjer for bruk, dokumentasjon og rapportering. (2003). (Strålevern rapport 2003:12). Oslo: Statens strålevern. Retrieved from http://www.nrpa.no/dav/a1de986ad7.pdf

von Minckwitz, G., du Bois, A., Schmidt, M., Maass, N., Cufer, T., de Jongh, F. E., . . . Loibl, S. (2009). Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. J Clin Oncol., 27(12), 1999-2006. https://doi.org/10.1200/JCO.2008.19.6618

von Minckwitz, G., Huang, C. S., Mano, M. S., Loibl, S., Mamounas, E. P., Untch, M., . . . Geyer, C. E., Jr. (2019). Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. The New England journal of medicine, 380(7), 617-628. https://doi.org/10.1056/NEJMoa1814017

von Minckwitz, G., Procter, M., de Azambuja, E., Zardavas, D., Benyunes, M., Viale, G., . . . Baselga, J. (2017). Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. The New England journal of medicine, 377(2), 122-131. https://doi.org/10.1056/NEJMoa1703643

von Minckwitz, G., Schneeweiss, A., Loibl, S., Salat, C., Denkert, C., Rezai, M., . . . Untch, M. (2014). Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. The Lancet. Oncology, 15(7), 747-756. https://doi.org/10.1016/s1470-2045(14)70160-3

von Schoultz, E., & Rutqvist, L. E. (2005). Menopausal hormone therapy after breast cancer: the Stockholm randomized trial. J Natl Cancer Inst., 97(7), 533-535. https://doi.org/10.1093/jnci/dji071

Waks, A. G., & Partridge, A. H. (2016). Fertility Preservation in Patients With Breast Cancer: Necessity, Methods, and Safety. J Natl Compr Canc Netw, 14(3), 355-363. https://doi.org/10.6004/jnccn.2016.0038

Wallis, M., Tardivon, A., Helbich, T., & Schreer, I. (2007). Guidelines from the European Society of Breast Imaging for diagnostic interventional breast procedures. European radiology, 17(2), 581-588. https://doi.org/10.1007/s00330-006-0408-x

Wang, F., Peled, A. W., Chin, R., Fowble, B., Alvarado, M., Ewing, C., . . . Sbitany, H. (2016). The Impact of Radiation Therapy, Lymph Node Dissection, and Hormonal Therapy on Outcomes of Tissue Expander-Implant Exchange in Prosthetic Breast Reconstruction. Plastic and reconstructive surgery, 137(1), 1-9. https://doi.org/10.1097/PRS.0000000000001866

Wang, K., Dai, Y., Pan, Y., Cheng, P., & Jin, X. (2020). Local-regional recurrence risk after autologous fat grafting in breast cancer patients: A systematic review and meta-analysis. J Surg Oncol, 121(3), 435-440. https://doi.org/10.1002/jso.25829

Wapnir, I. L., Gelber, S., Anderson, S. J., Mamounas, E. P., Robidoux, A., Martin, M., . . . Aebi, S. (2017). Poor Prognosis After Second Locoregional Recurrences in the CALOR Trial. Ann Surg Oncol, 24(2), 398-406. https://doi.org/10.1245/s10434-016-5571-y

Wapnir, I. L., Price, K. N., Anderson, S. J., Robidoux, A., Martín, M., Nortier, J. W. R., . . . Aebi, S. (2018). Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial. J Clin Oncol, 36(11), 1073-1079. https://doi.org/10.1200/jco.2017.76.5719

Warne, G. L., Fairley, K. F., Hobbs, J. B., & Martin, F. I. (1973). Cyclophosphamide-induced ovarian failure. The New England journal of medicine, 289(22), 1159-1162. https://doi.org/10.1056/NEJM197311292892202

Wassermann, J., Gelber, S. I., Rosenberg, S. M., Ruddy, K. J., Tamimi, R. M., Schapira, L., . . . Partridge, A. H. (2019). Nonadherent behaviors among young women on adjuvant endocrine therapy for breast cancer. Cancer, 125(18), 3266-3274. https://doi.org/10.1002/cncr.32192

Wazir, U., El Hage Chehade, H., Headon, H., Oteifa, M., Kasem, A., & Mokbel, K. (2016). Oncological Safety of Lipofilling in Patients with Breast Cancer: A Meta-analysis and Update on Clinical Practice. Anticancer Res, 36(9), 4521-4528. https://doi.org/10.21873/anticanres.10999

Weaver, D. L., Ashikaga, T., Krag, D. N., Skelly, J. M., Anderson, S. J., Harlow, S. P., . . . Wolmark, N. (2011). Effect of occult metastases on survival in node-negative breast cancer. N Engl J Med., 364(5), 412-421. https://doi.org/10.1056/NEJMoa1008108

Westling, P., Svensson, H., & Hele, P. (1972). Cervical plexus lesions following post-operative radiation therapy of mammary carcinoma. Acta radiologica: therapy, physics, biology, 11(3), 209-216. https://doi.org/10.3109/02841867209130761

Whelan, T. J., Julian, J. A., Berrang, T. S., Kim, D. H., Germain, I., Nichol, A. M., . . . Olivotto, I. A. (2019). External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. Lancet, 394(10215), 2165-2172. https://doi.org/10.1016/s0140-6736(19)32515-2

Whelan, T. J., Olivotto, I. A., Parulekar, W. R., Ackerman, I., Chua, B. H., Nabid, A., . . . Levine, M. N. (2015). Regional Nodal Irradiation in Early-Stage Breast Cancer. The New England journal of medicine, 373(4), 307-316. https://doi.org/10.1056/NEJMoa1415340

Whelan, T. J., Pignol, J. P., Levine, M. N., Julian, J. A., MacKenzie, R., Parpia, S., . . . Freeman, C. (2010). Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med., 362(6), 513-520. https://doi.org/10.1056/NEJMoa0906260

Widner, N., & Dabbs, D. J. (2012). Metaplastic breast carcinoma. In: D. J. Dabbs (Ed.), Breast pathology (p. 479-501). Philadelphia, PA: Elsevier (Saunders). (Reprinted from: Not in File).

Wilcken, N., Hornbuckle, J., & Ghersi, D. (2003). Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer. Cochrane Database Syst Rev, (2), CD002747. https://doi.org/10.1002/14651858.CD002747

Wilkinson, G. S., Kuo, Y. F., Freeman, J. L., & Goodwin, J. S. (2007). Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: a population-based analysis. J Natl Cancer Inst., 99(13), 1016-1024. https://doi.org/10.1093/jnci/djm025

Wilkosz, P., Greggains, G. D., Tanbo, T. G., & Fedorcsak, P. (2014). Female Reproductive Decline Is Determined by Remaining Ovarian Reserve and Age. PLoS ONE, 9(10), e108343. https://doi.org/10.1371/journal.pone.0108343

Willey, S. C., Fan, K. L., Luvisa, K., Graziano, F. D., Lau, S. H. Y., Black, C. K., . . . Pittman, T. (2020). Predicting Ischemic Complications in the Inframammary Approach to Nipple-Sparing Mastectomy: The Midclavicular-to-Inframammary Fold Measurement. Plastic and reconstructive surgery, 145(2), 251e-262e. https://doi.org/10.1097/PRS.0000000000006439

Willner, J., Kiricuta, I. C., & Kolbl, O. (1997). Locoregional recurrence of breast cancer following mastectomy: always a fatal event? Results of univariate and multivariate analysis. Int J Radiat Oncol Biol Phys., 37(4), 853-863.

Willner, J., Kiricuta, I. C., Kolbl, O., & Flentje, M. (1999). Long-term survival following postmastectomy locoregional recurrence of breast cancer. Breast, 8(4), 200-204. https://doi.org/10.1054/brst.1999.0033

Wirapati, P., Sotiriou, C., Kunkel, S., Farmer, P., Pradervand, S., Haibe-Kains, B., . . . Delorenzi, M. (2008). Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res., 10(4), R65. https://doi.org/10.1186/bcr2124

Wist, E. (2000). Onkologisk akuttilstander. In: R. Kåresen & E. Wist (Eds.), Kreftsykdommer: en basisbok for helsepersonell (p. 90-95). Oslo: Gyldendal akademisk. (Reprinted from: Not in File).

Wist, E. A., Sommer, H. H., Østenstad, B., Risberg, T., Bremnes, Y., & Mjaaland, I. (2004). Oral capecitabine in anthracycline- and taxane-pretreated advanced/metastatic breast cancer. Acta Oncol., 43(2), 186-189. https://doi.org/10.1080/02841860310023165

Wist, E. A., Sommer, H. H., Østenstad, B., Risberg, T., & Fjæstad, K. (2004). Weekly one-hour paclitaxel as first-line chemotherapy for metastatic breast cancer. Acta Oncol., 43(1), 11-14. https://doi.org/10.1080/02841860310017748

Wolff, A. C., Hammond, M. E. H., Allison, K. H., Harvey, B. E., Mangu, P. B., Bartlett, J. M. S., . . . Dowsett, M. (2018). Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol, 36(20), 2105-2122. https://doi.org/10.1200/jco.2018.77.8738

Yamamoto, M., Serizawa, T., Shuto, T., Akabane, A., Higuchi, Y., Kawagishi, J., . . . Tsuchiya, K. (2014). Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. The Lancet. Oncology, 15(4), 387-395. https://doi.org/10.1016/s1470-2045(14)70061-0

Yao, K., Liederbach, E., Tang, R., Lei, L., Czechura, T., Sisco, M., . . . Smith, B. L. (2015). Nipple-sparing mastectomy in BRCA1/2 mutation carriers: an interim analysis and review of the literature. Ann Surg Oncol, 22(2), 370-376. https://doi.org/10.1245/s10434-014-3883-3

Yardley, D. A., Burris, H. A., III, Simons, L., Spigel, D. R., Greco, F. A., Barton, J. H., . . . Hainsworth, J. D. (2008). A phase II trial of gemcitabine/carboplatin with or without trastuzumab in the first-line treatment of patients with metastatic breast cancer. Clin Breast Cancer, 8(5), 425-431. https://doi.org/10.3816/CBC.2008.n.051

Yazar, S., Bengur, F. B., Altinkaya, A., Kara, H., & Uras, C. (2021). Nipple-Sparing Mastectomy and Immediate Implant-Based Reconstruction with or Without Skin Reduction in Patients with Large Ptotic Breasts: A Case-Matched Analysis. Aesthetic Plast Surg, 45(3), 956-967. https://doi.org/10.1007/s00266-020-02000-w

Yen, M. F., Tabar, L., Vitak, B., Smith, R. A., Chen, H. H., & Duffy, S. W. (2003). Quantifying the potential problem of overdiagnosis of ductal carcinoma in situ in breast cancer screening. Eur J Cancer, 39(12), 1746-1754. https://doi.org/10.1016/s0959-8049(03)00260-0

Yu, K. D., Liu, X. Y., Chen, L., Mo, M., Wu, J., Liu, G. Y., . . . Shao, Z. M. (2021). Anthracycline-free or short-term regimen as adjuvant chemotherapy for operable breast cancer: A phase III randomized non-inferiority trial. Lancet Reg Health West Pac, 11, 100158. https://doi.org/10.1016/j.lanwpc.2021.100158

Yu, K. D., Ye, F. G., He, M., Fan, L., Ma, D., Mo, M., . . . Shao, Z. M. (2020). Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial. JAMA oncology, 6(9), 1390-1396. https://doi.org/10.1001/jamaoncol.2020.2965

Zaenger, D., Rabatic, B. M., Dasher, B., & Mourad, W. F. (2016). Is Breast Conserving Therapy a Safe Modality for Early-Stage Male Breast Cancer? Clin Breast Cancer, 16(2), 101-104. https://doi.org/10.1016/j.clbc.2015.11.005

Zagouri, F., Sergentanis, T. N., Azim, H. A., Jr., Chrysikos, D., Dimopoulos, M. A., & Psaltopoulou, T. (2015). Aromatase inhibitors in male breast cancer: a pooled analysis. Breast cancer research and treatment, 151(1), 141-147. https://doi.org/10.1007/s10549-015-3356-9

Zhan, Q. H., Fu, J. Q., Fu, F. M., Zhang, J., & Wang, C. (2018). Survival and time to initiation of adjuvant chemotherapy among breast cancer patients: a systematic review and meta-analysis. Oncotarget, 9(2), 2739-2751. https://doi.org/10.18632/oncotarget.23086

Zhang, F. F., Haslam, D. E., Terry, M. B., Knight, J. A., Andrulis, I. L., Daly, M. B., . . . John, E. M. (2017). Dietary isoflavone intake and all-cause mortality in breast cancer survivors: The Breast Cancer Family Registry. Cancer, 123(11), 2070-2079. https://doi.org/10.1002/cncr.30615

Zhang, H., Li, Y., Moran, M. S., Haffty, B. G., & Yang, Q. (2015). Predictive factors of nipple involvement in breast cancer: a systematic review and meta-analysis. Breast cancer research and treatment, 151(2), 239-249. https://doi.org/10.1007/s10549-015-3385-4

Zhang, L., Jin, K., Wang, X., Yang, Z., Wang, J., Ma, J., . . . Guo, X. (2019). The Impact of Radiotherapy on Reoperation Rates in Patients Undergoing Mastectomy and Breast Reconstruction. Ann Surg Oncol, 26(4), 961-968. https://doi.org/10.1245/s10434-018-07135-4

Zhang, X., Liu, W., Hai, T., & Li, F. (2021). Upgrade Rate and Predictive Factors for Breast Benign Intraductal Papilloma Diagnosed at Biopsy: A Meta-Analysis. Ann Surg Oncol, 28(13), 8643-8650. https://doi.org/10.1245/s10434-021-10188-7

Aapro, M. S., Bohlius, J., Cameron, D. A., Dal Lago, L., Donnelly, J. P., Kearney, N., . . . Treatment of, C. (2011). 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer, 47(1), 8-32. https://doi.org/10.1016/j.ejca.2010.10.013

Aas, T., Geisler, S., Paulsen, T., Borresen-Dale, A. L., Varhaug, J. E., Lonning, P. E., & Akslen, L. A. (1996). Primary systemic treatment with weekly doxorubicin monotherapy in women with locally advanced breast cancer; clinical experience and parameters predicting outcome. Acta Oncol., 35(Suppl 5), 5-8. https://doi.org/10.3109/02841869609083960

Sist faglig oppdatert: 23. mars 2022